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Resumo 
Esta dissertação baseia-se na síntese de novos compostos derivados do núcleo indólico e a sua 
avaliação biológica, de modo a procurar novos candidatos a fármacos, incluindo, antioxidantes, 
inibidores selectivos da ciclooxigenase-2 (COX-2) e antituberculares. 
Uma biblioteca de derivados do triptofano e da triptamina foi sintetizada, particularmente 
composta por compostos indólicos prenilados, e foi investigada a sua capacidade de captar espécies 
reactivas de oxigénio (ERO) e espécies reactivas de azoto (ERA). O padrão de substituição da biblioteca 
incluiu várias cadeias alquílicas nas posições N-1 e C-2 do núcleo de indole, assim como diferentes 
grupos na cadeia lateral (em C-3) que permitiram a investigação de uma possível estabilização de 
radicais. Os resultados obtidos mostraram que o triptofano (8), a triptamina (9), a N-ftaloil triptamina 
(5) e o N-prenil triptofano 13, foram os mais activos contra o radical peróxilo (ROO )̇, com actividades 
superiores à do trolox, que foi usado como controlo.  
A biblioteca de compostos foi também avaliada quanto à capacidade de captar o ácido 
hipocloroso (HOCl), tendo-se obtidos os valores de IC50 de 3,50 ± 0,40 e 6,00 ± 0,60 µM para o 
triptofano (8) e a triptamina (9), respectivamente. Os estudos foram alargados às ERA e os melhores 
resultados foram obtidos contra o anião peroxinitrito (ONOO-) na presença de NaHCO3. O derivado de 
triptofano 18 apresentou uma actividade elevada com um IC50 de 14,0 ± 6,8 µM.  
Os resultados obtidos neste estudo demonstraram que os compostos testados são captadores 
eficientes de ERO e ERA, e sugeriram que a estabilização radicalar é fortemente dependente do tipo de 
substituintes na unidade indólica assim como a sua posição relativa. Concluiu-se que a dissipação 
radicalar dentro do sistema indólico é obrigatória para a actividade antioxidante observada. Estudos de 
voltametria cíclica revelaram que todos os compostos apresentavam um pico de potencial de oxidação 
inferior ao observado para o indole (Epox = 1,035 V), mas superior ao descrito para o antioxidante, 
melatonina (Epox = 0,715 V). 
Na procura de potenciais candidatos a fármacos anti-inflamatórios, foi ainda utilizado o núcleo 
indólico, que foi funcionalizado de modo favorecer a inibição selectiva da COX-2. Uma pequena 
biblioteca de novos compostos indólicos, envolvendo dois padrões de substituição diferentes, foi 
sintetizada de modo a estabelecer uma relação entre a distribuição espacial de grupos funcionais 
conhecidos com a capacidade de inibição da COX-2. Os dois padrões de substituição investigados 
envolveram substituintes nas posições N-1, C-3 e C-5, e nas posições C-2, C-3 e C-5 do núcleo indólico. 
As posições C-5, C-3 e N-1 foram substituídas com um grupo sulfonamida ou metilsulfona em C-5, um 
grupo p-halo benzílico em C-3, e uma cadeia alquílica com um grupo trifluorometílico em N-1. 
Alternativamente, um grupo p-halo benzílico foi introduzido em C-2, deixando o átomo de azoto 
indólico livre. Foram realizados estudos de inibição e os resultados obtidos relativamente às isoformas 
da COX (COX-1 e COX-2) foram racionalizados, com base em estudos de docking e de RMN. Os 
estudos de docking demostraram que a dialquilação em C-2 e C-3 favorece a ligação à COX-2, com uma 
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orientação semelhante à do inibidor selectivo conhecido, SC-558. Verificou-se que este padrão de 
substituição está correlacionado com a actividade de inibição e selectividade mais elevada: 67 ± 5% de 
inibição da COX-2 e uma fraca inibição da COX-1 (18 ± 9%). Adicionalmente, os estudos de diferença 
de transferência de saturação (STD)-RMN revelaram padrões de interacção diferentes com ambas a 
isoformas da COX, os quais podem estar relacionados com as diferentes orientações do grupo 
sulfonamida no centro activo. 
Dada a importância do grupo sulfonamida nos compostos testados e em fármacos, foram 
realizados diversos ensaios com o objectivo de sintetizar um reagente de sulfonilação novo e versátil 
para a preparação de sulfonamidas. Os ensaios realizados consistiram sobretudo em sintetizar sulfinatos 
de sódio derivados de benzotriazole/benzimidazole, e em investigar o uso de carbenos N-heterocíclicos 
(NHC) na formação de aductos de carbeno∙SO2. Ambas as aproximações revelaram que os 
intermediários usados, ou gerados in situ, ou não se formaram ou não tinham estabilidade suficiente que 
permitisse o isolamento e caracterização dos compostos formados.  
Por último, cinco derivados de indole, direccionados por modelos computacionais, foram 
sintetizados e submetidos para avaliação como potenciais agentes antituberculares. Estes compostos 
foram divididos em três padrões de substituição diferentes: padrão A – substituição nas posições C-5 e 
N-1; padrão B – substituição em C-5 e C-2; e padrão C – substituição em C-5 e C-3 do núcleo indólico. 
Várias aproximações sintéticas e diferentes metodologias foram aplicadas na síntese destes compostos 
envolvendo, por exemplo, métodos de indolização tais como a indolização de Fischer. Os compostos 
sintetizados foram submetidos para avaliação biológica. 
Os resultados obtidos nesta dissertação permitiram o estudo e preparação de novos derivados 
indólicos e a sua aplicação em diversos alvos biológicos importantes. Este trabalho permitiu a elucidação 
dos mecanismos envolvidos, do reconhecimento molecular, e de interações importantes entre os 
compostos preparados e diversos alvos biológicos estudados. Desta forma este trabalho contribuiu para 
o design de novos fármacos antioxidantes, anti-inflamatórios e antituberculares mais potentes e 
selectivos. 
 
 
 
Termos chave: Síntese de indole, química medicinal, antioxidantes, inibidores da COX, agentes 
antituberculares 
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Abstract 
This dissertation is based on the synthesis of novel compounds with an indole scaffold and its 
biological evaluation, on the search for potential drug candidates, including, antioxidants, 
cyclooxygenase-2 (COX-2) selective inhibitors and antitubercular agents. 
A library of tryptophan and tryptamine derivatives was prepared, in particular prenylated indole 
compounds, and their scavenging activity for reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) was investigated. The library substitution pattern included several alkyl chains at 
positions N-1, C-2 of the indole nucleus, including prenyl and isopentyl chain, as well as different groups 
at the side chain (C-3), which allowed the investigation of a possible radical stabilization. The obtained 
results showed that tryptophan (8), tryptamine (9), N-phthaloyl tryptamine (5) and N-prenyl tryptophan 
13 were the most active against peroxyl radical (ROO )̇ with higher activities than trolox, which was 
used as control. The scavenging of hypochlorous acid (HOCl) was also evaluated and tryptophan (8) 
and tryptamine (9) showed IC50 of 3.50 ± 0.40 and 6.00 ± 0.60 µM, respectively.  
The studies were extended to RNS and best results were obtained against peroxynitrite anion 
(ONOO-) in the presence of NaHCO3. The tryptophan derivative 18 showed a high activity with an IC50 
of 14.0 ± 6.8 µM. The results show that the tested compounds are effective scavengers of ROS and RNS, 
and suggest that the radical stabilization is strongly dependent on the type of substituents on the indolic 
moiety and on their relative positions. In addition, the radical dissipation inside the indolic system is 
mandatory for the observed antioxidant activity. The cyclic voltammetry study undertaken showed that 
all the compounds presented an oxidation potential peak lower than that observed for indole (Epox = 
1.035 V), but higher than that described for the antioxidant melatonin (Epox = 0.715 V). 
The indole scaffold was further investigated on the search for COX-2 selective inhibitors, as 
potential anti-inflammatory drugs. Thus a small library of new indolic compounds involving two 
different substitutions patterns at the indole scaffold was synthesized in order to establish a relationship 
between the spatial distributions of known functional groups related with COX-2 inhibitory activity. 
The two substitution patterns explored involved substitution at positions N-1, C-3, C-5, and at positions 
C-2, C-3 and C5 of the indole scaffold. Accordingly, indole positions C-5, C-3 and N-1 were substituted 
with a sulfonamide or methylsulfone group at C-5, a p-halo-benzyl group at C-3, and an alkyl chain with 
a trifluoromethyl group at N-1. Alternatively, a p-halo-benzyl group was introduced at C-2, leaving the 
indolic nitrogen free. Inhibitory studies were performed and the activity results obtained against both 
COXs isoforms (COX-1 and COX-2) were rationalized based on docking and NMR studies. Docking 
studies showed that dialkyation at C-2 and C-3 favors binding, with an orientation similar to that of the 
known selective inhibitor, SC-558. It was verified that this substitution pattern is correlated with the 
highest inhibitory activity and selectivity found, 67 ± 5% COX-2 inhibition at 50 µM, and low COX-1 
inhibition (18 ± 9%). 
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Saturation transfer difference (STD) NMR experiments reveal different interaction patterns with 
both COXs isoforms that may be related with different orientations of the sulfonamide group in the 
binding pocket.  
Due to the high relevance of the sulfonamide group in the tested compounds as well as in several 
known drugs, several attempts were made to synthetize a new and versatile sulfonylation reagent for the 
synthesis of sulfonamides. The experiments performed relied mainly on two approaches, consisting on 
the synthesis of sodium benzotriazole/benzimidazole sulfinates, and on the use of N-heterocyclic 
carbenes (NHC) for the formation of carbene∙SO2 adduct. Both approaches revealed that the 
intermediates used, or generated in situ, either did not form or did not have enough stability to allow 
isolation and characterization of the formed compounds.  
The indole scaffold was also investigated on the search for novel and potent antitubercular 
agents. Thus, five indole derivatives, directed by computational models, were synthesized and were 
submitted to evaluation as antitubercular agents. These compounds were divided in three different 
substitution patterns: pattern A –substitution at C-5 and N-1 position; pattern B – substitution at C-5 and 
C-2 and; pattern C – substitution at C-5 and C-3 of the indole scaffold. Several synthetic approaches 
and methodologies were applied for the synthesis of these compounds involving, for example, 
indolization methods such as the Fischer indolization reaction. The synthetized compounds were 
submitted to biological evaluation. 
The results obtained in this work allowed the study and preparation of novel indole derivatives, 
and its application in several biologically important targets. This work contributed to the understanding 
of the molecular recognition, mechanisms involved and key interactions of the compounds prepared 
with the targets, and thus to the design of novel antioxidant, anti-inflammatory and antitubercular drugs 
with higher potency and selectivity.  
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red reduction 
rfx reflux 
RNS reactive nitrogen species 
ROS reactive oxygen species  
rt room temperature 
s singlet 
SAR structure-activity relationship 
SN2 bimolecular nucleophilic substitution 
SNAr nucleophilic aromatic substitution 
SSA silica-gel-supported sulfuric acid 
STD saturation-transfer difference 
t triplet 
TB tuberculosis 
TBAI tetrabutylammonium iodide 
tBu tert-butyl 
TEA triethylamine 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
TMS tetramethylsilane 
 
xxxvi 
 
Ts transition state 
Ts 4-toluenesulfonyl 
TX thromboxane 
vs. versus 
WHO World Health Organization 
XDR extensively drug resistant 
δ chemical shift 
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I.1 Drug development  
The process of drug development is challenging, expensive and time consuming. Developing a 
new drug from an original idea to the launch of a finished product is a complex process which can take 
12–15 years and cost in excess of €1 billion (figure I.1).  
 
 
Figure I.1 – Drug development process (adapted from Bayer).1 
 
The drug discovery process initiates with the identification of a medical need, including a 
judgment on the adequacy of existing therapies (if there are any). From this analysis, together with an 
evaluation of the current knowledge about the target disease, will come hypotheses on how to possibly 
improve therapy. Key subsequent steps in the process include detecting relevant biological activity (a 
‘hit’) for a structurally novel compound in vitro, then finding a related compound with in vivo activity 
in an appropriate animal model, followed by maximizing this activity through the preparation of 
analogous structures, and finally selecting one compound as the drug development candidate. This drug 
candidate then undergoes toxicological testing in animals, as required by law. If the compound passes 
all these tests, all the collected research data are assembled and submitted as an Investigational New 
Drug Application (IND) to the European Medicines Agency (EMA) in European Union or to the Food 
and Drug Administration (FDA) in the United States before clinical trials are initiated. In the clinic tests, 
there is sequential evaluation in normal human volunteers of toleration (Phase I), efficacy and dose 
range in patients (Phase II), followed by widespread trials in thousands of appropriate patients to develop 
a broad database of efficacy and safety. For the few (4–7%) drug candidates that survive this series of 
development trials, a New Drug Application (NDA) that contains all the gathered research data is filed 
for thorough review by the experts at the EMA or FDA. Phase IV consists on collecting the data (e.g. 
side effects) of the drug that has already been allowed onto the market.2 
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Drugs fail in the clinical studies due to two main reasons: either they are ineffective or are not 
safe. Thus, one of the most important steps in drug development is target identification and validation. 
A drug target is a biomolecule which is involved in signaling or metabolic pathways that are specific to 
a disease process which may include proteins, genes and RNA, for example. The ideal target has to be 
efficacious, safe, meet clinical and commercial needs and, most of all, has to be accessible to the alleged 
drug molecule, causing a biological response that can be measured in vitro and in vivo. Once identified, 
the target must be validated. Validation techniques range from in vitro tools through the use of animal 
models in order to modulate the desired target in human patients. After the validation target process, it 
is during the lead discovery phase that screening assays are developed.2 
Several approaches can be taken to identify a lead. The first requirement for all of the approaches 
is to have a resource to assay compounds for a particular biological activity, to know when a compound 
is active. A bioassay (or screen) is a mean of determining in a biological system, relative to a control 
compound, if a compound has the desired activity (biological or pharmacological effect), and what the 
relative potency (strength of that effect) of the compound is.3 Table I.1 summarizes some screening 
strategies used in lead discovery. 
 
Table I.1 – Screening strategies.2 
Screen Description 
High throughput 
screening (HTS) 
Very rapid and sensitive assay which can be carried out robotically in 1536- 
or 3456-well titer plates on submicrogram scale of compound 
Focused screen Compounds previously identified as hitting specific classes of targets (e.g. 
kinases) and compounds with similar structures 
Fragment screen Identification of small chemical fragments, which may bind only weakly to 
the biological target, and then growing them or combining them to produce a 
lead with a higher affinity 
Structural aided 
drug design 
Use of crystal structures to help design molecules 
Virtual screen Prediction of the binding orientation of small molecule drug candidates to 
their protein targets in order to in turn predict the affinity and activity of the 
small molecule (docking models) 
Physiological 
screen 
A tissue-based approach used to determinate the effects of a drug at the tissue 
rather than the cellular or subcellular level, e.g. muscle contractility 
NMR screen Exploits changes in either relaxation rates or diffusion rates of small 
molecules when they bind to a macromolecule. It also can be used to screen 
mixtures of compounds to determine the ones that bind best. 
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After the screen is developed, several approaches can be taken to obtain a lead compound. The 
typical lead compound for a receptor or enzyme is the natural ligand for the receptor or substrate for the 
enzyme. Another good source of lead compounds is marketed drugs. In the absence of known drugs and 
other compounds with desired activity, a random screening is a valuable approach. Random screening 
involves no rationalization. All compounds are tested in the bioassay without regard to their structures. 
This usually is the chosen method when nothing is known about the receptor target. However, none of 
these method approaches involves a rational element. 
The first step for a rational drug design is the identification of the disease state, since several 
diseases are caused from an imbalance of particular chemicals in the body, from the invasion of a foreign 
organism, or from aberrant cell growth.3,4 Therefore, it is necessary to perform a meticulous analysis of 
the structural and chemical features of the target binding site (i.e., amino acid residues of the protein 
pocket: tautomerism, protonation, ionization). Protein structures (apo, ligand-free; or holo, ligand-
bound) are experimentally determined by X-ray crystallography and NMR. Alternatively, protein 
structure homology models can be a valuable alternative.5-7 Several in silico methods can be used in 
combination with experimental evidences to extract and organize the molecular information in order to 
assist the understanding of the structural and chemical basis involved in receptor-ligand binding affinity 
and biological activity (pharmacodynamics).8 
There are other features to lead modification that are as important to increase the binding to the 
target receptor, such as pharmacokinetics (absorption, distribution, metabolism, and excretion or 
ADME). The identification of the pharmacophoric and auxophoric groups of the lead compound, and of 
the auxophoric groups, which are interfering with lead compound binding and which are not detrimental 
to binding, is crucial to know which groups must be removed and which can be kept or modified. 
The knowledge generated (chemical and biological) from these approaches is a key component 
in medicinal chemistry, and can be used in the iterative design of new ligands with improved properties 
characteristics. For this purpose, 3D quantitative structure-activity relationships (3D QSAR) methods 
are among the most important strategies that can be applied for the successful optimization of leads. In 
this context, 3D QSAR models are generated to explain the relationships between the intermolecular 
interactions related to the 3D conformations of a set of structurally related molecules and their 
experimental activity (e.g., IC50, Ki), therefore, providing a rational basis for the development of new 
promising compounds (figure I.2).9-11 
 
Chapter I   Introduction 
6 
 
 
Figure I.2 - Iterative process used in rational drug discovery.12 
 
Rational approaches have increasingly demonstrated their value in drug design. The impact of 
these technologies on early discovery and lead optimization is significant. The ability to make 
knowledge-based decisions during the early phases of drug discovery is the key to decreasing hit-to-
lead and lead optimization cycle times. The significant advances in structural capabilities (e.g., protein 
generation and purification techniques, high throughput crystallography, virtual screening, SAR by 
NMR) combined with robust and more efficient computational tools (faster and cheaper) have improved 
the drug discovery and development. 
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I.2 The indole scaffold 
I.2.1 Indole: a “privileged structure” 
The term “privileged structure” was introduced by Evans et al., in 1988, to define scaffolds that 
“are capable of providing useful ligands for more than one receptor and that judicious modification of 
such structures could be a viable alternative in the search for new receptor agonists and antagonists”.13 
In 1999, IUPAC defined this concept in its Glossary of Terms Used in Combinatorial Chemistry 
(Technical Report) as “substructural feature which confers desirable (often drug-like) properties on 
compounds containing that feature. Often consists of a semi-rigid scaffold which is able to present 
multiple hydrophobic residues without undergoing hydrophobic collapse”.14 
Indole (1), or benzo[b]pyrrole (figure I.3), is a benzopyrrole in which the benzene and pyrrole 
rings are fused through the 2- and 3-positions of the pyrrole nucleus. It is a privileged motif that enjoys 
widespread inclusion in molecules, both naturally occurring and designed, which find applications in 
pharmaceutical, agrochemical and materials industries.15  
 
 
 Figure I.3 – Chemical structure of the indole (1) scaffold.  
 
The indole (1) scaffold probably represents one of the most important structural subunits in drug 
discovery.16 Tryptophan (2) is one of the naturally-occurring amino acids and plays critical roles in 
protein-protein and protein-ligand recognition and binding as well as in human nutrition, as biosynthetic 
precursor of serotonin [5-hydroxytryptamine (3)]. This is a key neurotransmitter in central nervous 
system, regulates smooth muscle function in the cardiovascular and gastrointestinal systems, and 
regulates platelet function.17 Indole-3-acetic acid (4) is the most common, naturally-occurring, plant 
hormone of the auxin class. Figure I.4 depicts some examples of, both natural and synthetic, indole -
containing structures. 
 
Chapter I   Introduction 
8 
 
 
Figure I.4 – Examples of indole-containing structures. 
 
Thus, it is not surprising that there are several classes of active compounds comprising a central 
indole scaffold with elaborate and specific functionality. Indeed, several marketed drugs contain the 
indole nucleous: ondansetron (5) (a 5HT3 receptor antagonist) is a potent anti-emetic; sumatriptan (6) (a 
5HT1D receptor agonist) is used for the treatment of migraine; indomethacin (7) (cyclooxygenase 
antagonists) is a non-steroidal anti-inflammatory drug; tadalafil (8) (a PDE-5 selective inhibitor) is used 
for treating erectile dysfunction and pulmonary arterial hypertension; and fluvastatin (9) (a HMG-CoA 
reductase inhibitor) is administrated to treat hypercholesterolemia and to prevent cardiovascular 
disease.15,16,18 In addition to this, molecules containing the indole scaffold are aromatase (CYP19) 
ihnibitors,19 HIV-1 attachment inhibitors,20 selective cathepsin K inhibitors,21 and agonists of the CB1 
receptor,22 to name just a few. 
As a result of the overall drug-like character of these compounds, combined with their chemical 
tractability in both solution- and solid-phase synthesis, the preparation of indole-based collections seems 
an ideal approach to targeted library construction. Based on the privileged structure hypothesis, it should 
be possible to modify the indole core with diverse functionality to tune it for different biological 
activities. 
 
I.2.2 Synthesis and Functionalization of indoles 
Since the discovery of indole, by Adolf von Baeyer in 1869,23 synthesis24-26 and direct 
functionalization27-29 of this heteroaromatic scaffold has been a major area of research for synthetic 
organic chemists, and numerous methods have been developed.  
There are several routes for the indole synthesis and, very recently, Taber and Tarunahari30 
proposed a system for classifying indole synthesis that could be universally understood. For the 
classification of the methods of synthesis, the authors have focused on the last bond formed, from the 
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four bond in the five-membered indole ring (Type 1 to Type 6) (figure I.5). They also differentiated 
between forming a bond to a functionalized aromatic carbon, and forming a bond to an aromatic carbon 
H-substituted (Type 1 vs. Type 2 and Type 3 vs. Type 4). 
 
 
Figure I.5 – The nine types of indole synthesis and some associated name reaction, proposed by Taber and 
Tirunahari.30 
The last step of the Type 5 is the C-N bond formation, while in Type 6 the last step is a C-C 
bond formation. In Type 7, the benzene ring has been derived an existing cyclohexane, and in Type 8, 
the benzene ring has been built onto an existing pyrrole, Finally, in Type 9, both rings have been 
constructed. 
Despite the existence of several name reactions associated with indole synthesis, the classical 
Fischer indole synthesis is reported as one of the first choice route to prepare this scaffold (figure I.5, 
Type 1). The first indolization of an arylhydrazone was reported in 1883 by Fischer and Jourdan,31 and 
for over a century, the Fischer indole reaction has remained an extremely useful and important method 
for the synthesis of a variety of indole intermediates and biologically active compounds. This reaction 
often provides a simple, efficient method for the transformation of enolizable N-phenylhydrazones into 
indoles. In many cases, the indolization reaction is carried out by simply heating the ketone or aldehyde 
10 and the phenylhydrazine 11 with the appropriate acid or acid catalyst without isolation of the 
hydrazone intermediate (scheme I.1). 
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Scheme I.1 – Fischer indole synthesis. 
 
The mechanism of the Fischer indole cyclization involves the formation of a phenylhydrazone 
12 which isomerizes to the respective enamine 13. After protonation, a cyclic [3,3]-sigmatropic 
rearrangement occurs producing an imine 14. The resulting imine forms a cyclic aminoacetal 15, which, 
under acid catalysis, eliminates NH3, resulting in the thermodynamic favorable aromatic indole (scheme 
I.2). 
 
 
Scheme I.2 – Mechanism of the Fischer indole reaction. 
 
This reaction has been extensively modified to various conditions, such as alternative routes for 
the phenylhydrazones synthesis32,33 (scheme I.3A), microwave-assisted reaction34 (scheme I.3B) and 
solid-phase synthesis35 (scheme I.3C). 
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Scheme I.3 – Some modifications to the Fischer indole reaction. 
 
The Mori-Ban approach also allows an easy access to the indole nucleus (figure I.5, Type 2). In 
1977, Mori and Ban36 discovered that palladium catalyzes the intramolecular reaction of o-halo-N-
allylanilines to indoles under Heck reaction conditions [Pd(OAc)2, PPh3 and 
tetramethylethylenediamine (TMEDA)] (scheme I.4).  
It was the first intramolecular Heck reaction applied for the synthesis of heterocyclic 
compounds. In the past three decades, the Mori-Ban reaction has been improved and applied to a variety 
of organic compound synthesis.37-41 
 
 
Scheme I.4 – The Mori-Ban indole synthesis. 
 
Unlike the Fischer indole synthesis, the C3–C3’ bond is already present in the precursor for the 
Hemetsberger reaction (figure I.5, Type 3).42 It is thus particularly suited to the regiospecific synthesis 
of 4- or 6-substituted indoles from ortho- or para-substituted benzaldehydes (scheme I.5). Since the 
reaction is effected simply by heating, it can be used in combination with other thermal processes such 
as the Claisen rearrangement.43 Despite the potential hazards associated with the use of azides, the 
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Hemetsberger reaction is amenable to scale up and has been carried on 90 g scale in Cook’s synthesis 
of roeharmine.44 
 
 
Scheme I.5 – The Hemetsberger indole synthesis. 
 
In 1998, Buchwald et al.45 described a new approach for the construction of indoles, employing 
the air- and moisture-stable reagent Cp2TiCl2 (figure I.5, Type 4). This procedure involves two key 
steps: the intermolecular insertion reactions of an olefin and a titanocene-stabilized benzyne complex; 
and the Pd-catalyzed aryl amination reaction followed by oxidation of the resulting indoline to the 
corresponding indole (scheme I.6). This approach has been modified over the past years and applied in 
several organic synthesis reactions.46-48 
 
 
Scheme I.6 – The Buchwald indole synthesis. 
 
In 1969, Sundberg et al.49 reported an indole synthesis (figure I.5, Type 5) consisting on the 
thermolysis of o-azidostyrenes to give indoles via a nitrene intermediate (scheme I.7A). The heating of 
o-nitrostyrenes in the presence of triethyl phosphite also affords the indole ring (scheme I.7B).50  
 
 
Scheme I.7 – The Sundberg indole synthesis. 
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In 1912, Madelung51 (figure I.5, Type 6) reported that o-acetotoluidine and o-benzotoluidine 
provided the corresponding 2-methylindole and 2-phenylindole, respectively, when heated to 360-
380°C with 2 equivalents of sodium ethoxide (scheme I.8). The Madelung reaction could be performed 
at lower temperature when n-BuLi or lithium diisopropylamide (LDA) are employed as bases.52 Also, 
the introduction of an electron withdrawing group (EWG) at the benzylic carbon atom of the N-acylated-
o-alkylanilines affords the indole moiety effectively.53-55 
 
 
Scheme I.8 – The Madelung indole synthesis. 
 
In 1929, Nenitzescu56 (figure I.5, Type 7) reported that p-benzoquinone treated with ethyl 3-
aminocrotonate, in boiling acetone, yielded ethyl 5-hydroxy-2-methylindole-3-carboxylate (scheme 
I.9). The procedure was largely ignored until the 1950s when interest in melanin-related substances and 
recognition of serotonin as a 5-hydroxy indole derivative stimulated the exploration of the scope of the 
reaction. Nowadays, the Nenitzescu reaction is one of the most efficient processes for the preparation 
of 5-hydroxyindoles.57-59 
 
 
Scheme I.9 – The Nenitzescu indole synthesis. 
 
In 1986, van Leusen et al.60 (figure I.5, Type 8) established a route to highly substituted indoles, 
based on the condensation of isonitriles with unsaturated ketones to give the 2,3-bisalkenylpyrrole . 
Heating followed by aromatization with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) completed 
the synthesis of the indole nucleus (scheme I.10). Over the past decades this approach has been modified 
and applied on several indole derivatives synthesis reactions.61-65 
 
 
Scheme I.10 – The van Leusen indole synthesis. 
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Kanematsu et al.66 described a pioneer route for the synthesis of indoles, in 1986 (figure I.5, 
Type 9). The key step of this approach is an intramolecular Diels-Alder reaction to simultaneous 
construction of both rings of the indole nucleus (scheme I.11).Three more related approaches were 
reported since that time.67-69 
 
 
Scheme I.11 – The Kanematsu indole synthesis. 
 
Indole is a π-excessive aromatic heterocycle and is highly reactive towards classical 
electrophilic substitution reactions such as protonation, halogenation, alkylation and acylation. Thus, 
electrophilic substitution in the indole ring has been extensively studied.70 In these reactions, the indole 
moiety can undergo attack under neutral, positively and also negatively charged particles (scheme I.12). 
 
 
Scheme I.12 – Resonance structures of indole negatively and positively charged, respectively. 
 
Indole is a weak acid (pKa 16.7 and 21.0, in water71 and DMSO,72 respectively), a weak base 
(pKb -3.5)73 and only forms ions in strongly acid or basic media. As a consequence of the non-uniform 
distribution of the electron density in the neutral form of indole, the most nucleophilic position is C-3. 
The nitrogen atom can be made the most reactive nucleophilic site by deprotonation, so procedures for 
N-1 substitution normally involve base-catalysed nucleophilic substitution or conjugate addition 
reactions. The most versatile methods for C-2 substitution involve organometallic intermediates 
obtained by C-2 lithiation. 
 
I.2.2.1 Functionalization at N-1 position 
Despite the neutral indole ring is not very nucleophilic at nitrogen, the corresponding anion is a 
good nucleophile (scheme I.12). Therefore, procedures for N-alkylation typically are done under 
conditions where the nitrogen is deprotonated, using a strong base in a polar aprotic solvent. The 
alkylating reagents must be able to undergo through a bimolecular nucleophilic substitution (SN2) 
reaction. Primary alkyl, benzyl and allyl halides as well as sulfonates are usually excellent electrophiles  
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(scheme I.13A).25 Indoles can also be N-alkylated using alcohols, via Mitsunobu reaction (scheme 
I.13B).74-76  
Concerning the N-arylation of indole, nucleophilic aromatic substitution (SNAr) reactions allow 
access to these compounds. However, they are limited to strongly electron-deficient arenes, or by 
Ullmann-type reactions (scheme I.13C).77 Since the pioneering work by Buchwald et al78 alternative 
reaction conditions for the N-arylation reaction have been investigated with improvements in terms of 
mildness, functional group tolerance, and eventual omission of the base and ligand.29  
 
 
Scheme I.13 – Strategies for N-1 functionalization of indole compounds. 
 
I.2.2.2 Functionalization at C-2 position 
Lithiation of N-substituted indoles is one of the premiere methods for preparing 2-substituted 
indoles. 1-Alkylindoles, such as 1-methylindole, are readily lithiated and undergo typical reactions, such 
as n-BuLi at low temperature, with electrophiles. Thus, to synthesize N-unsubstituted indoles as final 
products, the use of a protecting group is required (scheme I.14A).79-81 More recently, examples of direct 
C-2 alkylation via transition-metal catalyzed C−H activation were reported (scheme I.14B). The 
iridium-catalyzed C-2 alkylation reaction of N-substituted indole derivatives with several alkenes 
afforded linear or branched 2-alkylindoles in high to excellent selectivity.82 Likewise, the direct 
alkenylation of the C-2 position, of indoles bearing an easily removable N-pyrimidyl group with alkynes, 
has been achieved by using a cobalt catalyst in a highly efficient and regioselective manner.83 
To date, three main strategies have been adopted for the C-2 arylation of indoles. All these 
approaches rely on the use of a transition metal catalyst, and vary depending on the level of pre-
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functionalization on the substrate starting materials: i) traditional cross-coupling reaction between two 
pre-functionalized substrates (for example, Stille and Suzuki couplings); ii) direct arylation, where only 
the arene coupling partner is pre-functionalized; and iii) oxidative couplings, where neither the indole 
nor the arene coupling partner are pre-functionalized (scheme I.6C).84 
 
 
Scheme I.14 – Strategies for C-2 functionalization of indole compounds. 
 
I.2.2.3 Functionalization at C-3 position 
C-3 position is the most reactive position on indole over electrophilic aromatic substitution 
reactions (scheme I.12), and it is 1013 times more reactive than benzene positions.25 The Friedel–Crafts 
alkylation is one of the archetypical acid catalyzed C–C bond-forming reactions to introduce alkylic 
chains onto aromatic compounds via electrophilic reagents.85 Many electrophiles can be employed for 
the Friedel–Crafts alkylation of indoles, such as: α,β-unsaturated carbonyl compounds via Michael 
addition (scheme I.15A);86-88 epoxides/aziridines (scheme I.15B);89,90 nitroolefins (scheme I.15C);91,92 
imines (scheme I.15D);93-95 π-activated alcohols (scheme I.15E);96-98 and allylic acetates/carbonates 
(scheme I.17F).99,100  
Concerning to C-3 arylation, the same strategies used for C-2 arylation can be applied.29 
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Scheme I.15 – Strategies for C-3 functionalization of indole compounds via Friedel–Crafts alkylation. 
 
Several other methodologies for the synthesis/functionalization of the indole ring have been 
described and reviewed.15 Nevertheless, due to its great importance and presence in diverse fields, from 
materials to medicine, the indole chemistry is still a growing research area. 
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I.3 Objectives 
The aim of this study was to explore the indole scaffold as a privileged structure, in order to find 
new compounds with relevant biological activities. Therefore, novel synthetic strategies were developed 
to achieve a proper substitution pattern in this moiety, attaining new indole-based libraries with 
antioxidant, anti-inflammatory and antitubercular activities.  
Thus, this work had the following objectives: 
 Identification of new compounds with radical (ROS and RNS) scavenging activity, and 
consequently potential drug candidates to the oxidative/nitrosative stress related diseases; 
 Establishment of a set of indolic compounds with different substitutions that would 
improve the radical scavenging activity and perform an SAR study; 
 To explore the mechanisms involved in their scavenging activity in order to establish a 
new platform for future drug development; 
 Design, synthesis and biological evaluation of a new indole-based selective COX-2 
inhibitors, concerning the development of novel anti-inflammatory drugs candidates; 
 Investigation of different substitution patterns of the indole scaffold in order to explore 
the different interactions with key residues of COX-1 vs. COX-2; 
 Use of different tools, such as NMR and docking, to rationalize the obtained results in  
the biological evaluation; 
 Validate and integrate a medicinal chemistry approach to find selective COX-2 inhibitors 
and understanding the mode of action of the new compounds; 
 Develop the synthesis of new indolic compounds in which the functionalization has been 
directed by computational models and evaluate their activity as antitubercular agents. 
These objectives intent to contribute to the development of new, better and safer antioxidant, 
anti-inflammatory and antitubercular drugs. 
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I.4 Thesis structure 
This thesis is the result of the work developed from 2009 to 2013 and originated four 
publications in international and peer-reviewed journals. 
This work is divided in three main sections. The first describes the synthetic approaches used to 
assemble a trytamine/tryptophan-based library as well as the evaluation of its radical scavenging 
potency, for ROS and RNS and also the assessment of its electrochemical behavior, by cyclic 
voltammetry. 
This work is published in:  
Estevão, M. S.; Carvalho, L. C.; Ribeiro, D.; Couto, D.; Freitas, M.; Gomes, A.; Ferreira, L. M.; 
Fernandes, E.; Marques, M. M. B., Antioxidant activity of unexplored indole derivatives: Synthesis and 
screening Eur. J. Med. Chem. 2010, 45, 4869;  
Estevão, M. S.; Carvalho, L. C.; Ferreira, L. M.; Fernandes, E.; Marques, M. M. B., Analysis of 
the antioxidant activity of an indole library: cyclic voltammetry versus ROS scavenging activity 
Tetrahedron Lett. 2011, 52, 101. 
Also contributes for the work developed in:  
Carvalho, L. C.; Estevão, M. S.; Ferreira, L. M.; Fernandes, E.; Marques, M. M. B., A new 
insight on the hypochlorous acid scavenging mechanism of tryptamine and tryptophan derivatives 
Bioorg. Med. Chem. Lett. 2010, 20, 6475. 
 
The second section refers to the search for novel selective COX-2 inhibitors, including the 
establishment of the substitution patterns, the synthetic approach and protocol development to attain the 
desired indole-based library. Several synthetic routes were explored and, in some cases, synthetic steps 
were optimized based on the reported literature as well as some mechanistic studies were developed. 
This section also describes the tools used to evaluate the inhibitory capacity of the synthesized 
compounds and its rationalization using NMR and in silico tool, as well as the efforts carried towards a 
new methodology for the synthesis of sulfonyl-containing compounds. 
This work is published in:  
Estevão, M. S.; Carvalho, L. C. R.; Freitas, M.; Gomes, A.; Viegas, A.; Manso, J.; Erhardt, S.; 
Fernandes, E.; Cabrita, E. J.; Marques, M. M. B., Indole based cyclooxygenase inhibitors: Synthesis, 
biological evaluation, docking and NMR screening Eur. J. Med. Chem. 2012, 54, 823. 
Estevão, M. S.; Duarte, F. J. S.; Fernandes, E.; Santos, A. G.; Marques, M. M. B., Unexpected 
reactivity of trifluoromethylated olefins with indole: a mechanistic investigation Tetrahedron Lett. 2012, 
53, 2132. 
 
The last section involves the description of the synthetic strategy developed to prepare indole -
based compound as potential antitubercular agents. 
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II.1 Introduction 
Aerobic organisms are normally under a dynamic equilibrium between free radical generation 
and quenching. Over the past decades, these species and other reactive small molecules have emerged 
as important regulators of many physiological and pathological processes. 
Currently, it is well established that - at physiological low levels - reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) regulate growth, apoptosis and other signaling, at the cellular level. 
At the systems level, ROS and RNS contribute to complex functions such as blood pressure regulation, 
cognitive function and immune function. These reactive species enable the response to growth factor 
stimulation and the generation of the inflammatory response. Also, they have a vital role in the immune 
system, where they are capable to directly kill pathogens.1,2 However, it is also known that at high levels, 
these short-lived reactive molecules can cause harmful effects by disturbing the cellular reduction-
oxidation (redox) balance. This perturbation leads to an imbalance between the relative rates of 
production and degradation of ROS/RNS, called oxidative or nitrosative stress, respectively. The excess 
of these reactive species can damage cellular lipids, proteins or DNA, inhibiting their normal function, 
and are associated with a wide range of pathologies and diseases such as cancer, ischemic/reperfusion 
injury, cardiovascular disease, rheumatoid arthritis, diabetes and neurological disorders, such as 
Alzheimer and Parkinson disease (figure II.1).2 
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Figure II.1 - Examples of oxidative/nitrosative stress related diseases . 
 
The “primary” ROS is the superoxide anion radical (O2˙̄ ) arising of metabolic processes or 
from oxygen “activation” by physical irradiation. This reactive specie can further interact with other 
molecules, directly or through enzyme- or metal-catalyzed processes, generating “secondary” ROS, 
such as hydroxyl radical (˙OH), hydrogen peroxide (H2O2), peroxyl radical (ROO )̇, hypochlorous acid 
(HOCl). Molecular oxygen can be itself a ROS because it can exist in a singlet state (1O2) for short 
periods of time, alongside with its more stable triplet state (3O2). RNS include mainly nitric oxide 
radical (˙NO) and peroxynitrite anion (ONOOˉ).2,3 
Despite being typically formed as a result of normal cellular metabolism, studies have shown 
that the concentration of free radical in the organism increases when cells are exposed to harmful 
environmental influences such as pollutants, radiation, stress, smoking, and nutrition.4 It is often 
assumed that mitochondria (mainly complex I and III, but also monoamino oxidase, α-ketoglutarate 
dehydrogenase, glycerol phosphate dehydrogenase, p66shc) is the primary endogenous source of 
oxidative stress in mammalian cells.5 However, there is no convincing experimental evidence to 
support this postulate.6 Another major source of ROS is the endoplasmic reticulum (mostly cytohrome 
P-450 and b5 enzymes, diamine oxidase, Ero1).7 Peroxissomes (acid fatty acid oxidation, D-amino acid 
oxidase, L-2-hydroxyacid oxidase and urate oxidase),8 cytosol (NO synthases, lipoxygenases and PGH 
Chapter II   New indole derivatives as antioxidants agents 
27 
 
synthase),9 plasma membrane (NADPH oxidases, lipoxygenase),10 and extracellular space (xanthine 
oxidase)11 are other cellular sources of ROS (figure II.2).  
 
 
Figure II.2 - Sources of ROS (adapted from Ding 2010).12 
 
Due to the constant exposure to free radicals, organisms developed different mechanisms to 
prevent or repair free radical-induce damages, and as well as physical and antioxidant defenses. These 
mechanisms include non-enzymatic proteins (transferrin, ferritin, ceruleoplasmin), enzymes (such as 
superoxide dismutases, catalase, glutathione peroxidase), oxidizable molecules (glutathione, vitamins 
E, A, C, carotenoids, flavonoids), and trace elements (copper, zinc, selenium).13,14 These different kinds 
of defense systems restrain the damage induced by ROS. However, these mechanisms are not always 
sufficient during pathologic conditions, so the development of antioxidant compounds that are able to 
scavenge ROS and RNS, and restore the homeostasis, is essential.  
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Several indole derivatives have been reported for their antioxidant proprieties and for their free 
radical scavenger capacities. One of the most recognized natural antioxidants is the indole hormone 
melatonin (figure II.3). Melatonin is produced in the body and acts as receptor-independent free-radical 
scavenger, and has a broad-spectrum of antioxidant effects.15,16 With reference to ROS, melatonin has a 
well-known potent scavenging effect against 1O2, O2˙̄ , H2O2, ̇ OH, and ROO .̇
17 The high reactivity of 
melatonin with pro-oxidant reactive species is probably due to the electron-rich aromatic ring system, 
allowing the indoleamine to easily function as an electron donor to form the melatoninyl cation radical, 
or through an electrophilic radical addition at the C-3 position of indole.16 This type of reactivity with 
ROS is extended to other indole derivatives, namely tryptophan, serotonin, 5-methoxytryptamine, 6-
chloromelatonin and related indoles,18-21 indole 3-acetic acid (IAA) and other plant-derived indoles,21,2 2  
the well-known non-steroidal anti-inflammatory drug (NSAID) indomethacin and its derivatives,23,24  
indole derivatives containing an pyrimidine and fused pyrimidine systems25, indole amino acids 
derivatives,26 2- phenylindole derivatives,27 indolin-2-one and indoline-2-thione derivatives,28 and 
stobadine.29 Some of these representative examples of indole derivatives showing antioxidant activity 
are displayed in figure II.3. 
 
 
Figure II.3 - Some examples of indole derivatives that show antioxidant activity. 
 
Moreover, HOCl scavenging activity has been investigated for the marketed indole derived 
NSAIDs, but no activity was found against this ROS.23  
Thus, a small library of novel synthetic tryptophan and tryptamine derivatives was prepared to 
explore their radical scavenging potency, by evaluation of their in vitro scavenging activity for ROS 
(O2˙̄ , H2O2, HOCl, ROO ,̇ 
1O2) and RNS (˙NO and ONOOˉ), as well as their electrochemical behavior, 
by cyclic voltammetry. Due to the similarity between electrochemical and biological reactions, it can be 
assumed that the oxidation mechanisms taking place at the electrode and in the body share similar 
principles.30 Therefore, the redox proprieties of drugs and biomolecules might be extremely relevant to 
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understand their in vivo redox behavior. In fact, this technique has been used to investigate how 
melatonin31 and other indole derivatives32,33 scavenge a variety of free radicals. 
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II.2 Results and discussion 
The development of novel indole derivatives with ROS and RNS scavenging activities 
constitutes a step forward in this area in view of the myriad of different biological activities displayed 
by compounds belonging to this family. The discovery of new derivatives with high antioxidant 
potential, but without other biological effects, may be important to avert adverse reactions that may arise 
within a clinical setting. 
The strategy followed envisaged the insertion of several groups at the indole moiety to facilitate 
either a radical scavenging mechanism via electron donation/H-abstraction or as traps for reactive 
species that react via an ionic mechanism. 
The prenyl chain at N-1 or C-2 was chosen on the basis of a possible H-abstraction from the α 
position, allowing a radical stabilization by the allylic double bond as well as by dissipation into the 
indole ring. Some reactive species are known to react with double bonds by either radical or ionic 
mechanism, such as the 1O2 and the ˙NO. It is worth noting that natural prenylated indolic compounds 
belong to a large class of alkaloids isolated from fungi, possessing a tryptophan moiety substituted with 
isoprenic units.34 The presence of an exocyclic double bond would enhance the scavenging activity with 
these species by both mechanisms. Scheme II.1 shows the proposed plan for substitution pattern of the 
indole library. 
 
 
Scheme II.1 – Proposed substitution pattern for the indole library. 
 
The influence of the position of the prenyl chain was also evaluated, and consequently the 
importance of a free indolic nitrogen. 
Moreover, the substitution of the alkyl chain at C-3 was further explored. Different electron 
withdrawing groups were used at the nitrogen atom from the side chain, such as the acetyl group and 
the phthaloyl group. These groups were selected due to their easy preparation, stability and most 
important the radical stabilization whether H-abstraction occurs at the β position. 
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II.2.1 Synthesis of the indole-based library 
In order to conduct a structure-activity relationship (SAR) study, the first step consisted on the 
synthesis of an indole-based library. This was done by conducting the synthesis of a library of fifteen 
compounds starting from L-tryptophan methyl ester (10) and tryptamine (9) (figure II.4). 
The synthesis of compounds 1-7, 11 and 12 was previously described35 and these compounds 
were prepared according to following procedures: protection of the nitrogen atom of the side chain, of 
compounds 9 and 10, with phthalimide and acetyl groups (compounds 5, 11 and 12); subsequent N-
prenylation using either 3,3-dimethylallyl bromide or 3-bromo-1-phenyl-1-propene afforded 
compounds 3, 4, 6 and 7; removal of the phthalimide group from 4 provided compound 2; treatment of 
6 with BF3.OEt2 afforded 1, according to the Lobo-Prabhakar sigmatropic rearrangement conditions of 
N-prenylindole derivatives.36 
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Figure II.4 - Synthesized indole based library (compounds 1-7 and 11-18), trypthopan (8), tryptamine (9) 
and trypthophan methyl ester (10). 
 
Compounds 13 and 14 were synthesized from the corresponding prenylated precursors 6 and 1, 
respectively, by treatment with hydrazine hydrate, to remove the phthalimide group, followed by 
alkaline hydrolysis, affording the desired products. Thus, the influence of the free amino acid group 
could be evaluated.  
In order to study the effect of the exocyclic double bond on the reactivity, some hydrogenated 
compounds were prepared. Therefore, compounds 15, 16, 17 and 18 were obtained by hydrogenation of 
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the corresponding prenylated precursors (4, 3, 7 and 1, respectively) under Pd/C at room temperature 
and atmospheric pressure. 
Scheme II.2 depicts the synthetic routes adopted for the synthesis of the indole based library. 
 
 
Scheme II.2 - Synthetic routes adopted for the synthesis of the indole based library. 
 
II.2.2 Radical scavenging assays 
The radical scavenging activity of the synthesized library was evaluated by in vitro assays with 
different methodologies. Table II.1 shows the results obtained for the screening assays against ROS, 
namely ROO ,̇ HOCl and 1O2. 
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Table II.1 - ROS scavenging activities of the synthesized indole library (IC50 in µM; Mean±SD, n = 3-4) 
 
Compound R1 R2 R3 R4 R5 ROO˙ HOCl 1O2 
 ORACa IC50 (µM) 
1 CO2Me Phth Phth H CH2CHC(Me)2 0.45 ± 0.05 7.18 ± 0.41 2307 ± 447 
2 H H H CH2CHC(Me)2 H 0.96 ± 0.07 26.2 ± 9.55 618 ± 94 
3 CO2Me H Ac CH2CHC(Me)2 H 0.21 ± 0.03 32.8 ± 6.82 777 ± 155 
4 H Phth Phth CH2CHC(Me)2 H --- 6.34 ± 1.54 --- 
5 H Phth Phth H H 1.46 ± 0.08 11.1 ± 0.78 --- 
6 CO2Me Phth Phth CH2CHC(Me)2 H 0.36 ± 0.01 34.3 ± 6.26 2859 ± 499 
7 CO2Me H Ac CH2CHCHPh H 0.44 ± 0.01 67.7 ± 9.24 971 ± 69 
8b CO2ˉ H H H H 2.74 ± 0.07 3.50 ± 0.40 992 ± 220 
9 H H H H H 1.86 ± 0.03 6.00 ± 0.60 682 ± 102 
10 CO2Me H H H H 2.60 ± 0.16 9.60 ± 0.76 1043 ± 320 
11 CO2Me H Ac H H 1.21 ± 0.06  ≈ 50 1559 ± 271 
12 CO2Me Phth Phth H H 1.09 ± 0.13 27.3 ± 4.84 943 ± 168 
13b CO2ˉ H H CH2CHC(Me)2 H 1.05 ± 0.05 4.13 ± 0.17 841 ± 59 
14b CO2ˉ H H H CH2CHC(Me)2 0.48 ± 0.04 4.56 ± 0.48 * 
15 H Phth Phth CH2CH2CH(Me)2 H --- 10.6 ± 4.80 1029 ± 216 
16 CO2Me H Ac CH2CH2CH(Me)2 H 0.28 ± 0.02 8.35 ± 1.08 718 ± 128 
17 CO2Me H Ac CH2CH2CH2Ph H 0.44 ± 0.07 14.2 ± 2.95 506 ± 44 
18 CO2Me Phth Phth H CH2CH2CH(Me)2 0.97 ± 0.09 3.75 ± 0.52 750 ± 128 
*Compound not tested; --- not active 
a Trolox was used as control (ORAC = 1) 
b Under physiological conditions this compound exists in the zwitterionic form 
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All compounds except 4 and 15 were shown to be effective scavengers of the ROO .̇ Indeed 
some were more active than trolox (used as control), and also more active than some NSAIDs possessing 
the indole ring, like indomethacin, etodolac and acemetacin.23 The scavenging activity order found for 
compounds 1 to 14 was: 8 > 10 > 9 > 5 > 11 ≈ 12 ≈ 13 ≈ 2 > 14 ≈ 1 ≈ 7 > 6 > 3. According to the 
obtained results, the compounds' library can be divided in two sets: the non-alkylated compounds 
(without the prenyl chain) and the alkylated (prenylated) ones. Figure II.5 shows the obtained results in 
the ROO -̇scavenging assay for compounds 5, 8, 11 and 14. 
 
 
Figure II.5 - ROO˙-scavenging activity of compounds 5, 8, 11 and 14. Each point represents the values 
obtained from four experiments performed in triplicate (mean ± SEM). 
 
The presence of a free amine in the side chain, as well as free indolic nitrogen is important for 
scavenging activity. Under these conditions (physiological pH), compounds 14 and 13 exist in solution 
in the zwitterionic form. The non-alkylated compounds revealed to be the best scavengers of ROO .̇ 
Indeed the protection of both nitrogen atoms (from the side chain C-3 and the indolic nitrogen N-1), 
combined with the lack of the carbomethoxy group at the side chain (C-3) seems to be detrimental for 
activity (compounds 4 and 15). 
In order to investigate the relevance of the unsaturated chain at the C-2 and N-1 position of 
indole, several hydrogenated compounds were prepared (compounds 15 to 18, figure II.4) and tested. 
The total order of reactivity found was 8 > 10 > 9 > 5 > 11 ≈ 12 ≈ 13 ≈ 18 ≈ 2 > 14 ≈ 1 ≈ 17 ≈ 7 > 6 > 
16 ≈ 3. The hydrogenated compounds 16, 17, 18 were shown to be effective scavengers of the ROO ,̇ 
and some with higher activities than the corresponding unsaturated compounds (compounds 18 and 1). 
These results indicate that the external double bond is not crucial for measured activity, and suggest that 
for the scavenging of ROO  ̇the indole nitrogen is the active redox center of indoles. The indole nucleus 
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is already reported as the reactive center towards radical species, and this reactivity has been attributed 
to its high resonance stability and very low energy barrier towards radical reactions.37 Nevertheless, the 
evaluated prenylated compounds possessing a free amine at the side chain (e.g. 13 and 2) have a potency 
close to that observed for Trolox, and most of the tested compounds are even more active than 
indomethacin (ORAC reported 0.17).23 Furthermore, the presence of a prenyl chain makes these 
compounds more lipophilic. Lipophilicity is a major determinant for the disposition and biological 
action of drugs, making them suitable for membranes protection against peroxidation. 
The same library was screened as scavenger of HOCl (table II.1). Scavengers of HOCl are of 
reassured relevance since most NSAIDs (indole derived) are not able to scavenge this ROS. 23 All the 
tested compounds were found to be active against HOCl, and all hydrogenated compounds (except 15) 
were more active than the corresponding unsaturated compounds. Table II.2 shows the chemical 
structures of the most and less active compounds against HOCl. 
 
Table II.2 - Chemical structures of the most and less active compounds against HOCl. 
Most active Less active 
 
 
IC50 = 3.50 ± 0.40 µM IC50 = 67.7 ± 9.24 µM 
 
The order of potencies found was 8 ≈ 18 > 13 ≈ 14 > 9 ≈ 4 > 1 > 16 ≈ 10 ≈ 15 ≈ 5 > 17 > 2 ≈ 12 
> 3 ≈ 6 >> 11 > 7. Considering that the reaction of amines with HOCl is well known,38 it was anticipated 
that compounds possessing a free amine on the side chain would show higher activity. Indeed 
compounds 8, 13, 9, 10 and 2 revealed to be potent scavengers of HOCl. The carboxylic acid at the side 
chain (C-3) (8 and 13), revealed to be important for activity since when the carboxylic acid is methylated 
(8 vs. 10) or is absent (13 vs. 2) its potency decreases. 
The influence of the side chains of the indole nucleus on the HO  ̇ scavenging ability by 
comparing melatonin with several analogs was previously evaluated. It was found that the 5-methoxy 
group as well the N-acetyl group at the side chain (C-3), were essential for melatonin to display potent 
HO  ̇scavenging activity.15 However, in the present study, the N-acetyl group, by itself, was detrimental 
for HOCl scavenging activity, as may be ascertained by comparing compound 10 with N-acetyl-
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methyltryptophan (11), and also for the lower activity found for compounds 3 and 7, suggesting that a 
different reaction mechanism is involved. 
Nevertheless, these results are in accordance to those of Poeggeler et al.,18 who demonstrated 
that tryptamine is a better HO  ̇scavenger in the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
(ABTS) competition assay than N-acetyltryptamine and 5-methoxytryptamine. On the other hand, the 
N-acetyl group may be physiologically important due to its preventing effect on the degradation of these 
compounds by monoamine oxidase. In that aspect, the replacement of the secondary amine by the N-
phthaloyl group may achieve the same protective effect, while maintaining an effective scavenging 
activity, as shown for compounds 1, 4, 5, 6, 12, 15 and specially 18. It was not possible to conclude the 
effect of the loss of saturationat the exocyclic double bond in the scavenging activity of this family of 
compounds. Compound 18 showed a high potency when compared to the corresponding unsaturated 
compound 1. The same was observed for compounds 16 and 3, and for compounds 17 and 7. However, 
compounds 4 and 15 showed inverted reactivity. The obtained results suggest that the observed 
reactivity with HOCl results from a conjugation of different functions within the tested substitution 
pattern and not from an isolated functionalization. 
This indole-based library was also evaluated as scavenger of 1O2. All the assayed compounds, 
except 4 and 5, were shown to be effective scavengers for this ROS, in a concentration dependent 
manner, and the sequence of activity found was 17 ≈ 2 ≈ 9 ≈ 16 ≈ 18 ≈ 3 > 13 ≈ 12 ≈ 7 > 8 ≈ 15 ≈ 10 > 
11 > 1 > 6.  
Since reactions with 1O2 could take place at the exocyclic double bond, the reactivity of 
hydrogenated compounds was investigated. Compounds 17, 16 and 18 were more active than the 
corresponding unsaturated compounds. From the activity results obtained, it is not possible to 
understand which structural motifs control the reactivity of the tested compounds with singlet oxygen. 
None of the tested compounds was able to scavenge O2˙̄  and in what concerns to H2O2 only a 
residual activity was found for some of the compounds in the highest tested concentration (2 mM). 
 
Next the synthesized library was evaluated against RNS. 
Table II.3 shows the results obtained for the scavenging activity of the synthesized library 
against RNS, in particular the scavenging effect of ˙NO and ONOOˉ. 
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Table II.3 – RNS scavenging activities of the synthesized indole library (IC50 in µM; Mean±SD, n=3-4). 
 
Compound R1 R2 R3 R4 R5 ˙NO 
ONOOˉ 
without NaHCO3 
ONOOˉ 
with NaHCO3 
  IC50 (µM) 
1 CO2Me Phth Phth H CH2CHC(Me)2 239 ± 7 --- 28 ± 10 
2 H H H CH2CHC(Me)2 H 1430 ± 108 905 ± 66 234 ± 46 
3 CO2Me H Ac CH2CHC(Me)2 H 980 ± 142 545 ± 118 162 ± 76 
4 H Phth Phth CH2CHC(Me)2 H --- --- 192 ± 31 
5 H Phth Phth H H --- 93 ± 36 41 ± 10 
6 CO2Me Phth Phth CH2CHC(Me)2 H --- --- 241 ± 93 
7 CO2Me H Ac CH2CHCHPh H --- 218 ± 26 36 ± 3 
8a CO2ˉ H H H H 1151 ± 203 32 ± 10 19 ± 2 
9 H H H H H 672 ± 105 32 ± 10 10 ± 3 
10 CO2Me H H H H --- 48 ± 7 13 ± 6 
11 CO2Me H Ac H H --- 223 ± 128 23 ± 9 
12 CO2Me Phth Phth H H --- 208 ± 49 30 ± 4 
13a CO2ˉ H H CH2CHC(Me)2 H 208 ± 26 95 ± 40 42 ± 23 
14a CO2ˉ H H H CH2CHC(Me)2 * * * 
15 H Phth Phth CH2CH2CH(Me)2 H 1526 ± 62 --- 237 ± 55 
16 CO2Me H Ac CH2CH2CH(Me)2 H --- 548 ± 154 315 ± 83 
17 CO2Me H Ac CH2CH2CH2Ph H --- --- 142 ± 24 
18 CO2Me Phth Phth H CH2CH2CH(Me)2 --- --- 14 ± 7 
*Compound not tested; --- not active 
a Under physiological conditions this compound exists in the zwitterionic form 
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From the studied compounds, only 1, 2, 3, 8, 9, 13 and 15 were able to scavenge ˙NO achieving 
the IC50 in the tested range, and the order of reactivity found was 13 ≈ 1 > 9 > 3 > 8 > 2 > 15. The 
presence of a prenyl chain is important for the activity against this RNS, on position N-1 as well as at 
position C-2, since compounds 13 and 1 are the most actives. The N-alkylated compounds are more 
active against ˙NO than those possessing indolic free nitrogen, with exception of compound 9, which 
has a free amine at the side chain. In addition, considering the IC50, the hydrogenated compound 15 is 
the less active, supporting that the loss of unsaturation is detrimental for the activity with this species. 
Nitric oxide is known as a nitrating agent in many processes and it has been used in the nitration of 
olefins as an economic and straightforwardly available source of nitrogen.39,40 This may explain the 
scavenging activity found for the prenylated compounds of this library.  
Concerning ONOOˉ, scavenging activity was observed for all the studied compounds when the 
study was carried in the presence of NaHCO3, plus under these conditions the activity increased. The 
aim of performing scavenging studies of ONOOˉ, in the presence of NaHCO3 is to simulate the 
physiological concentrations of CO2 due to its fast reaction in vivo with ONOOˉ with formation of 
CO3˙̄  and ˙NO2 leading to oxidation and nitration, respectively.
41 The fact that a scavenging of ˙NO2 
and CO3˙̄  can enhance the compounds' efficiency
42 may explain why the library compounds were 
more active in the presence of NaHCO3. Figure II.6 depicts the obtained results in the ONOO -̄
scavenging assay (in the presence of NaHCO3) for compounds 5, 7, 8 and 13. 
 
 
Figure II.6 - ONOOˉ scavenging activity (in the presence of NaHCO3) of compounds 5, 7, 8 and 13. Each 
point represents the values obtained from four experiments performed in triplicate (mean ± SEM). 
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The order of reactivity found was 9 ≈ 10 ≈ 18 ≈ 8 ≈ 11 ≈ 1 ≈ 12 ≈ 7 ≈ 5 ≈ 13 >> 17 ≈ 3 ≈ 4 > 
2 ≈ 15 ≈ 6 > 16. The results obtained for this library show that the presence of a free amine at the side 
chain, as well as a free indolic nitrogen atom is important for activity. For the scavenging of ONOO ,̄ 
alkylation at N-1 is detrimental. However when alkylation occurs at C-2 (compounds 18 and 1), 
leaving the N-1 position free, the reactivity of the indolic moiety is increased, since compound 12 is 
less active. The fact that the prenylated and hydrogenated compounds' activities were slightly different 
(4/15, 18/1 and 16/3) indicates that the reaction with this radical has a different mechanism than with 
˙NO, and that the indolic moiety is the crucial reaction center. 
 
II.2.3 Cyclic voltammetry assays 
The cyclic voltammetry methodology has been found to be an important tool for understanding 
the electrochemical behavior of compounds. 
In order to investigate how these compounds scavenge the chosen ROS, and explore their 
scavenging mechanisms, a cyclic voltammetry study was undertaken. Table II.4 shows the oxidation 
potentials obtained from the cyclic voltammograms of the screened indole library. 
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Table II.4 – Chemical structures and oxidation potentials of the indole library. 
 
Compound R1 R2 R3 R4 R5 Epox (V) vs. Ag/AgCl 
 1st peak 2nd peak 
1 CO2Me Phth Phth H CH2CHC(Me)2 0.930 --- 
2 H H H CH2CHC(Me)2 H 0.852 1.084 
3 CO2Me H Ac CH2CHC(Me)2 H 0.959 1.152 
4 H Phth Phth CH2CHC(Me)2 H 0.986 --- 
5 H Phth Phth H H 1.028 --- 
6 CO2Me Phth Phth CH2CHC(Me)2 H 1.016 --- 
7 CO2Me H Ac CH2CHCHPh H 1.011 --- 
8 CO2H H H H H 0.996 --- 
9 H H H H H 0.767 1.199 
10 CO2Me H H H H 1.055 --- 
11 CO2Me H Ac H H 0.967 --- 
12 CO2Me Phth Phth H H 0.999 --- 
13 CO2H H H CH2CHC(Me)2 H 1.008 --- 
14 CO2H H H H CH2CHC(Me)2 1.002 --- 
15 H Phth Phth CH2CH2CH(Me)2 H 0.979 --- 
16 CO2Me H Ac CH2CH2CH(Me)2 H 0.984 1.177 
17 CO2Me H Ac CH2CH2CH2Ph H 0.993 --- 
18 CO2Me Phth Phth H CH2CH2CH(Me)2 0.968 --- 
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All the compounds showed an oxidation potential peak lower than that observed for indole (Epox 
= 1.035 V), except for compound 10. The relative order found for the oxidation potential of the studied 
indoles was: 9 < 2 < 1 < 3 < 11 < 18 < 15 < 16 < 4 < 17 < 8 < 12 < 14 < 13 < 7 < 6 < 5 < 10. Tryptamine 
(9) and its derivative 2 show two peaks in the voltammograms, while its N-phthaloyl protected 
derivatives 4, 5 and 15 show only one peak (figure II.7). It suggests that the first oxidation peak is due 
to the nitrogen from the side chain and the second oxidation peak is due to the indolic nitrogen. 
 
 
Figure II.7 – Voltammograms of tryptamine (9) and its derivatives (compounds 2, 5, 4 and 15). 
 
For the tryptamine derivatives, it was observed that the presence of an alkyl substituent at the 
indolic nitrogen results in a lower oxidation potential (compounds 4 and 15 vs. compound 5), turning 
these compounds into better reducing agents. When the nitrogen atom of the side chain is protected with 
an electron withdrawing group, like phthaloyl, the first oxidation peak disappears and a decrease of the 
second oxidation potential is observed (compounds 2 vs. 4 and compounds 9 vs. 5). The same effect is 
observed for tryptophan derivatives. For these compounds that have no electron withdrawing groups at 
the side chain, it was observed that alkylation of the indole ring, either on N-1 or C-2 (compound 8 vs. 
compounds 13 and 14), did not significantly influence the oxidation potential (figure II.8). 
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Figure II.8 - Voltammograms of tryptophan (8) and its derivatives (compounds 13 and 14). 
 
However, when both the nitrogen and the carboxylic acid of the side chain are protected 
[compound 12 and 11 vs. tryptophan methyl ester (10)] a decrease in the oxidation potential was 
observed (figure II.9).  
 
 
Figure II.9 – Voltammograms of tryptophan methyl ester (10) and its N-protected derivatives (compounds 
11 and 12). 
 
This effect is more evident when alkylation occurs at C-2 position rather than at N-1 (compound 
6 vs. compound 1). Indeed, the N-alkylated and non-alkylated N-phthaloyl derivatives (compounds 6 
and 12) showed similar potentials. These results suggest that when the nitrogen at the side chain is 
protected with an electron withdrawing group the indolic ring becomes the redox center, responsible for 
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the electron donation of these compounds. Reduction of the double bond at C-2 (compound 18) led to a 
potential close to that observed for compounds 6 and 12 (figure II.10). 
 
 
Figure II.10 – N-phathaloyl methyl ester tryptophan (12) and its derivatives (compounds 6, 1 and 18). 
 
The only tryptophan derivatives showing two peaks on the voltammograms were compound 3 
and the corresponding hydrogenated compound (16). The substitution of the alkylic chain from 3,3-
dimethylallyl to phenylallyl leads to the increase of the oxidation potential (figure II.11). 
 
 
Figure II.11 – N-acetyl methyl ester trypthopan derivatives (compounds 3, 7, 16 and 17). 
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The cyclic voltammograms of the indole library demonstrated that the oxidation potential peak 
values were close to those of the non-substituted indole nucleus, but higher than those described for the 
antioxidant melatonin (Epox = 0.715 V). In addition, no reversibility was observed in the obtained 
voltammograms. The lack of reversibility is an advantage, meaning that once oxidized these species do 
not tend to receive electrons.31 
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II.3 Conclusions 
A library of tryptamine and tryptophan derivatives was prepared and evaluated for the 
scavenging activity against ROS and RNS. The tested indole derivatives share a heteroaromatic ring 
system, differing among them by the presence of diverse side chains with different functionalizat ion 
(figure II.12). The results obtained in the present study reveal a strong scavenging effect of tryptophan 
and tryptamine for the tested ROS and RNS, which activity varies in different extensions, depending 
on the substituents. Best results of HOCl scavenging were obtained for the tryptophan (8) and 
tryptophan derivative 18 with IC50s of 3.50 ± 0.4 and 3.75 ± 0.52 µM, respectively.  
Furthermore, the prenylated compounds 13 and 14 also demonstrated to be potent scavengers 
with IC50 of 4.13 ± 0.17 and 4.56 ± 0.48 µM, respectively. Although the position of the prenyl chain 
is not relevant for this ROS, these are relevant results since the presence of a prenyl chain turns these 
compounds more lipophilic. For the ROO˙ some compounds were more potent than trolox (control).  
The library was also evaluated against RNS and the best result was obtained for the scavenging of 
ONOOˉ, in the presence of NaHCO3, by the N-alkylated tryptophan (18), with an IC50 of 14 ± 6.8 µM, 
which demonstrated that the double bond is not crucial for the reactivity with this species. 
 
 
Figure II.12 – Indole-based library tested against ROS and RNS. 
 
Unquestionably, the potent free radical scavenging capacity found for the tested compounds 
relies mainly on their electron-rich indole moieties, which hold high resonance stability. On the other 
hand, the substituents at the indole backbone substantially change the reactivity, potency and 
efficiency of radical scavenging. The effect of the prenyl chain was sometimes favorable and others 
unfavorable, depending on the reactive species.  
The cyclic voltammetry showed that all the compounds have an oxidation potential peak lower 
than that observed for indole (Epox = 1.035 V), except for compound 10 (Epox = 1.054 V), but higher 
that those described for melatonin (Epox = 0.715 V). Tryptamine (9) and its derivative (2) presents two 
Chapter II   New indole derivatives as antioxidants agents 
47 
 
oxidation peaks, as well as tryptophan derivatives 3 and 16, meaning that these compounds can undergo 
two oxidation processes. No reversibility was observed in neither of the evaluated compounds. The lack 
of reversibility is an advantage, since once oxidized these species do not tend to receive electrons. 
The indole derivatives synthesized and tested in the present study were shown to be of 
reassuring importance for the development of new antioxidant drugs. 
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II.4 Experimental 
II.4.1 General 
Melting points were determined on a Reichert Thermovar apparatus and are uncorrected. 1H- 
and 13C-NMR spectra were recorded in CDCl3 or DMSO-d6 on a Bruker ARX 400 spectrometer at 400 
and 100.62 MHz respectively. Chemical shifts are expressed in parts per million (ppm) relative to 
tetramethylsilane (TMS). The coupling constants (J) are reported in Hertz (Hz). High resolution mass 
spectra were recorded on an AutoSpecQ spectrometer. IR spectra were run on an FT PerkinElmer 683 
instrument, with absorption frequencies expressed in reciprocal centimeters. The progress of all reaction 
was monitored by thin-layer chromatography, which was performed on Merck silica gel 60 F254 plates. 
Flash column chromatography was carried out on Merck silica gel 60 (230-400 mesh).  
A microplate reader (Synergy HT, BIO-TEK), with spectrophotometric, fluorimetric, and 
chemiluminometric detection, plus temperature control capacity, was used for the ROS and RNS 
scavenging assays. All the chemicals and reagents were of analytical grade. Dihydrorhodamine 123 
(DHR), 4,5-diaminofluorescein (DAF-2), 30% hydrogen peroxide, sodium hypochlorite solution, with 
4% available chlorine, diethylenetriaminepentaacetic acid (DTPA), 3-(aminopropyl)-1-hydroxy-3-
isopropyl-2-oxo-1-triazene (NOC-5), β-nicotinamide adenine dinucleotide (NADH), phenazine 
methosulfate (PMS), nitroblue tetrazolium chloride (NBT) and lucigenin were obtained from Sigma-
Aldrich. α,α’-Azodiisobutyramidine dihydrochloride (AAPH), histidine and trolox were obtained from 
Fluka Chemie GmbH. Fluorescein sodium salt and quercetin were obtained from Aldrich. 
Electrochemical experiments were conducted in a conventional three-electrode cell under argon 
atmosphere at 21°C, performed using a computer controlled potentiostat AUTOLAB (Eco-Chemie). 
The working electrode was a glassy carbon disk (BAS) polished with 0.05 µm alumina (Metkron) before 
each run, for linear cyclic voltammetry measurements. The auxiliary electrode was a platinum wire and 
the reference electrode was Ag/AgCl (BAS). 
  
Chapter II   New indole derivatives as antioxidants agents 
49 
 
Compounds 1-7, 11 and 12 were synthesized according to procedures described in the previous 
work,35 except compounds 8, 9 and 10 that were purchased from Sigma-Aldrich. 
 
II.4.2 General procedure for the deprotection of amino and carboxylic acid 
groups 
To a solution of Nb-phthaloyl-tryptophan methyl ester derivative, in 3:1 MeOH/DCM was added 
hydrazine hydrate (3.5 equiv.). The flask was capped and the solution stirred at room temperature for 
24 h, during which time a white precipitate formed. The solution was poured into water (73 mL) and 
extracted with DCM (4 x 15 mL). The combined organic extracts were dried over Na2SO4, filtered and 
concentrated. The resulting crude was purified by flash column chromatography (DCM/MeOH 10:1).43  
The product previously prepared was dissolved in 1 M NaOH aqueous solution (1 equiv.) and 
MeOH (0.6 M). The resulting mixture was stirred at room temperature overnight. The mixture was 
concentrated and acidified with 1 M HCl to pH 7-8 at 0ºC. The precipitate which formed was filtrated, 
washed with cold water and dried.44 
 
II.4.2.1 Synthesis of N-(3,3-dimethylallyl)-tryptophan (13) 
 
Compound 13 was isolated as light beige solid in 73% yield. 
m.p. 203-204ºC (MeOH) [lit. 201-202ºC (MeOH)];45  
1H NMR (400 MHz, DMSO-d6) δ 7.58 (d, J = 7.5 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.18 (s, 
1H), 7.11 (t, J = 8.0 Hz, 1H), 7.00 (t, J = 7.5 Hz, 1H), 5.36-5.26 (m, 1H), 4.69 (d, J = 6.1 Hz, 2H), 3.30 
(2H, under the water peak ), 2.99-2.88 (m, 1H), 1.81 (s, 3H), 1.71 (s, 3H); 
IR (KBr) 3448, 1720 cm-1; 
Spectral data were in accordance with the literature.45  
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II.4.2.2 Synthesis of 2-(3,3-dimethylallyl)-tryptophan (14) 
 
Compound 14 was isolated as light beige solid in 87% yield. 
m.p. > 300ºC (decomp.); 
1H NMR (400 MHz, DMSO-d6)  10.72 (s, 1H; NH), 7.50 (d, J = 7.6 Hz, 1H, H4), 7.25 (d, J = 
8.0 Hz, 1H, H7), 6.98-6.88 (m, 2H, H5 and H6), 5.29 (m, 1H, H11), 4.03-3.98 (m, 1H, H9), 3.30 (2H, 
under water peak ), 2.89-2.83 (m, 2H, H8), 1.70 (s, 3H, H12), 1.66 (s, 3H, H12); 
 13C NMR (101 MHz, DMSO-d6)  170.8 (C=O), 136.8 (C2), 135.5 (C7’), 131.7 (C11’), 128.1 
(C3’), 121.7 (C6), 120.0 (C11), 118.1 (C5), 117.7 (C4), 110.6 (C7), 105.0 (C3), 55.6 (C9), 26.5 (C8), 
25.5 (C10), 24.7 (C12), 17.8 (C12); 
IR (KBr) 1748 cm-1; 
HRMS (ESI-TOF) m/z 272.1528 [M+H]+ (calcd for C16H20N2O2 272.1525) 
 
II.4.3 General procedure for hydrogenation 
To a solution of tryptophan or tryptamine derivatives in MeOH (55 mM) was added 10% Pd/C 
(ca. 61 mg per mmol). The mixture was stirred at room temperature under H2 atmosphere. After starting 
material consumption, the reaction mixture was filtered and concentrated under reduce pressure. 
 
II.4.3.1 Synthesis of Na-(isopentyl)-Nb-phthaloyl-tryptamine (15) 
 
Purified by flash chromatography (n-hexane/Et2O, 3:2) affording compound 15 with 88% yield 
as yellow oil. 
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1H-NMR (400 MHz, CDCl3) δ 7.84-7.77 (m, 2H, H10), 7.72 (d, J = 7.5 Hz, 1H, H4), 7.69-7.64 
(m, 2H, H11), 7.28 (d, J = 7.8 Hz, 1H, H7), 7.19 (t, J = 7.8 Hz, 1H, H6), 7.10 (t, J = 7.5 Hz, 1H, H5), 
6.98 (s, 1H, H2), 4.05 (t, J = 7.3 Hz, 2H, H12), 3.98 (t, J = 7.8 Hz, 2H, H9), 3.13 (t, J = 7.8 Hz, 2H, 
H8), 1.69-1.63 (m, 2H, H13), 1.58-1.49 (m, 1H, H14), 0.92 (d, J = 6.6 Hz, 6H, H15); 
13C-NMR (101 MHz, CDCl3)  168.3 (C=O), 136.2 (C7’), 133.8 (C11), 132.2 (C10’), 127.8 
(C3’), 125.6 (C2), 123.1 (C10), 121.5 (C6), 119.1 (C4), 118.8 (C5), 110.7 (C3), 109.3 (C7), 44.3 (C12), 
39.0 (C13), 38.6 (C9), 25.6 (C14), 24.4 (C8), 22.4 (C15); 
IR (NaCl) 2955, 1770, 1714, 1396 cm-1;  
HRMS (EI) m/z 360.1836 [M]+ (calcd for C23H24N2O2 360.1838). 
 
II.4.3.2 Synthesis of Na-(isopentyl)-Nb-acetyl-tryptophan methyl ester (16) 
 
Purified by flash chromatography (Et2O) affording compound 16 with 85% yield as a colorless 
oil. 
 1H-NMR (400 MHz, CDCl3) δ 7.52 (d, J = 7.9 Hz, 1H, H4), 7.31 (d, J = 8.2 Hz, 1H, H7), 7.20 
(t, J = 7.5 Hz, 1H, H6), 7.10 (t, J = 7.4 Hz, 1H, H5), 6.88 (s, 1H, H2), 6.15 (d, J = 7.5 Hz, 1H, NH), 
4.96-4.91 (m, 1H, H9)), 4.08 (t, J = 7.3 Hz, 2H, H12), 3.69 (s, 3H, H11), 3.37-3.23 (m, 2H, H8), 1.95 
(s, 3H, H10), 1.72-1.67 (m, 2H, H13), 1.61-1.51 (m, 1H, 14), 0.96 (d, J = 6.6 Hz, 6H, C15); 
13C-NMR (101 MHz, CDCl3)  172.4 (C=O ester), 169.6 (C=O acetyl), 136.1 (C7’), 128.3 
(C3’), 126.2 (C2), 121.6 (C6), 119.1 (C5), 118.7 (C4), 109.5 (C7), 108.4 (C3), 53.1 (C9), 52.2 (C11), 
44.4 (C12), 38.9 (C13), 27.5 (C8), 25.6 (C14), 23.2 (C10), 22.4 (C15);  
IR (NaCl) 3286, 2955, 1745, 1656, 1469 cm-1;  
HRMS (EI) m/z 330.1941 [M]+ (calcd for C19H26N2O3 330.1943). 
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II.4.3.3 Synthesis of Na-(3-phenylpropyl)-Nb-acetyl-tryptophan methyl ester (17) 
 
Purified by flash chromatography (Et2O) affording compound 17 as a pale yellow oil with 88% 
yield. 
1H-NMR (400 MHz, CDCl3)  7.52 (d, J = 7.8 Hz, 1H, H4), 7.32-7.09 (m, 8H, H5, H6, H7, 
H15, H16 and H17), 6.87 (s, 1H, H2), 5.99 (d, J = 7.3 Hz, 1H, NH), 4.98-4.93 (m, 1H, H9), 4.10 (t, J = 
6.9 Hz, 2H, H12), 3.70 (s, 3H, H11), 3.37-3.26 (m, 2H, H8), 2.61 (t, J = 7.5 Hz, 2H, H14), 2.19-2.12 
(m, 2H, H13), 1.96 (s, 3H, H10); 
13C-NMR (101 MHz, CDCl3)  172.4 (C=O ester), 169.6 (acetyl), 140.8 (C14’), 136.2 (C7’), 
128.5 (C16), 128.4 (C3’), 128.3 (C15), 126.3 (C2), 126.1 (C17), 121.7 (C6), 119.2 (C5), 118.8 (C4), 
109.5 (C7), 108.6 (C3), 53.2 (C9), 52.3 (C11), 45.5 (C12), 32.9 (C14), 31.5 (C13), 27.6 (C8), 23.2 
(C10);  
IR (NaCl) 3392, 2926, 1744, 1656, 1469 cm-1;  
HRMS (EI) m/z 378.1948 [M]+ (calcd for C23H26N2O3 378.1943). 
 
II.4.3.4 Synthesis of 2-(isopentyl)-Nb-phthaloyl-tryptophan methyl ester (18) 
 
Purified by column chromatography (n-hexane/Et2O, 1:1) affording compound 18 with 83% 
yield as yellow solid.  
m.p. 51-53ºC; 
1H-NMR (400 MHz, CDCl3)  7.75-7.72 (m, 3H, NH and H10), 7.65-7.63 (m, 2H, H11), 7.48 
(d, J = 7.6 Hz, 1H, H4), 7.16 (d, J = 7.8 Hz, 1H, H7), 7.03-6.94 (m, 2H, H5 and H6), 5.21 (dd, J = 5.5, 
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10.0 Hz, 1H, H9), 3.79 (s, 3H, H12), 3.68-3.64 (m, 2H, H8), 2.74-2.57 (m, 2H, H13), 1.56-1.44 (m, 1H, 
H15), 1.38-1.30 (m, 2H, H14), 0.90 (d, J = 6.4 Hz, 3H, H16), 0.87 (d, J = 6.4 Hz, 3H, H16);  
13C-NMR (101 MHz, CDCl3)  169.7 (C=O ester), 167.4 (C=O phth), 137.3 (C7’), 135.1 (C2), 
133.9 (C11), 131.7 (C10’), 128.5 (C3’), 123.3 (C10), 121.0 (C6), 119.3 (C5), 117.8 (C4), 110.2 (C7), 
106.0 (C3), 52.7 (C9), 52.5 (C12), 38.6 (C14), 27.9 (C13), 24.0 (C8), 23.8 (C13), 22.3 (C16);  
IR (NaCl) 3401, 2955, 1715 cm-1;  
HRMS (EI) m/z 418.1894 [M]+ (calcd for C25H26N2O4 418.1893). 
 
II.4.4 ROS and RNS scavenging assays 
II.4.4.1 Peroxyl radical scavenging assay  
The ROO  ̇scavenging activity was measured by monitoring the effect of the tested compounds 
on the fluorescence decay resulting from ROO -̇induced oxidation of fluorescein and expressed as the 
“Oxygen Radical Absorbance Capacity” (ORAC), as previously described.46 ROO  ̇was generated by 
thermodecomposition of AAPH. Reaction mixtures in the sample wells contained the following reagents 
at the indicated final concentrations (in a final volume of 200 µL): fluorescein (61 nM), the tested 
compounds (0.25-2.00 µM), dissolved in acetone and subsequently diluted in 75 mM phosphate buffer, 
pH 7.4, and AAPH (19 mM). The mixture was preincubated in the microplate reader for 15 min at 37ºC. 
The fluorescence signal was then monitored every minute at the emission wavelength 528 ± 20 nm with 
excitation at 485 ± 20 nm until the total decay of fluorescence. Trolox (0.25-2.00 µM) was used as a 
control standard in each assay. Each study corresponds to four experiments, performed in triplicate. 
ORAC values were calculated according to a previous paper.47 The net protection provided by 
a putative antioxidant sample was calculated using the difference between the area under the 
fluorescence decay curve in the presence of the sample (AUCsample) and in its absence (AUCblank). 
Regression equations between net AUC and the concentration of the sample were calculated for all the 
compounds. ORAC values were calculated by using the standard curve of each assay. Final results were 
expressed in micromole of Trolox equivalents/µmol of compound. 
 
II.4.4.2 Hypochlorous acid scavenging assay 
The HOCl scavenging activity was measured by monitoring the effect of the tested compounds 
on HOCl-induced oxidation of DHR to rhodamine 123, as previously described.46 HOCl was prepared 
by adjusting the pH of a 1% solution of NaOCl to 6.2 with dropwise addition of 10% H2SO4. Lipoic 
acid was used as positive control. The inhibition (in percentage) of HOCl-induced oxidation of DHR by 
each compound was calculated. The results were expressed by the IC50 values. Each study corresponds 
to four experiments, performed in triplicate. 
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II.4.4.3 Singlet oxygen scavenging assay 
The 1O2 scavenging activity was measured by monitoring the effect of the tested compounds on 
the oxidation of non-fluorescent DHR to fluorescent rhodamine 123 by this ROS, as previously 
described.46 Ascorbic acid was used as positive control. The inhibition (in percentage) of 1O2-induced 
oxidation of DHR by each compound was calculated. The results were expressed by the IC50 values. 
Each study corresponds to four experiments, performed in triplicate. 
II.4.4.4 Superoxide radical scavenging assay 
The O2˙̄  was generated by the NADH/PMS system and the O2˙̄  scavenging activity was 
determined by monitoring the effect of the tested compounds on the O2˙̄  -induced reduction of NBT at 
560 nm as previously described.46 The antioxidant tiron was used as positive control. The inhibition (in 
percentage) of the NBT reduction to diformazan by each compound was calculated. The results were 
expressed by the IC50 values. Each study corresponds to four experiments, performed in triplicate. None 
of the tested compounds was able to scavenge this ROS. 
 
II.4.4.5 Hydrogen peroxide scavenging assay 
The H2O2 scavenging activity was measured by monitoring the effect of the tested compounds 
on the H2O2-induced oxidation of lucigenin as previously described.
46 The antioxidant ascorbic acid was 
used as positive control. The inhibition (in percentage) of the H2O2-induced oxidation of lucigenin by 
each compound was calculated. The results were expressed by the IC50 values. Each study corresponds 
to four experiments, performed in triplicate. Only a residual activity was found for some of the 
compounds in the highest tested concentration (2 mM). 
 
II.4.4.6 Nitric oxide scavenging assay 
The ˙NO scavenging activity was measured by monitoring the effect of the tested compounds 
on ˙NO-induced oxidation of non-fluorescent DAF-2 to the fluorescent triazolo fluorescein (DAF-2T), 
as previously described.46 Rutin was used as positive control. The inhibition (in percentage) of ˙NO 
induced oxidation of DAF-2 by each compound was calculated. The results were expressed by the IC50 
values. Each study corresponds to four experiments, performed in triplicate. 
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II.4.4.7 Peroxynitrite scavenging assay 
The ONOOˉ scavenging activity was measured by monitoring the effect of the tested 
compounds on ONOOˉ-induced oxidation of non-fluorescent DHR to fluorescent rhodamine 123, as 
previously described.46 Ebselen was used as positive control. In a parallel set of experiments, the assays 
were performed in the presence of 25 mM NaHCO3 in order to simulate the physiological CO2 
concentrations. The inhibition (in percentage) of ONOOˉ-induced oxidation of DHR by each compound 
was calculated. The results were expressed by the IC50 values. Each study corresponds to four 
experiments, performed in triplicate. 
 
II.4.5 Cyclic voltammetry 
Tryptophan and tryptamine derivatives were dissolved in acetone and further diluted in a 
supporting electrolyte, consisting of a LiClO4, reaching a final concentration of 1 mM. Deoxygenation 
of the solutions at the cell was achieved by bubbling argon for at least 5 min.  
Cyclic voltammograms were obtained by a single cycle performed at a scan rate of 100 mV s -1. 
For the scan rate studies, the scan rate was varied from 10 to 150 mV s-1. Voltammetric scans were 
carried out in the potential interval of -0.1 to +1.5 V versus Ag/AgCl. 
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III.1 Introduction 
III.1.1 Cyclooxygenase and non-steroidal anti-inflammatory drugs 
Inflammation is the immune system’s response to infection and injury and has been implicated 
in the pathogeneses of arthritis, cancer, and stroke, as well as in neurodegenerative and cardiovascular 
diseases.1 Inflammation is an intrinsically beneficial event that leads to removal of pernicious factors 
and renewal of tissue structure and physiological function. It is characterized by five signs: pain, redness, 
immobility (loss of function), swelling and heat. These symptoms are caused by the rapid influx of blood 
granulocytes, typically neutrophils, followed by monocytes, which mature into inflammatory 
macrophages that subsequently proliferate and thereby affect the functions of resident tissue 
macrophages.1 
Prostaglandins (PGs) play a key role in the generation of the inflammatory response. Their 
biosynthesis is significantly increased in inflamed tissue, and they contribute to the development of the 
cardinal signs of acute inflammation.2 The initial step in biosynthesis of prostanoids (subclass of 
eicosanoids consisting in PGs and thromboxane A2 (TXA2)) is the liberation of arachidonic acid (AA), 
a 20-carbon unsaturated fatty acid, from the phospholipids of the cell membrane catalyzed by 
phospholipase A2. The subsequent and key step is the biotransformation of AA by cyclooxygenase 
(COX), also known as prostangladin endoperoxide synthase. AA is first oxidized to the unstable PGG2, 
at the COX active site, that diffuses to the peroxidase (POX) active site in which is reduced to PGH2 
(figure III.1).3,4  
There are four principal bioactive PGs generated in vivo: prostaglandin E2 (PGE2), prostacyclin 
(PGI2), prostaglandin D2 (PGD2), and prostaglandin F2α (PGF2α). They are ubiquitously produced and 
act as autocrine and paracrine lipid mediators to maintain local homeostasis in the body.5 The presence 
of the different prostaglandin synthases varies from tissue to tissue. For example, lung and spleen tissues 
are able to synthesize the whole range unlike other tissues. Platelets synthesized mainly TXA2, while 
blood vessel walls primarily produce PGI2. PGE2 is an important mediator in the kidney and in 
inflammation, whereas PGD2 is produce in mast cells and in the brain.
6 
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Figure III.1 – Prostaglandin biosynthetic cascade (adapted from FitzGerald 2003).7 
 
In 1971, Vane demonstrated that the mechanism of action of aspirin and related non-steroidal 
anti-inflammatory drugs (NSAIDs) is through COX blockade, hence inhibition of prostanoid synthesis.8 
After these findings, a new course has been given to the field of inflammation research with the 
discovery that two isoforms of COX, a constitutive form (COX-1) and an inducible form (COX-2), 
exist.4 The constitutive isoform, COX-1, is expressed in nearly all tissues including the kidney, spleen, 
stomach, liver, lung, heart and brain, and has clear physiological functions. For example, in the kidney 
and in the stomach, prostanoids synthesized by COX-1 acts as vasodilators. COX-1 performs the 
“housekeeping” function by synthesizing prostaglandins that regulate normal cell activity. Its activity 
leads, for instance, to the production of PGI2 which, when released by the endothelium, is anti-
thrombogenic9 and when released by the gastric mucosa, it is cytoprotective.10 Additionally, COX-1 in 
platelets leads to TXA2 production, causing aggregation of the platelets to prevent inappropriate 
bleeding.11 Contrariwise, COX-2 is induced by inflammatory stimuli, hormones, and growth factors, 
and is the most important source of prostanoid formation in inflammation and in proliferative diseases, 
such as cancer.12 Up-regulation of COX-2 expression has also been implicated with a number of other 
pathophysiological conditions such as schizophrenia and major depression,13 ischemic brain injury,1 4  
and diabetic peripheral nephropathy.15 COX-2 has been identified as therapeutic target by researchers 
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to intervene with several disease conditions, demonstrating that the future of selective COX-2 inhibitors 
is not limited to management of inflammation and pain. 
COX-1 and COX-2 are isoenzymes, therefore they are genetically independent proteins. The 
genes in humans for the two enzymes are located on different chromosomes (chromosome 9 and 1, for 
COX-1 and COX-2, respectively) and show different properties.16,17 Both isoforms are dimeric and each 
monomer has a molecular weight of 71 kDa. COX-1 and COX-2 are almost identical in length, with just 
over 600 amino acids, of which 63% are in identical sequence.18 Twenty-four residues line the COXs 
active site with only one difference between both isoforms, an isoleucine (Ile) at position 523 in COX-
1 and a valine (Val) at the same position in COX-2. This difference has consequences for the size and 
shape of NSAID binding site. The COX-2 structure revealed a second internal pocket extending off the 
binding site. In this isoform, the volume of primary inhibitor binding site and the side pocket is 
calculated to be 394Å, whereas the volume of NSAID binding site of COX-1 is 316Å. The side pocket 
contributes significantly to the larger volume of this site in COX-2, although the central channel is also 
larger, 371Å, a 17% increase compared to COX-1 (figure III.2).19 
 
 
Figure III.2 – Contour of COX-1 and COX-2 cyclooxygenase active sites. The solvent-accessible surfaces 
of the COX-1 and COX-2 active sites, with important surrounding amino acid residues, are shown. 
Highlighted in yellow on the left is the effect of Ile523 on COX-1 and the effect of Val523 in COX-2, on the 
right side.2 
 
The extensive structural analysis of the two COX isoforms allowed the design of drugs that 
reduce inflammation without removing the protective PGs in the stomach and kidney produced by COX-
1. 
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Kurumbail et al.20 established a classification of four classes of COX inhibitors, based on their 
interaction with the protein: i) irreversible inhibitors of COX-1 or COX-2, such as aspirin. Aspirin 
acetylates irreversibly the enzyme, blocking its activity; ii) reversible, competitive inhibitors of COX-1 
and COX-2, such as indomethacin, naproxen, ibuprofen, diclofenac. These drugs compete with AA for 
binding in the COX active site; iii) slow time-dependent, reversible inhibitors of COX-1 and COX-2, 
such as indomethacin and flurbiprofen. These seem to act by ionic interactions between their acid 
carboxylic group and the arginine residue of the enzyme; iv) slow, time-dependent irreversible inhibitors 
of COX-2. This group includes the coxibs (selective inhibitors of COX-2), such as, celecoxib, rofecoxib, 
valdecoxib, etoricoxib and the coxib-like structure SC-558 (figure III.3).3,21 
 
 
Figure III.3 - Chemical structures of some classical NSAIDs and coxibs. 
 
For a long time the presence of a carboxyl group was thought to be a pre-requisite for the 
classical NSAIDs. Today it is known that this functional group accounts for the formation of a salt 
bridge between the carboxylic group of the drug and Arg120 at the bottom of the active site of the 
enzyme thus, generating COX-1 inhibition.22 Therefore, in place of the carboxyl group of the classical 
NSAIDs, the structure of the COX-2 selective inhibitors contain a sulfonamide group (celecoxib, 
valdecoxib, SC-558) or a methylsulfone (rofecoxib, etoricoxib). The sulfur-containing substituent in the 
phenyl rings of these drugs binds into the side pocket of the catalytic site of COX-2 but interact weakly 
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with the active site of COX-1.20 Thus, they are potent inhibitors of COX-2 and weak inhibitors of COX-
1. 
Figure III.4 depicts a schematic representation of SC-558 (A) and indomethacin (B) binding to 
COX-2. 
 
 
Figure III.4 - Schematic representation of SC-558 (A) and indomethacin (B) binding to COX-2.23 
 
Administration of NSAIDs, for example to treat inflammatory diseases such as osteoarthritis or 
rheumatoid arthritis, unavoidably leads to a lack of the prostaglandins required for the physiological 
functions. Therapeutic effects and side-effects of this class of anti-inflammatory drugs are closely related 
to their biochemical mechanism of action. Long-term NSAIDs users suffer from a high incidence of 
gastrointestinal tract irritation that may lead to ulceration and bleeding.24 Due to a reduced production 
of PGs, such as PGI2, PGE2 and PGD2, in the regulation of renal blood circulation, the rate of 
glomeruleric filtration is reduced. In patients with reduced renal function, this leads to retention of water, 
hypertension and, in some cases, to renal failure.25,26 
Although coxib compounds benefit from the lack of gastrointestinal toxicity, this risk/benefit 
balance was recently considered negative as a result of the increased incidence of cardiovascular events. 
Consequently, rofecoxib and valdecoxib were removed from the market. The mechanism underlying the 
adverse cardiovascular effects is due to an imbalance between COX-1 thrombotic TXA2 in platelets and 
COX-2 derived vasoprotective PGI2 in endothelium.
27 
Therefore, the discovery of new COX-2 selective inhibitors, without cardiac effects, are crucial 
in the future of anti-inflammatory therapies. 
For the development of a new class of inhibitors the choice of a scaffold and of its substitution 
pattern are of almost importance. When considering the vast amount of work published concerning 
specific COX-2 inhibitors, several heterocyclic scaffolds have been investigated, such as pyrrole,28  
imidazole,29 thiazolidine,30 pyrazole (celecoxib analogs)31 and indole (indomethacin analogs)32 (figure 
III.5). 
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Figure III.5 – Chemical structures of several heterocyclic scaffolds investigated as selective COX-2 
inhibitors. 
 
From these, the indole ring is considered a privileged structure and an attractive scaffold for 
drug discovery. Structural diversity can easily be achieved via ring substitution and consequently diverse 
biological activities are associated with indole-derived drug-like molecules, including COX-1 and COX-
2 inhibition. 
Thus, further investigation should be carried on indole-based compounds as COX-2 selective 
inhibitors. One of the aims of this thesis was the development of novel and selective COX-2 inhibitors 
and indole was selected as scaffold for that purpose.  
 
III.1.2 Fluorine in medicinal chemistry  
Organic fluorinated compounds have received great attention in all fields of science. Currently 
approximately 30% of all agrochemicals and 20% of pharmaceuticals contain fluorine. Incorporation of 
fluorine has also been applied in material sciences such as the useful polymer polytetrafluoroethylene 
(Teflon®) that is perfluorinated and exemplifies the strength of the C-F bond.33 
Flourine is a small atom (van der Waals radius of 1.47Å) and the most highly electronegative 
element in the Periodic Table (3.98 Pauling scale). Covalently bound fluorine occupies a smaller volume 
than a methyl, amino, or hydroxyl group, but is larger than a hydrogen atom (van der Waals radius of 
1.2Å). 
Traditional medicinal chemistry was based on the use of natural compounds or closely related 
derivatives, where there is a low abundance of compounds containing fluorine, thus fluorinated 
compounds were rare in medicinal chemistry until the 1970s.34 Currently, many fluorinated compounds 
are synthesized routinely in pharmaceutical research and are widely used in treatment of diseases, such 
as anti-cancer agents,35 antidepressants, anti-inflammatory agents, anesthetics and central nervous 
system drugs.36 Figure III.6 shows some representative examples of drugs containing fluorine. 
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Figure III.6 – Some marketed drugs containing fluorine. 
 
The fast progress in this field is promoted by the development of new fluorinated reagents and 
fluorination processes increasing the range of synthetic fluorinated building blocks.37 
Despite the fact that fluorine is larger than hydrogen, several studies have demonstrated that it 
is a reasonable hydrogen mimic and is expected to cause minimal steric perturbations with respect to 
the mode of binding of the compound to a receptor or enzyme.38 
Introduction of fluorine atoms into molecules improves metabolic stability, bioavailability and 
protein-ligand interactions.39 One example of the importance of fluorine in determining metabolic 
stability is demonstrated in the development of the COX-2 selective inhibitor, celecoxib. Penning et al.40 
observed that a substitution of the fluorine on the benzene ring for a methyl group reduced the plasma 
half-life in rat from 221 to 3.5 hours (figure III.7). 
 
 
Figure III.7 – Chemical structures of SC-58125 and celecoxib. 
 
Taking in consideration the fact that the selective COX-2 inhibitor (celecoxib) possess a CF3 
group and due to the important role of fluorine in drug discovery, it was envisaged to include a 
trifluoromethylated chain at the nitrogen atom ring. 
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III.1.3 The sulfonyl group in medicinal chemistry and synthetic approaches 
towards sulfonylation 
Compounds containing the sulfonyl group, which mainly include sulfones and sulfonamides, 
have been studied for decades due to their significant role in developing therapeutics for a number of 
diseases. 
Since the introduction in the 1930s of the so-called “sulfa-drugs” such as sulfanilamide and 
Prontosil (figure III.8), sulfonyl-containing compounds have found widespread use in the 
pharmaceutical industry and the motif is still considered valuable and safe for drug development.41 
Sulfonyl group has been used as a biologically active moiety in the development of drugs for 
the treatment of bacterial infections,42 in the design of inhibitors of carbonic anhydrases43 (that are useful 
as diuretics, or in the treatment and prevention of a variety of diseases such as glaucoma, epilepsy, 
congestive heart failure, mountain sickness, gastric and duodenal ulcers, neurological disorders, and 
osteoporosis, among others),44 and inhibitors of protein phosphatase methylesterase-1, implicated in a 
wide range of pathologic processes, including tumerigenicity.45 Recent studies also suggested that this 
class of compounds represents promising antitumor agents.46,47 Further, some studies demonstrated that 
sulfonyl is a key functional group for the various ligands binding at human 5-HT6 serotonin receptors, 
which could be involved in central neural systems pathologies related to this receptor, for example, 
schizophrenia, convulsive disorders, memory, cognition, sensory processing, circadian rhythm, brain 
development, and cardiovascular function.48,49 Moreover, sulfonyl-containing compounds have been 
found in the design of numerous anti-Alzheimer50 and anti-HIV51,52 agents. 
Figure III.8 depicts some available marketed drugs containing the sulfonyl group. 
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Figure III.8 - Some marketed drugs containing the sulfonyl group. 
 
Despite the great importance of sulfonyl-containing compounds, a general and versatile method 
for their preparation does not exist.  
The most common route for the synthesis of sulfonamides involves the reaction of sulfonyl 
chlorides with ammonia, followed by reaction with primary or secondary amines. This approach requires 
the availability of the sulfonyl chloride, some of which can be hard to prepare and difficult to store or 
handle. The frequently used aryl sulfonyl chlorides can be prepared via electrophilic aromatic 
substitution using [HSO3]
+ or [ClSO2]
+ synthons.53 However, this is generally limited to electron-rich 
aromatic substrates and those that can tolerate the harsh acidic conditions. Side reactions are also 
possible due to the presence of the base or the liberated chlorine nucleophile. Moreover, the 
corresponding disulfonimide is stated to be a byproduct in reactions of sulfonyl chlorides with primary 
amines or ammonia.54 Sulfuryl chlorides can also be prepared by oxidative chlorination of sulfur 
compounds, such as thiols, sulfides, thioacetates and thiocarbamates.55-57 
These concerns have led to the development of several synthetic routes to prepare sulfonamides 
(Scheme III.1). Thus, sulfonamides are formed: i) by reaction of sulfinic acid salts with hydroxylamine -
O-sulfonic acid;58 ii) by synthesis59 and reduction of arylsulfonyl azides;60 iii) from aromatic and 
aliphatic sulfinic acid salts using bis(2,2,2-trichloroethyl)azodicarboxylate as an electrophilic nitrogen 
source;61 iv) from alkyl or aryl halides by means of sodium 3-methoxy-3-oxopropane-1-sulfinate transfer 
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reagent;62 v) by the radical addition of organo halides to pentafluorophenyl vinylsulfonate followed by 
substitution of the pentafluorophenyl moiety by amines;63 vi) by sulfamoylation of aromatics using 
sulfamoyl chloride;64 vii) using alkyl/arylsulfonylimidazoles as sulfonyl transfer reagents;65 viii) from 
the reaction of sulfonic acids with isocyanides, in the presence of water;66 ix) from the reaction of 
sulfonic acids and amines using cyanuric chloride (TCT)-DMF adduct;67 x) from one-pot reaction from 
thiols using 1,3-dichloro-5,5-dimethylhydantoin (DCH),68 trichloroisocyanuric acid (TCCA),69 H2O2-
POCl3 system,
70 or N-chlorosuccinimide (NCS).71 
 
 
Scheme III.1 – Several routes of sulfonamide synthesis (adapted from Katritzky 2004).72 
 
Although these additional synthetic routes have proven to be of great utility for specific substrate 
classes, sulfonic acids and sulfonyl chlorides are rarely introduced into an advanced intermediate via C-
S bond formation. Therefore, the diversity of sulfonamide functionality in pharmaceutical discovery is 
actually limited and cannot be readily varied at both nitrogen and sulfur in the final stage of a library 
synthesis. 
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Barrett et al.73 reported a one-pot sulfonamide formation from aryl or heteroaryl halides, which 
involves the use of Grignard reagents with sulfur dioxide, sulfuryl chloride and secondary amines 
(scheme III.2). 
 
 
Scheme III.2 – One-pot sulfonamide synthesis reported by Barrett et al.73 
 
However, this method requires the use of sensitive organometallics, which can be incompatible 
with polar functionalities, and the use of hazardous and difficult to handle sulfur dioxide gas.74 
During the course of this work, Willis et al.75-77 described an interesting procedure using 
DABCO-bis(sulfur dioxide), DABSO, as the sulfur dioxide source in several organic transformations 
(scheme III.3). Since the limitation of sulfur dioxide application in organic synthesis is mainly due to 
the difficulties associated with the handling and use of this toxic gaseous reagent, the use of DABSO, a 
bench-stable solid, constituted a breakthrough in the introduction of sulfur dioxide into simple organic 
molecules. 
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Scheme III.3 – Some applications of DABSO in organic synthesis, reported by Willis et al.75-77 
 
Although DABSO constitutes a major advance in the synthesis of sulfur-containg compounds, 
this reagent presents an important limitation since it does not work with anilines or aliphatic amines. 
Thus, the synthesis of sulfonamides is only possible via a sulfonyl chloride intermediate or via an N-
aminosulfonamide deprotection sequence (scheme III.3C). 
Wu et al.78 also applied DABSO for the synthesis of N-aminosulfonamides via a palladium-
catalyzed three-component coupling of arylboronic acids, sulfur dioxide and hydrazines in the presence 
of a balloon of dioxygen. The authors proposed a mechanism for this reaction represented in scheme 
III.4. 
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Scheme III.4 – Mechanism for the palladium-catalyzed reaction of arylboronic acids, DABSO and 
hydrazines, proposed by Wu et al.78 
 
A transmetallation of Pd(II) with arylboronic acid occurs first generating a Pd(II) species A 
(sheme III.4). Formation of the intermediate B results from the coordination and insertion of sulfur 
dioxide. Then a nucleophilic attack of hydrazine takes place affording the coupling product and Pd(0). 
The latter is oxidized in the presence of dioxygen to afford Pd(II), which re-enters the catalytic cycle. 
The same authors also published a similar methodology for the synthesis of N-
aminosulfonamides but instead of using DABSO they used potassium metabisulfite as the sulfur dioxide 
source.79 However, this reaction presents the same limitation as with DABSO, since it only affords N-
aminosulfonamides. 
 
In this thesis studies were carried towards the synthesis of a versatile intermediate that would 
allow the preparation of several sulfonyl-containing compounds under mild conditions. 
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III.2 Results and discussion 
This subchapter includes the discussion of the results obtained on the study for the development 
of new COX-2 selective inhibitors. This included the library synthesis, the biological evaluation and 
rationalization of the obtained data. During this study several challenges emerged, leading to the 
investigation of a reaction mechanism as well as the exploration of new synthetic routes. 
Thus, this subchapter is divided in three main subjects: i) synthesis, biological evaluation, 
docking and STD-NMR studies of an indole based library as COX-2 selective inhibitors; ii) mechanistic 
investigation of the reaction of indole with trifluoromethylated olefins and; iii) studies towards a new 
methodology for the synthesis of sulfonyl-containing compounds. 
 
III.2.1 Synthesis, biological evaluation, docking and STD-NMR studies of an 
indole based library as COX-2 selective inhibitors 
The initial strategy envisaged the preparation of an indole-based library involving substitution 
of the ring in order to generate a "Y shape" structure similar to selective COX-2 inhibitor SC-558. Two 
substitution patterns were considered (A and B), concerning the inclusion of three substituents to afford 
three different interaction regions and relying on modification at Region III (figure III.9). 
 
 
Figure III.9 – Proposed substitution pattern for the indole library. 
 
Following detailed analysis of the reported inhibitor structures and previous theoretical studies 
(data not shown), the pattern included substitutions at positions: C-3 (Region I) by a p-halobenzyl group 
in order to fill the hydrophobic channel while exploring other possible hydrophobic interactions with 
residues at this cavity; C-5 position of the indole ring (Region II). According to previous reports, a 
methylsulfone80 or a sulfonamide seem to be crucial for selectivity,81-83 and comparing to indomethacin 
(methoxy group at C-5) would allow an extension of this ring, long enough to fill properly the selective 
pocket and allowing interaction with key residues (His90, Gln192 and Arg513). Additionally, the 
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modification on the nitrogen atom (Region III, pattern A) by an allyl chain carrying a trifluoromethyl 
group at the end of the chain, was expected to give higher mobility and chain extension. The N-
substitution intended to increase the selectivity for COX-2 by establishing unfavourable interactions 
with Arg120 (important for COX-1 inhibition), while enhancing the steric interaction with Ile523 (COX-
1). Finally, C-2 substitution was also considered (Region III, pattern B), since a p-halobenzyl chain at 
C-2 would have the ideal shape for filling the hydrophobic pocket (figure III.4A).  
In order to establish a relation between the spatial distribution of the previously described 
functional groups, related with COX inhibition, activity studies were performed against both COXs 
isoforms and the results were rationalized based on docking and NMR studies. 
 
III.2.1.1 Synthesis of the indole-based library 
The first library (pattern A, figure III.9) was divided in two groups, those carrying a 
methylsulfone at C-5 and those with a sulfonamide group at the same position. The library synthesis 
involved three main steps: the introduction of a sulfonamide/methylsulfone at C-5, for which no direct 
sulfonylation has yet been reported for the indole nucleus; regioselective alkylation at C-3 and alkylation 
of N-1. The second library (pattern B, Figure III.9) relied on the exploration of substitution at C-2 
position of indole which was achieved via dialkyaltion of compounds 5 and 7. 
At the time the synthesis was performed no direct method was been reported for the insertion of 
the groups –SO2NH2 and –SO2Me at position C-5 of the indole ring. Thus, the 1H-indole-5-sulfonamide 
(5) was prepared according to a reported procedure,84 consisting on the chlorosulfonation of position C-
5 of 1-acetylindoline (1), followed by treatment with a solution of ammonium hydroxide, amide 
hydrolysis and oxidation of the indoline to the indole derivative 5 in 33% yield (overall yield) (scheme 
III.5) 
 
 
Scheme III.5 – Synthetic scheme followed for the synthesis of 1H-indole-5-sulfonamide (5). 
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For the synthesis of 5-(methylsulfonyl)-1H-indole (2) it was adopted a method reported by Ma 
et al.85 that consist in a C-S coupling between aryl halides and sulfinic acid salts via L-proline-promoted 
CuI-catalyzed reaction. The reaction of 5-iodoindole (6) with sodium methanesulfinate afforded 5-
(methylsulfonyl)-1H-indole (7) in 92% yield (scheme III.6). 
 
 
Scheme III.6 – Synthesis of 5-(methylsulfonyl)-1H-indole (7). 
 
The synthetic procedures for alkylation of C-3 usually involve magnesium salts prepared by 
reaction of the indole with a Grignard reagent.86 The magnesium salts tend to give C-3 substitution, 
rather than N-substitution, presumably because of the tight coordination of magnesium at nitrogen that 
reduces its nucleophilicity. 1-Lithioindoles are equally useful but, the position of attack depends on both 
solvent and the nature of the electrophile. C-Alkylation is favored in the order Mg2+ > Li+ > Na+ > K+.86 
The first approach for the synthesis of indole derivatives substituted at C-3 position consisted 
of the reaction of 5-(methylsulfonyl)-1H-indole (7) with n-BuLi, in dry THF, at -78ºC for 30 min. After 
that time, a solution of p-chlorobenzyl bromide was added and the mixture was warmed up to room 
temperature. This reaction afforded the N-substituted derivative (scheme III.7) instead of the desired 
product. The product, 1-(4-chlorobenzyl)-5-(methylsulfonyl)-1H-indole (9) was obtained in 63% yield 
as a white solid. 
 
 
Scheme III.7 – Reaction of 5-(methylsulfonyl)-1H-indole (7) with n-BuLi and p-chlorobenzyl bromide. 
 
Since the reaction with the indole lithium salt afforded exclusively the N-alkylated product, the 
next choice relied on the formation of indole magnesium salt. Therefore, 5-(methylsulfonyl)-1H-indole 
(7) was reacted with PhMgBr in dry THF, at -78ºC, for 30 min. Then, a solution of p-chlorobenzyl 
bromide, in dry THF, was added and the mixture was warmed up to room temperature for 24 h. No 
product formation was observed after TLC control. The next attempt consisted of changing the Grignard 
reagent. Thus, MeMgI was used instead of PhMgBr. The same conditions of the previously experiment 
were used. After stirring for 3 h at room temperature no product formation was observed by TLC, 
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therefore, the reaction was heated to 50ºC and was let at that temperature overnight. Even so no product 
formation was observed.  
After searching in the literature for alternative methods a report was found concerning to the 
regioselective synthesis of 3-alkylindoles mediated by zinc triflate.87 The authors have developed a 
simple one-pot procedure for the direct formation of 3-alkylindoles from indole and alkyl halides that 
can react by a SN1-like pathway. The indole nitrogen does not require prior protection and the avoidance 
of strong bases for deprotonation permits compatibility with a wide range of functional groups.  
Mechanistically, the authors proposed that zinc activates the halide and also coordinates to the 
indole nitrogen. They observed that zinc species are serving as a Lewis acid in activating the halide, by 
1H-NMR experiments. When zinc triflate (1 equiv.) is added, the proton spectrum of prenyl bromide 
immediately shows additional sets of signals. Also, in the case of the less acidic zinc acetate, the same 
changes only began to appear after 2 h. On the other hand, no changes in 1H-NMR spectrum were 
observed with zinc triflate and an unactivated halide such as isoamyl bromide. Zinc triflate also plays 
an important role in the formation indolylzinc species, fact that it is evidenced by the poorer yield of the 
reaction with N-methylindole, which cannot form an indolylmetal salt. Furthermore, several metals that 
form stronger Lewis acidic triflates than zinc were poorer reagents.87 
Therefore, this procedure mediated by zinc triflate, in the presence of Hünig’s base and 
tetrabutylammonium iodide, was applied for the regioselective alkylation of indoles derivatives 5 and 7 
(scheme III.8). 
 
 
Scheme III.8 – Synthesis of 3-alkylindole derivatives 11a-g. 
 
Several attempts were made to improve the yield of these compounds, such as reaction 
temperature and solvent, since compounds 5 and 7 are not soluble in toluene. At room temperature, no 
reaction occurred. At higher temperatures (> 50ºC), as well as in more polar solvents (DMF, THF), 
compounds 11a-f were obtained with lower yields, since that in these reaction conditions the formation 
of the dialkylated side-product (positions C-3 and C-2) is favored. Reaction of 5-bromoindole (10) with 
Chapter III   New indole derivatives as cyclooxygenase inhibitors 
78 
 
4-(bromomethyl)benzenesulfonamide was performed at room temperature since this indole is soluble in 
toluene, also no formation of the dialkylated side-product was observed. 
In order to proceed to N-alkylation, the sulfonamide derivatives would require additional 
protection-deprotection steps of the amine group. Celecoxib and valdecoxib possess a sulfonamide 
group while rofecoxib and etericoxib have a methylsulfone (figure III.3). Thus, at this stage it was 
decided to focus on the methylsulfones derivatives for further functionalization at N-1. To perform the 
N-alkylation of compounds 11a-c, different approaches were tested such as the Mitsunobu reaction. 
The Mitsunobu reaction consists in the formation of C-O, C-S, C-N, or C-C bond by the 
condensation of an acidic component with a primary or a secondary alcohol in the presence of 
triphenylphosphine (or another suitable phosphine) and diethyl azodicarboxylate (DEAD) or diisopropyl 
azodicarboxylate (DIAD).88 Despite the fact that the Mitsunobu reaction is widely used in synthetic 
organic chemistry, the mechanistic details, particularly at the intermediate stages, are still a subject of 
debate and intensive studies.89-91 A possible pathway is shown in scheme III.9. 
 
 
Scheme III.9 - A possible mechanism of the Mitsunobu reaction. 
 
Therefore, the Mitsunobu reaction was performed for the N-alkylation of indole derivatives 
following two different reaction conditions. These consisted on the Mitsunobu reaction under the 
classical reaction conditions (DEAD/PPh3) (scheme III.10, route a);
92 and a modified Mitsunobu 
reaction [cyanomethylenetrimethyl phosphorane (CMMP) (generated in situ)] (scheme III.10, route b)93. 
In both approaches 3-(4-bromobenzyl)-5-(methylsulfonyl)-1H-indole (11c) was reacted with the 
commercial available alcohol (E)-4,4,4-trifluorobut-2-en-1-ol. However, these conditions were not 
successful since no product formation was observed by TLC after 24 h of reaction. 
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Scheme III.10 – Reaction of 3-(4-bromobenzyl)-5-(methylsulfonyl)-1H-indole (11c) with (E)-4,4,4-
trifluorobut-2-en-1-ol under classical (route a) and modified (route b) Mitsunobu conditions. 
 
The next approach consisted on a bimolecular nucleophilic substitution (SN2) reaction. To 
perform this reaction was necessary to form an indole metal salt and to transform the hydroxyl group of 
the (E)-4,4,4-trifluorobut-2-en-1-ol into a good leaving group. The methanesulfonyl (mesyl, -SO2CH3) 
group was chosen to protect the hydroxyl group due to its electronegativity and also because is a 
relatively small group.  
Thus, 3-(4-chlorobenzyl)-5-(methylsulfonyl)-1H-indole (11b) was treated with sodium hydride, 
affording the indole sodium salt derivative and then reacted with the previously prepared (E)-4,4,4-
trifluorobut-2-en-1-yl methanesulfonate (12). Surprisingly, product 14 was isolated as a mixture of 1:0.5 
of Z/Z and Z/E isomers in 27% yield, instead of the expected SN2 product (13) (scheme III.11). 
 
 
Scheme III.11 – Reaction of 3-(4-chlorobenzyl)-5-(methylsulfonyl)-1H-indole (11b) with (E)-4,4,4-
trifluorobut-2-en-1-yl methanesulfonate (12). 
 
The mechanism of this reaction will be described in detail in section III.2.2. 
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Since this approach failed, the next attempt to synthesize N-alkylated indole derivatives 
consisted on the introduction of the alkyl chain via epoxide opening, using the commercial (2,2,2-
trifluoro-ethyl)-oxirane, that afforded compounds 15a-c. Mesylation of the resulting alcohol and 
elimination by treatment with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) afforded compounds 16a-c 
(scheme III.12). However, the isolated products presented a double bond conjugated with the indole ring 
instead of the desired allylic chain. 
 
 
Scheme III.12 – Preparation of the compounds 16a-c from the reaction of 3-(p-halobenzyl)-5-
(methylsulfonyl)-1H-indole derivatives 11a-c with (2,2,2-trifluoro-ethyl)-oxirane. 
 
For the preparation of pattern B (compounds 17a-f), compounds 5 and 7 were dialkylated using 
the same procedure used to prepare compounds 11a-f, but with an excess of 3 equivalents of the different 
p-halobenzyl bromides and heating the reaction up to 70ºC. Formation of compounds 17a-f was also 
observed in small amount (η ≈ 15%) during mono-alkylation reaction of 5 and 7. 
Scheme III.13 depicts the synthetic routes adopted for the synthesis of the indole based library. 
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Scheme III.13 - Synthetic routes adopted for the synthesis of the indole based library. 
 
Compounds 11a-g, 15a-c, 16a-c and 17a-f were tested in vitro for COX-1 and COX-2. 
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III.2.1.2 Biological assays 
Chemical structures of all tested compounds are depicted in figure III.10. 
 
 
Figure III.10 - Chemical structures of the tested compounds. 
 
Inhibition of COX-1 and COX-2 by the synthesized compounds is expressed as the percentage 
of inhibition of control COX-1 or COX-2 activity as displayed in table III.1. The known COX inhibitors 
indomethacin (non-selective) and celecoxib (COX-2 selective) were used as positive controls. The 
inhibitory activity of the studied compounds was first tested at 50 µM however, since some compounds 
were not active at this concentration, the inhibitory activity was also tested at 100 µM. Though, 
compounds were insoluble at this concentration. 
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Table III.1 – Percent inhibition of control COX-1 or COX-2 activity, determined by EIA. Each value represents mean ± SEM of at least 4 experiments performed in 
duplicate. 
 
Compound R1 R2 R3 R4 COX-1 COX-2 COX-1 COX-2 
     50 µM 100 µM 
11a SO2Me p-CH2(C6H5)F H H INS INS --- --- 
11b SO2Me p-CH2(C6H5)Cl H H NA NA 28 ± 7 24 ± 16 
11c SO2Me p-CH2(C6H5)Br H H NA 9 ± 5 13 ± 7 26 ± 16 
11d SO2NH2 p-CH2(C6H5)F H H 40 ± 9 32 ± 9 31 ± 8 20 ± 10 
11e SO2NH2 p-CH2(C6H5)Cl H H 21 ± 4 32 ± 11 19 ± 5 31 ± 8 
11f SO2NH2 p-CH2(C6H5)Br H H 19 ± 7 23 ± 5 INS INS 
11g Br p-CH2(C6H5)SO2NH2 H H 11 ± 6 22 ± 1 33 ± 8 27 ± 2 
15a SO2Me p-CH2(C6H5)F H CH2CHOHCH2CF3 14 ± 11 16 ± 7 41 ± 10 9 ± 2 
15b SO2Me p-CH2(C6H5)Cl H CH2CHOHCH2CF3 8 ± 4 20 ± 8 NA 34 ± 8 
15c SO2Me p-CH2(C6H5)Br H CH2CHOHCH2CF3 12 ± 8 23 ± 5 20 ± 6 15 ± 9 
16a SO2Me p-CH2(C6H5)F H CHCHCH2CF3 8 ± 5 12 ± 7 48 ± 11 18 ± 28 
16b SO2Me p-CH2(C6H5)Cl H CHCHCH2CF3 11 ± 10 NA 26 ± 15 23 ± 22 
16c SO2Me p-CH2(C6H5)Br H CHCHCH2CF3 20 ± 10 21 ± 6 16 ± 10 19 ± 10 
17a SO2Me p-CH2(C6H5)F p-CH2(C6H5)F H NA NA NA NA 
17b SO2Me p-CH2(C6H5)Cl p-CH2(C6H5)Cl H 25 ± 4 24 ± 4 42 ± 1 NA 
17c SO2Me p-CH2(C6H5)Br p-CH2(C6H5)Br H NA NA NA NA 
17d SO2NH2 p-CH2(C6H5)F p-CH2(C6H5)F H 18 ± 9 67 ± 5 INS INS 
17e SO2NH2 p-CH2(C6H5)Cl p-CH2(C6H5)Cl H 41 ± 6 46 ± 1 INS INS 
17f SO2NH2 p-CH2(C6H5)Br p-CH2(C6H5)Br H 35 ± 8 8 ± 4 84 ± 5 NA 
Positive Controls     1 µM 10 µM 
Celecoxib     --- --- --- 75 ± 8 
Indomethacin     46 ± 5 78 ± 3 --- --- 
NA – no activity was found; INS – insoluble compound
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Some compounds, like 15b or 16a (50 µM, COX-1) displayed inhibition values less than 10%, 
which were considered to be not significant. Nevertheless, most of the obtained results were well above 
this percentage. Additionally it was observed that some compounds such as 11d, inhibit both isoforms 
at the higher concentration to a lesser extent than at the lower. In fact, some compounds with low 
activities, it was difficult to achieve a concentration-dependent effect, due to the high values of SEM. 
Indomethacin (1 µM) inhibits COX-1 (46 ± 5%) and COX-2 (78 ± 3%) while celecoxib (10 µM) inhibits 
only the last one (75 ±8%). 
From the C-5, C-3 disubstituted compounds (11a-g) only the sulfonamide derivatives (11d-g) 
showed to be active at 50 µM, although not selective (figure III.11). 
 
 
Figure III.11 – Inhibition of COX-1 and COX-2 activity (% ), respectively, of the synthesized compounds 
11a-g, indomethacin and celecoxib (only for COX-2). 
 
N-alkylation, in compounds 15a-c and 16a-c (figure III.9, pattern A), did not result in an 
improvement of activity/selectivity. At 100 µM, compounds 15a and 16a showed inhibitory activity 
against COX-1 (41 ± 10% and 48 ± 11%, respectively) (figure III.12). 
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Figure III.12 - Inhibition of COX-1 and COX-2 activity (% ), respectively, of the synthetized compounds 
15a-c and 16a-c, indomethacin and celecoxib (only for COX-2). 
 
Compounds 17a-f allowed the investigation of the C-5, C-3, C-2 substitution pattern (figure 
III.9, pattern B). Compound 17f showed the strongest inhibition of COX-1 enzyme's activity at the 
concentration of 100 µM (84 ± 5%). In addition, 17d resulted in 67 ± 5% (50 µM) of COX-2 and 18 ± 
9% of COX-1 inhibition, revealing its relative selectivity to inhibit COX-2. Compound 17e  inhibits both 
enzyme isoforms at 50 µM (41 ± 6% and 46 ± 1% for COX-1 and COX-2, respectively) (figure III.13).  
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Figure III.13 - Inhibition of COX-1 and COX-2 activity (% ), respectively, of the synthetized compounds 
15a-c and 16a-c, indomethacin and celecoxib (only for COX-2). 
 
III.2.1.3 Docking studies 
All molecules were docked to the active site of both COX-1 and COX-2 using the docking 
program Autodock4 (this work was performed by Dr. Stefan Erhardt from Edinburgh University). The 
docking study suggested that most studied compounds are more active for COX-1 which is in agreement 
with the observed inhibitory activity. Indeed, compounds 11a-g were all found to be COX-1 selective. 
They docked inside the binding pocket for both COXs isoforms. Overall, compounds 11a-g bind less 
strongly to COX-2 than to COX-1. This can be explained by the fact that they use the existing space in 
COX-1 binding pocket, with the sulfonamide/methylsulfone close to Arg120 and Tyr355, similar to the 
binding of the acid group in indomethacin, while the benzyl chain binds in the hydrophobic pocket. The 
selectivity is reversed for the dialkylated compounds 17a-f when compared to the mono-alkylated ones 
11a-f. Compounds 17a-f were the most promising compounds by studies, which is almost consistent 
with the COX-2 inhibition evaluation assays. Due to the increased flexibility introduced by the benzyl 
group, the 2,3-dibenzyl substituted indoles show a potential higher affinity to COX-2. According to the 
docking results, compounds 17d-f, with a sulfonamide at C-5, are more active than the corresponding 
methylsulfones 17a-c, what is in accordance with the experimental data. From the 17 series, the 
computational study indicated that the most promising compounds are the fluorinated ones 17a and 17d, 
with a methylsulfone and a sulfonamide, respectively. In both cases these compounds strongly bind to 
COX-2, but not COX-1. Also they do bind in the same orientation as the selective SC-558 inhibitor, 
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such as 17d in which the sulfonamide group binds to the side pocket next to Val523 and might establish 
hydrogen bonding via the oxygen atoms with Arg513 (Figure III.14A). 
 
 
Figure III.14 – Docking of compound 17d (A) and selective inhibitor SC-558 (B) in COX’s-2 active site. 
 
Although compounds 17 only binds inside the COX-2 binding pocket, some very strong 
interactions in the region of the entrance channel can occur with COX-1. Thus, their strong binding 
close to the entrance channel, suggests that they have the potential to block COX-1 effectively. 
Moreover, it was found that the binding affinities for COX-2 do not strongly depend on the type of 
halogen present in the aromatic ring. Nevertheless, the same was not observed in the docking for COX-
1, where stronger binding is observed for heavier halogens.  
For compounds 15a-c and 16a-c, the biological screening results showed only low activity. 
Additionally the docking predicts that they do not fit inside the binding pocket, due to their bulkiness.  
 
III.2.1.4 NMR studies 
In order to have a deeper insight about the mode of interaction of the mono-alkylated (11a-g) 
and the di-alkylated compounds (17a-f) with both enzyme isoforms it was performed saturation-transfer 
difference NMR (STD-NMR) experiments.94,95 Recently it was demonstrated that STD-NMR can be 
effectively used to characterize the binding of the anti-inflammatory drugs ibuprofen, diclofenac and 
ketorolac to COX-1 and COX-2.96 The STD-NMR experiment is based on the nuclear Overhauser effect 
and in the observation of the ligand resonance signals.94,95,97 This technique can be used not only for 
screening ligands with dissociation constants KD ranging from ca. 10
-8 to 10-3 M but also to provide 
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insight about the moieties of the ligand that are most important for binding, since it is expected that the 
regions of the ligand having the strongest contact to the protein will show the most intense STD NMR 
signals.97 
The STD-NMR of known drugs with COX-2 has been reported96 and demonstrates that COX-2 
can be used under those conditions to identify key substituents, although it was not possible to study 
celecoxib due to solubility reasons. 
Considering the percentage of inhibition presented in table III.1 and the results of the docking 
studies, compounds 11d and 17d were chosen for this study. Compound 11d is a mono-alkylated 
compound with a higher selectivity for COX-1 and 17d is, from the di-alkylated series, the one that 
shows the highest selectivity to COX-2, binding well inside the COX-2 pocket, according to the docking 
studies. 
The STD-NMR results are presented in figure III.15. STD signals were observed for both 
compounds and for both enzyme isoforms. The fact that STD responses were obtained for all cases is in 
accordance with 11d and 17d binding reversibly to COX-1 and COX-2, as well as with the inhibition 
and docking results. 
 
 
Figure III.15 – Expansions of the aromatic region of the STD-NMR spectra of the compounds 11d and 17d 
with COX-1 and COX-2. STD intensities relative to the corresponding reference intensities are shown in 
each signal as percentage. 
 
When considering the interaction of 11d, from the comparison of the STD spectra with the 
reference spectra it can be seen that not all protons gave identical STD responses. For this compound, 
the most intense STD signals originate from the aryl moiety and the response of protons 6 and 7 of the 
indole ring is higher in COX-1 than in COX-2. These results may be indicative of a more extended and 
uniform interaction of 11d with COX-1 than with COX-2. When considering 17d, the most intense STD 
signals originate also from the aryl moieties. In COX-1 there is an appreciable decrease in STD response 
from proton 4 of the indole ring. This may evidence that the sulfonamide moiety in 17d may be more 
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important to promote the association with COX-2 than with COX-1 and partly responsible for the 
selectivity observed in the inhibition and docking studies. Also, contrary to 11d, it is clear that protons 
6 and 7 from the indole ring receive less saturation from the protein, what can be indicative of a different 
conformation in the binding site. These results are in good agreement with the inhibition and docking 
studies and they provide an experimental validation of the methodology. 
 
From the library of the 19 new indole based compounds synthesized, the biological tests 
revealed that the presence of a sulfonamide (11d-g) was more favorable for interaction with both COXs, 
being more active than the corresponding methylsulfones (11a-c). These sulfonamides 11d-g when 
docked have a similar binding mode as the selective inhibitor SC-558, but the docking studies predicted 
a slight preference for COX-1 binding. Indeed 11d demonstrated a percent of inhibition higher for COX-
1 (40 ± 9%) than for COX-2 (32 ± 10%) at 50 µM. This observation was further supported by the STD-
NMR study that demonstrated that compound 11d, despite interacting with both COX isoforms, displays 
a more extended STD response for COX-1, confirming a superior interaction with this enzyme.  
These results indicate that the selective inhibitory activity associated with the introduction of a 
sulfonamide group is dependent on the overall geometry of the molecule. The orientation of the 
sulfonamide group towards the selective pocket is determined by the shape of the molecule. Thus, the 
Y shape is necessary for the correct positioning of the groups in the pocket. 
 
 
Figure III.16 - Indole-based library tested as selective COX-2 inhibitor. 
 
With compounds 15a-c and 16a-c (figure III.16, pattern A) it was tested if a trifluoromethyl 
allylic chain would introduce flexibility to the Y shape, when compared to the benzoyl group present in 
indomethacin. The presence of the CF3 group was thought to establish favorable interactions with the 
key residue Arg120 in COX-2. The biological evaluation of these compounds only revealed low activity 
and no selectivity for COX-2. The docking results show that these compounds are too bulky to enter the 
binding pocket, although interactions can be established and a partial blocking can occur, what would 
Chapter III   New indole derivatives as cyclooxygenase inhibitors 
90 
 
explain the low activity found. This shows that the bulkiness of the substituents is important for binding. 
If the substituents are too bulky the molecule will not enter the binding site. However, once in the 
binding pocket they need to be bulky enough to orient the sulfonamide to the selective pocket. 
The second library prepared (figure III.16, pattern B) envisaged exploration of C-2 substitution 
with a group that has enough volume to fill the hydrophobic pocket interacting with residues in this 
region. This substitution pattern (C-2, C-3 and C-5 - compounds 17a-f) also leaves the indolic NH free 
allowing a possible stabilization of the binding with the enzyme via hydrogen bonding, which was 
shown by docking to be important to interact with the hydroxyl group of with Tyr355 (figure III.14). 
As also shown by the calculations, 17a-f bind to COX-2 in a similar manner to that of SC-558, 
and different from indomethacin. Furthermore, these studies indicate that the volume, nature and shape 
of the benzyl group at C-2 are the most appropriate for stable binding to hydrophobic pocket. The 
activity results for compounds 17a-f, confirm that substitution at C-2 with a benzyl group possessing a 
halogen at para position, is important. The results obtained also indicate that the halogen atom at the 
aromatic side chain is a key substituent. Compound 17d was found to be the most promising showing 
67 ± 5% COX-2 inhibition at 50 µM, demonstrating that fluorine seems to be crucial, this inhibition 
percentage is close to the one of celecoxib (75 ± 8%) at 10 µM. 
The lack of activity of the methylsulfones 17a and 17c is most probably related to the lower 
electronic density of the sulfone oxygen atoms when compared with the corresponding sulfonamides 
(17d-f). 
STD-NMR studies performed with 17d highlighted that the sulfonamide group is indeed 
important to promote the interaction with COX-2 rather than with COX-1, as evidenced by the close 
proximity of the indolic proton H4 to COX-2, supporting the observed selectivity in the inhibition 
evaluation. 
In summary, the studies undertaken with the indole-based library served as a platform for the 
design of new compounds with improved selectivity. 
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III.2.2 Mechanistic investigation of the reaction of indole with 
trifluoromethylated olefins 
The unexpected reactivity found on the introduction of a trifluoromethylated olefin at the 
nitrogen atom of the indole (scheme III.11, page 79) was further investigated. 
In the literature it is shown that trifluoromethylated allyl methanesulfonate 12 and the toluene-
4-sulfonic acid derivative 18 afford exclusively the SN2 product (scheme III.14, route a) when reacted 
with nucleophiles.98-101 Trifluoromethylated allyl bromide 19 has been used in indium-mediated 
allylations to afford γ-coupling products when reacting with aldehydes (scheme III.14, route b) (SN2 
product was observed only in a small amount).102,103 
 
 
Scheme III.14 – Reactions of β-substituted trifluoropropenes. 
 
It is also reported that trifluoromethylated alkenes, without other reactive functional groups 
easily react via SN2’ mechanisms, in the presence of nucleophiles (preferentially metallic) (scheme 
III.15).104-106 
 
 
Scheme III.15 – Reactions of trifluoropropene derivatives with nucleophiles. 
 
Surprisingly, under the experimental conditions of the reaction of compound 11b and (E)-4,4,4-
trifluorobut-2-en-1-yl methanesulfonate (12) fluorine is a better leaving group then mesyl (scheme 
III.11, page 79). The same reaction conditions were tested with the indole (20). Product 22 was isolated 
as a mixture of Z/Z and Z/E isomers (1:0.6) with 38% yield. It was also isolated a little amount of 
isomerized compound 23 in 16% yield (scheme III.16). 
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Scheme III.16 – Reaction of indole (20) with (E)-4,4,4-trifluorobut-2-en-1-yl methanesulfonate (12). 
 
In order to understand the role of the solvent and reaction outcome, several reaction conditions 
were tested (table III.2). 
 
Table III.2 – Conditions of the reaction of indole (20) with (E)-4,4,4-trifluorobut-2-en-1-yl 
methanesulfonate (12). 
Entry Solvent Base (equiv.) Products Yield (%) 
1 DMF NaH (1) 22(Z/Z)(Z/E) (1:0.6) 
23 
38 
16 
2 DMF NaH (0.25) 22(Z/Z)(Z/E) (1:0.6) 12 
3 DMF NaH (0.5) 22(Z/Z)(Z/E) (1:0.6) 22 
4a DMF NaH (2) 22(Z/Z)(Z/E) (1:0.5) 83 
5b DMF NaH (1) 22(Z/Z)(Z/E) (1:0.6) 
23 
47 
1 
6c DMF NaH (1) 22(Z/Z)(Z/E) (1:0.5) 
23 
32 
40 
7 MeCN NaH (1) 22(Z/Z)(Z/E) (1:0.5) 31 
8d MeCN NaH (1) 22(Z/Z)(Z/E) (1:0.6) 
23 
40 
7 
9 THF NaH (1) 22(Z/Z)(Z/E) (1:0.6) 
23 
3 
9 
10d THF NaH (1) 22(Z/Z)(Z/E) (1:0.6) 
23 
25 
19 
11d THF 
tBuOK (1) 22(Z/Z)(Z/E) (1:0.6) 
23 
29 
6 
12e THF n-BuLi (1) --- --- 
a 2 equiv of 20 were used; b 5 times diluted; c inversion of reagents addition; d addition of crown ether (1 
mol%); e no reaction occurred. 
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First experiments were carried in DMF and the base loading was investigated (table III.2, entries 
1 to 4). The yield of 22 is dependent on the amount of NaH, with smaller amounts leading to lower 
product yields. In all experiments unreacted 20 was recovered. The dilution of the mixture had no 
influence on the reaction outcome (table III.2, entry 5). However, the use of 2 equivalents of the sodium 
salt of indole 21 (table III.2, entry 4), significantly increased the yield of 22. 
The nature of the metal revealed to be crucial for the fluorine elimination, since the formation 
of 22 was suppressed when n-BuLi was used (table III.2, entry 12), but the formation of products 22 and 
23 still occurred when tBuOK was used (table III.2, entry 11). 
The change in solvent influenced the products formation (table III.2, entries 7 and 9). When 
MeCN or THF were used, the yield of 22 decreased, and this might be due the poor solubility of 
compound 21 in these solvents. When crown ether was used (table III.2, entries 8 and 10) the yield of 
22 increased. This yield improvement is due the formation of a complex between crown ether and the 
cations Na+ or K+, increasing the solubility of the formed salt. 
The best results were obtained when DMF was used as solvent. Inverting the order of the 
reagents addition, addition of a suspension of 21 to a solution of 12, enhanced the yield of the isomerized 
23 supporting, that two competitive mechanisms take place. 
When (E)-4,4,4-trifluorobut-1-en-1-yl 4-methylbenzenesulfonate (18) was used the 
corresponding products 24 (17% yield as a mixture of Z/Z:Z/E 1:0.3) and 25 (51% yield) were isolated  
(Scheme III.17). 
 
 
Scheme III.17 - Reaction of indole (20) with (E)-4,4,4-trifluorobut-1-en-1-yl 4-methylbenzenesulfonate 
(18). 
In any case was observed the formation of the SN2 product. The importance of the electron-
withdrawing effect of the CF3 group on the reaction outcome was confirmed, as when this group was 
replaced by a methyl group (compound 26). This reaction was performed using NaH as base, in DMF 
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and also using n-BuLi, in THF. In both cases, the SN2 product 27 was obtained in 34 and 18% yield, 
respectively (scheme III.18). 
 
 
Scheme III.18 - Reaction of indole (20) with but-2-en-1-yl methanesulfonate (26). 
 
The corresponding SN2 product 28 was also isolated, in 72% yield, when 12 reacted with 
cylohexylamine (scheme III.19). 
 
 
Scheme III.19 – Reaction of cyclohexylamine with (E)-4,4,4-trifluorobut-2-en-1-yl methanesulfonate (12). 
 
In all experiments the 23 Z/Z isomer was the major product. Structure 22 (Z/Z and Z/E) was 
assigned by 1H, 13C, 19F NMR, and 2D experiments.  
Figure III.17 shows an expansion of the allylic region of the 1H-NMR spectrum of compound 
22. Each isomer presents only 3 protons in this region, the resonance signal of proton Hc appears as a 
doublet, and the resonance signals of protons Ha and Hb appear as double doublets.  
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Figure III.17 – 1H-NMR expansion of the allylic region (6.9-5.2 ppm) of the two isomers of compound 22, 
Z/Z and Z/E. 
 
Isomers 22 Z/Z and Z/E were separated by HPLC and each isomer was characterized by 1H, 13C, 
19F NMR and 2D techniques and also by mass spectrometry. 
The 1H-NMR signal of proton Ha of the Z/Z isomer shows a coupling constant of 28.9 Hz with 
fluorine, while the E/Z isomer has a coupling constant of 5.9 Hz with this nucleus. These constants are 
in accordance with the 19F-NMR of these two species (figure III.18) and confirm the proposed 
stereochemistry.107 
 
 
Figure III.18 – 19F-NMR of the isomers Z/Z and E/Z, respectively, of compound 22. 
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The doublets found in 13C-NMR confirm that only one fluorine atom is present (figure III.19). 
 
 
Figure III.19 – 13C-NMR expansion of the isomer 22 E/Z. 
 
As stated above, fluoride elimination from trifluoro allylic chains is known, as a side product, 
under metal-mediated reactions. Yamazaki et al108 reported the formation of difluorinated products 
during the Michael addition of organocopper species to 3-[(E)-4,4,4-trifluorobut-2-enoyl]oxazolidin-2-
ones. The same group observed the formation of a difluorinated diene as a product in SN2 reactions of 
Grignard reagents toward CF3-containing allylic acetates, in the presence of CuCN and TMSCl.
109-112 
In contrast with the literature known substrates, compounds 12 and 18 have a good leaving 
group at β-position (mesyl or tosyl group, respectively), and as it is accepted that the C-F bond is strong 
and chemically stable, the formation of 22 from 12 under these experimental conditions was an 
unexpected reaction outcome. 
In order to understand the mechanism of this reaction, GC-MS studies (GC-FI and GC-EI) were 
performed, since the identification of minor products and intermediates would be helpful in the 
disclosure of the mechanism. 
Three assays were performed using the GC-FI technique consisting on the analysis of the: a) 
reaction crude without work-up; b) reaction crude after work-up but without purification and; c) reaction 
products isolated by PTLC (table III.3). For GC-EI, only the reaction crude without work-up was 
analyzed [condition a)]. These reactions were performed according to the reaction conditions described 
in table III.2, entry 9. Despite better yields were observed using DMF as solvent (table III.2) THF was 
used instead due to spectrometer requirements.  
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Table III.3 – GC-MS assays of the reaction of indole (20) with compound 12. 
 
  Relative intensity (%)  
Retention time (min) [M]+ (FI) a) b) c)* Fragmentations (EI)** 
11.77 203.99 
49 64 
100 126.02; 78.97 
11.83 183.99 --- 105.01 
12.79 204.00 15 12 24 126.03; 108.99; 78.98 
13.31 204.00; 184.00 17 22 --- 125.01; 109.01; 78.97; 64.96 
15.63 225.04 28 13 --- 156.08; 116.05 
16.15 225.06 32 27 --- 156.08 
17.93 117.06 100 100 --- 90.02; 63.01; 58.52 
20.21 195.05 11 8 --- 116.04 
20.77 225.08 5 --- --- --- 
a) reaction crude without work-up; b) reaction crude after work-up but without purification and; c) 
reaction products isolated by PTLC. 
--- not detected; *between 20-28 min there is a broad peak corresponding to a compound with a MW of 
281.05. This occurs due to the retention of the compound in the column; **only for condition a). 
 
GC-MS spectra of the starting materials, indole (20) and (E)-4,4,4-trifluorobut-2-en-1- yl 
methanesulfonate (12), were also performed. Therefore, the peaks with a retention time of 17.93 min 
and 13.31 min corresponds to indole (20) and (E)-4,4,4-trifluorobut-2-en-1-yl methanesulfonate (12), 
respectively. Compound 12 co-elutes with a compound with MW of 184.00. 
In table III.4 are represented some proposed structures and its fragmentations of the observed 
peaks obtained for the reaction crude without work-up [condition a)], by the GC-EI technique.  
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Table III.4 – Proposed structures for the peaks obtained from the GC-MS assays.  
[M]+ Proposed structure  Fragmentations  Proposed fragmentation structure 
204.00; 203.99 
 
109.01 
 
125.01 
 
78.97 
 
108.99 
 
183.99; 184.00 
 
105.01 
 
225.04; 225.06 
 
156.08 
 
116.05 
 
195.05 
 
116.05 
 
 
The same peaks were observed before and after work-up (table III.3, a) and b), respectively), 
although with different relative intensities. Meaning that all the products are formed during the reaction. 
After purification by PTLC (table III.3, c)) two peaks corresponding to compounds 23 (100%) and 12 
(24%) were observed. Also a broad peak with MW of 281.05, which corresponds to product 22, was 
detected. 
Once product 22 is retained in the column, and possibly other compounds, the same three assays 
a), b) and c) were performed using MS-FI (table III.5, without heating and temperature on probe = 
50ºC). 
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Table III.5 – MS (FI) assays of the reaction of indole (20) with compound 12, without heating and Tprobe = 50ºC. 
Relative intensity (%) 
[M+] 
a) b) c) 
Proposed structure 
without Δ T = 50ºC without Δ T = 50ºC without Δ 
T = 50ºC 
1st 2nd 
117.06 100 4 100 --- --- --- --- 
 
184.00 4 1 15 --- --- 11 --- 
 
195.04 14 14 1 --- --- --- --- 
 
203.99 25 7 34 5 100 100 5 
 
225.08 45 7 8 --- --- --- --- 
 
281.05 --- 100 --- 100 --- --- 100 
 
301.06 --- 12 --- --- --- --- 5 
 
--- not detected a) reaction crude without work-up; b) reaction crude after work-up but without purification and; c) the mixture of isomers after purification by 
PTLC. 
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A new peak was observed corresponding to a compound with MW 301.06, but all the other 
peaks are the same observed using the GC-MS technique. Using the collected experimental data during 
reaction optimization and also the results from the mass spectrometry analysis, an explanation for the 
reaction mechanism was attempted. 
To achieve a proposal of a possible mechanism, a full density functional theory (DFT) study 
was performed,113 by calculating all the intermediates (some of them observed by MS) and transition 
states (TSs) along the possible reaction pathways (these calculations were performed by Dr. Filipe 
Duarte under the supervision of Prof. Gil Santos from FCT-UNL). In scheme III.20 is depicted a 
proposed mechanism on the basis of the calculated data, which indicates that the reaction occurs in three 
steps. 
 
 
Scheme III.20 – Proposed mechanism for the formation of 22. 
 
Scheme III.21 details the mechanism by presenting all the important TSs and intermediates as 
well as their relative energies. In all TSs it is very important to consider the explicit participation of a 
sodium ion. In the absence of this ion the TS energies become extremely high or the TS structures cannot 
even be obtained, which is in agreement with the experimental data. 
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Scheme III.21 - Proposed mechanism for the formation of 22. B3LYP/6-311++G(2df,2p)//B3LYP/6-
31G(d,p), DMF, T = 25 °C (similar conclusions at 0 °C), radii = uaks. 
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The energy difference between the double-bond migration (TS-1) and the indole addition with 
concerted elimination of fluorine (TS-2) is minimal. Thus, these two pathways can co-exist and one or 
the other can be dominant depending on the reaction conditions (solvent, temperature, concentration), 
as was experimentally observed. The Z isomer of 23 is preferentially formed due to strong restrictions 
on the TS conformation, as the sodium ion has to coordinate between the mesyl and the indole groups. 
While compound 23 (Z) is a dead-end, intermediate 29 can undergo flourine substitution by 
indole anion to afford intermediate 30. According to calculations, only the E isomer of 30 can be formed, 
due to the lack of important electrostatic interactions in the TS with Z configuration. An alternative 
mechanism for the formation of 30 was tested, via an addition-elimination process, in which the indole 
anion adds to the intermediate 29 to form an anionic intermediate that undergoes fluorine elimination to 
originate 30. 
However, this possibility is not discussed, as it originates considerably higher energetic TSs. 
Indole can be eliminated from intermediate 30 via two diastereomeric concerted TSs (TS-4), but high 
selectivity is expected, as TS-4 (Z/E) is ca. 11.5 kJ mol-1 less energetic than TS-4 (E/E). Thus, product 
22 (Z/E) is predicted to be preferentially formed, which does not fully agree with the experiment. Indeed, 
while the double-bond at the mesyl group side was experimentally obtained in Z configuration, the 
second double-bond was obtained as a Z/E mixture, with preference for the Z configuration. Though, 
this result can be explained, as the indole can catalyze the conversion of 22 (Z/E) into 22 (Z/Z), via TS-
5, thus allowing for a mixture of configurations experimentally observed. The conclusion is that while 
structure 22 (Z/E) is formed under kinetic control, isomer 22 (Z/Z) is formed under thermodynamic 
control, which explains the relative variable amounts of both isomers, depending on the reaction 
conditions. 
 
An unexpected reactivity was observed when compounds 12 and 18 were treated with indole 
sodium salt (21). A mechanism was proposed, based on DFT studies, which fully rationalizes the 
experimental data. The proposed mechanism identifies the importance of the metal ion and the reaction 
conditions on the final reaction outcome. 
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III.2.3 Studies towards a new methodology for the synthesis of sulfonyl-
containing compounds. 
Recently, new strategies have been introduced to progress the sustainability of organic synthesis  
(scheme III.1, page 70). The main objective of this study was the development of a novel methodology 
for carbon-sulfur bond formation via a sustainable route. This would constitute a platform for the 
efficient synthesis of compounds with a sulfonamide group – a crucial and unique functional group 
present in many relevant therapeutic drugs, such as COX-2 selective inhibitors. 
Recently, there has been significant interest in the coupling of sulfinic acid salts with aryl halides 
to prepare sulfones and vinyl sulfones,114 and an improvement in the metal-mediated coupling of sulfinic 
acid salts,115,116 such as the Ullmann-type reaction.85 However, these methods are extremely limited, 
since only a small number of sulfinic acid salts are commercially available (tolyl, phenyl and methyl), 
or require the preparation of complex template starting materials, suffer from harsh conditions, high 
costs of metal reagents and/or corresponding ligands. Furthermore, most of these methods are not atom 
economic. 
A proposal to overcome these drawbacks is the development of an atom economy approach to 
the synthesis of sulfones, by developing a versatile and recyclable sulfonylation agent. 
The strategy consisted on the immobilization of a heterocycle scaffold such as a benzotriazole 
ring, or equivalent, on a solid-support, and prepare the corresponding sulfinic acid salt. Next step would 
consist on the use transition metal-mediated coupling of this sulfinic acid salt with several carbon 
electrophiles (halides, boronic acids) allowing in situ formation of an intermediate that can be further 
converted to sulfones, sulfonamides, and other derivatives, in a one-pot procedure by addition of a 
suitable nucleophile. The ultimate formation of the sulfone, or derivative, would be the detachment of 
the product from the solid-support leaving the benzotriazole, or equivalent, moiety ready for the next 
sulfinic acid formation (figure III.20). This approach would enable recycling of the intermediate used 
without any loss of organic material, constituting a new platform for the preparation of a very versatile 
sulfinic acid salt. 
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Figure III.20 – Proposed strategy for the sulfonylation. 
 
From the synthetic strategies available for C-S bond formation, the Ulmann reaction, direct 
coupling of aryl halide with a sulfinic acid salt, shows some advantages. 
Thus, the first objective of this study was to synthesize an intermediate that would be both 
versatile and react under mild conditions. A solution-phase approach was first attempted to establish the 
sulfonylation route. The use of N-substituted benzotriazole unit, an interesting scaffold for sulfinic acid 
salt formation, was investigated. In order to prepare the key sulfonic acid salt, several routes were 
explored.  
The first choice relied on the use the sulfonylbenzotriazole moiety,72 due to its interesting 
properties as leaving group in its reactions with N- and O-nucleophiles, as well as it replaces the highly 
reactive and often difficult to access sulfonyl halide unit. Katriztky has demonstrated the use of 
benzotriazole (Bt) in the preparation of sulfonamides. However, the preparation of the sulfonylated 
derivative consisted on a multi-step synthesis, involving the use of Grignard reagents and SO2 (scheme 
III.22).72  
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Scheme III.22 – The use of benzotriazole in the preparation of sulfonamides, reported by Katriztky et al.72 
 
Therefore, based on a different approach developed by the same author117 the first attempt 
consisted on the synthesis of sodium benzotriazolesulfinate (30) (scheme III.23). Thus, this molecule 
has a nucleophilic sulfur atom (sulfinate) and a good leaving group (benzotriazole, 31), allowing the 
attack from a nucleophile in an advanced stage. The strategy adopted consisted on the treatment of 1-
trimethylsilylbenzotriazole (32) with sulfuryl chloride, affording 1,1’-sulfonylbis(1H-benzotriazole) 
(Bt2SO2, 33), as described in the literature.
117 Then, compound 33 was treated with sodium sulfite and 
sodium hydrogenocarbonate, in aqueous media118 (scheme III.23). 
 
 
Scheme III.23 – Synthetic pathway adopted for the synthesis of compound 30. 
 
It was expected to obtain compound 30 and benzotriazole (31). However after several attempts 
to separate 31 from the crude, such as: filtration with diethyl ether or acetone; hot filtration with 
dichloromethane in a soxhlet extractor; recrystallization with methanol/diethyl ether; and purification 
by HPLC; only benzotriazole (31) was isolated and identified. 
To avoid having benzotriazole (31) as a side product, it was envisaged that benzotriazole-1-
sulfonyl chloride (34) could be achieved from 32 after treatment with an excess of sulfuryl chloride. 
This way, after treatment with sodium sulfite and sodium hydrogenocarbonate, the leaving group would 
be the chlorine anion instead of benzotriazole (31) (scheme III.24). 
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Scheme III.24 – Another synthetic pathway adopted for the synthesis of compound 30. 
 
When a slight excess (1.1 equiv.) of sulfuryl chloride was used, compound 33 was afforded, in 
41% yield, instead of the desired product 34. To overcome that result, an excess (5 equiv.) of sulfuryl 
chloride was used. However, benzotriazole (31) was isolated, independently of the order of addition of 
the reagents (addition of SO2Cl2 to compound 32 or addition of compound 32 to SO2Cl2).  
 
An alternative approach was attempted with benzimidazole (35) because it was envisaged that 
the corresponding sulfinic acid salt would be more stable under the reaction conditions.  
A method described in the literature for the synthesis of 1-substituted benzimidazoles,119 was 
adopted to synthesize sodium benzimidazolesulfinate (36) (scheme III.25). 
 
 
Scheme III.25 - Synthetic pathway adopted for the synthesis of compound 36. 
 
Unfortunately, instead of obtaining the sulfinic sodium salt (36), the product isolated was the 
sodium salt of the benzimidazole. 
Despite all efforts to synthesize either sodium benzotriazole or benzimidazole sulfinic salts, all 
the attempts revealed unsuccessful, thus this strategy was abandoned. 
 
After the unsuccessful results obtained, an alternative method was investigated and the 
following route was focused on the use of N-heterocyclic carbenes (NHCs). Since the first reports of 
stable nucleophilic carbenes by Arduengo et al.120 in the early 1990s, the broad application of NHCs in 
organic synthesis has been widely demonstrated and their corresponding metal complexes have attracted 
enormous attention in the past two decades.121,122 The broad application of NHCs in organic synthesis 
has been impressively demonstrated. The usefulness of NHCs is due to the relative ease of synthetic 
preparations, nearly independent manipulations of the electronic and steric properties, and the strong -
donating character. Recently, it has been demonstrated that NHC∙CO2 adducts are readily formed by 
reaction of virtually all types of NHCs with carbon dioxide.123-125 This zwitterionic adducts have been 
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used as NHC transfer agents in organometallic chemistry for the synthesis of NHC metal complexes and 
lately as organic (pre)catalyst. Moreover, the formation of NHCs adducts with sulfur dioxide126 and 
more recently with nitrous oxide127 (scheme III.26) have been also reported. 
 
 
Scheme III.26 – Reaction of NHCs with nitrous oxide.127 
 
Therefore, the strategy adopted in this study consisted on reacting a preformed NHC with sulfur 
dioxide, in order to afford a carbene∙SO2 adduct (scheme III.27). This adduct would result from SO2 
capture by the NHC for a subsequent transfer of this moiety to an aromatic unit. 
 
 
Scheme III.27 – Proposed formation of the carbene∙SO2 adduct. 
 
The first choice relied on the use of carbene 1,3-di-tert-butylimidazol-2-ylidene (37) (scheme 
III.28), that is a stable carbene and was readily available (kindly provided by Professor Teresa Avilés, 
from FCT-UNL).  
 
Scheme III.28 – Reaction of carbene 37 with SO2. 
 
For the SO2 capture different reaction conditions were tested, such as neat conditions (the 
solvent was liquid SO2) or use of dry and degassed organic solvents (toluene or Et2O and bubbling SO2 
gas). In table III.6 are listed the chemical shifts of the corresponding imidazolium chloride 38,128 the 
corresponding carbene 37,129 as well as the spectroscopic data and elemental analysis of the obtained 
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crudes (X) from the three different reaction conditions. The reaction crudes were analyzed after 
evaporation of the reaction solvent, and without further purification. 
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Table III.6 - Chemical shifts and elemental analysis of 1,3-di-tert-butylimidazolium chloride (38), 1,3-di-tert-butylimidazol-2-ylidene (37) and reaction crudes (X) 
from the different tested conditions. 
 
 
 Compound 
38128 
Compound 
37129 
Reaction conditions (X) 
 neat toluene Et2O 
NMR solvent DMSO-d6 C6D6 CDCl3 DMSO-d6 DMSO-d6 
1H-NMR 
(δ ppm) 
H1 9.37 (s, 1H) --- 
10.17 (s, < 1H) 
9.59 (s, < 1H) 
9.88 (s, < 1H) 
9.17 (s, < 1H) 
9.06 (s, < 1H) 
9.88 (s, < 1H) 
9.05 (s, < 1H) 
H2 8.11 (s, 2H) 6.79 (s, 2H) 7.56 (s, 2H) 8.07 (s, 2H) 8.07 (s, 2H) 
H4 1.60 (s, 18H) 1.51 (s, 18H) 1.71 (s, 18H) 1.61 (s,18H) 1.61 (s, 18H) 
13C-NMR 
(δ ppm) 
C1 132.7 212.9 134.2 132.2 132.3 
C2 120.4 115.0 120.2 120.4 120.5 
C3 59.6 55.8 60.9 59.6 59.6 
C4 29.1 31.5 30.1 29.1 29.1 
Elemental 
analysis 
--- --- 
Calcd.: C, 54.07; N, 11.46; H, 8.25; S, 
13.12 
Found: C, 47.11; N, 9.62; H, 6.88; S, 
10.50 
--- 
Calcd.: C, 54.07; N, 11.46; H, 8.25; S, 
13.12 
Found: C, 49.20; N, 10.13; H, 7.33; S, 
11.27 
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All the reaction crudes (X) presented in the 1H NMR spectra signals that correspond to the 
resonance of H1 proton. However, the final result from the signals integration showed that this signal 
does not integrate for one proton (figure III.21). This fact indicated that there are different species of the 
imidazolium salt presented in the final mixture. Even though, the elemental analysis revealed the 
presence of sulfur atom. Additionally, IR spectra showed bands at 1040 and 968 cm-1, characteristics of 
S-O bond stretching. All the data collected might indicate that the sulfur dioxide is interacting with the 
imidazolium salt (perhaps is coordinating with the nitrogen atoms -NCN- of the imidazolium salt), 
instead of being coordinated with the -NCN- carbon as it would be expected. The crudes composition, 
from the different reaction conditions used, revealed themselves to be very similar, since the 1H-NMR 
spectra were similar. This indicates that the formation of these species was independent of the solvent 
used. 
 
 
Figure III.21 – 1H-NMR spectrum of the crude from the reaction of carbene 37 with SO2, in toluene, 
performed in DMSO-d6. 
 
Another NHC, 1,3-di-tert-butylimidazolidine-2-ylidene (39), was chosen, since according to the 
literature,126 this would afford a stable adduct with SO2 (scheme III.29). 
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Scheme III.29 – Reaction of carbene 39 with SO2. 
 
Despite the authors claimed that the product is a stable adduct, it was not possible, in this work, 
to isolate compound 40. Due to the difficulties to reproduce the reported procedure it was conceived 
that this NHC was not nucleophilic enough and/or did not afford a stable product. Thus, two different 
carbenes were tested, 1,3-bis-(2,6-di-iso-propylphenyl)imidazolin-2-ylidene (41) and 1,3-bis(2,4,6-
trimethylphenyl)imidazol-2-ylidene (42) (figure III.22) (kindly provided by Professor Teresa Avilés, 
from FCT-UNL). Both possess a substituted benzene ring in the nitrogen atoms that would confer more 
stability to the carbene, as well as to the product. 
 
 
Figure III.22 – Structures of the carbenes 41 and 42, respectively. 
 
Three experiments were performed with carbene 41: a) reaction of 41 in liquid SO2 (neat 
conditions); b) reaction of a solution of 43, in dry and degassed THF, bubbled with SO2 (g) and; c) a 
one-pot reaction which consisted on the treatment of a solution of 1,3-bis(2,6-di-iso -
propylphenyl)imidazolinium chloride (43), in dry THF, with LiHMDS and stirred for 2 h, followed by 
bubbling of SO2 (g). The crude from the reaction performed under conditions a) was analyzed after 
removal of the solvent and without further purification, while the obtained crude from the reaction 
performed under conditions c) was washed with dry Et2O and was analyzed without further purification.  
Table III.7 summarizes the spectroscopic data collected for compounds 41 and 43 and for the crudes 
(X). 1H-NMR spectrum of the reaction condition b) showed a complex mixture of products and therefore 
this was not further analyzed. 
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Table III.7 - Chemical shifts of 1,3-bis(2,6-di-iso-propylphenyl)imidazolinium chloride (43), 1,3-bis-(2,6-di-iso-propylphenyl)imidazolin-2-ylidene (41) and, reaction 
crudes (X) from the different tested conditions. 
  
 
  
Compound 43 Compound 41 
Reaction conditions (X) 
  a) c) 
NMR solvent CDCl3 C6D6 d8-THF DMSO-d6 
1H-NMR (δ ppm) 
H1 10.02 (s, 1H) --- 10.60 (s, 1H) 10.60 (s, 1H) 
H2 8.13 (s, 2H) 6.61 (s, 2H) 8.23 (s, 2H) 8.55 (s, 2H) 
H5 7.35 (d, J = 7.7 Hz, 4H) 7.16 (4H, under the solvent peak) 7.39 (d, J = 7.7 Hz, 4H) 7.52 (d, J = 7.6 Hz, 4H) 
H6 7.57 (t, J = 7.7 Hz, 2H) 7.31-7.28 (m, 2H) 7.54 (t, J = 7.7 Hz, 2H) 7.68 (t, J = 7.6 Hz, 2H) 
H7 2.50-2.38 (m, 4H) 2.61-2.47 (m, 4H) 2.61-2.47 (m, 4H) 2.36-2.32 (m, 4H) 
H8 1.28 (d, J = 6.5 Hz, 12H) 1.28 (d, J = 7.0 Hz, 12H) 
1.26-1.25 (m, 24H) 
1.25 (d, J = 6.8 Hz, 12H) 
H9 1.24 (d, J = 6.6 Hz, 12H) 1.18 (d, J = 7.0 Hz, 12H) 1.15 (d, J = 6.8 Hz, 12H) 
13C-NMR (δ ppm) 
C1 138.7 220.4 141.7 
--- 
C2 126.9 121.4 127.5 
C3 130.0 138.8 131.9 
C4 145.1 146.1 146.4 
C5 124.9 123.5 125.2 
C6 132.3 128.8 132.4 
C7 29.3 28.6 30.0 
C8 24.9 24.6 24.8 
C9 23.9 23.5 24.1 
      
a) reaction of 41 in liquid SO2 (neat conditions); c) a one-pot reaction which consisted on the treatment of a solution of 43, in dry THF, with LiHMDS and 
stirred for 2 h, followed by bubbling of SO2 (g). 
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Both reaction crudes, from reaction conditions a) and c), showed, on the 1H NMR spectra, a 
signal that corresponds to a proton bonded to C1, and which the chemical shift is similar to the one from 
the starting imidazolium 43. Also, the IR spectra did not present any bands at ≈ 1030, ≈ 980 cm-1, 
characteristics of the S-O bond, contrary to the preliminary reactions carried with carbene 37, which 
indicates the absence of SO2 in these mixtures. 
One experiment was still performed with 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene 
(42), that consisted in reacting carbene 42 (pre-formed by treatment of 44 with KHMDS, in dry toluene, 
followed by filtration through celite and removal of the solvent), in a solution of dry THF, with a saturate 
atmosphere of SO2 (g). The obtained crude was washed with dry pentane and dried under vaccum, 
affording a beige solid that was analyzed without further purification. Table III.8 summarizes the 
elemental analysis data and NMR data obtained for the 1,3-bis(2,4,6-trimethylphenyl)imidazolinium 
chloride (44), for the carbene 42 and for the reaction crude (X). 
 
Table III.8 - Chemical shifts and elemental analysis of 1,3-bis(2,4,6-trimethylphenyl)imidazolinium 
chloride (44), 1,3-bis(2,4,6-trimethylphenyl)imidazol -2-ylidene (42) and reaction crude (X). 
  
 
  Compound 44 Compound 42 Reaction crude (X) 
NMR solvent CDCl3 C6D6 CDCl3 
1H-NMR 
(δ ppm) 
H1 10.62 (s, 1H) --- 9.37 (s, 1H) 
H2 7.66 (s, 2H) 6.81 (s, 4H) 7.67 (s, 2H) 
H5 6.94 (s, 4H) 6.49 (s, 2H) 6.99 (s, 4H) 
H7 2.27 (s, 6H) 
2.16 (s, 18H) 
2.31 (s, 6H) 
H8 2.10 (s, 12H) 2.10 (s, 12H) 
13C-
NMR (δ 
ppm) 
C1 130.7 219.2 130.7 
C2 124.8 120.6 125.3 
C3 141.2 137.3 141.4 
C4 134.1 135.4 134.3 
C5 129.9 129.1 129.9 
C6 139.4 139.3 138.2 
C7 21.1 21.1 21.3 
C8 17.6 18.1 17.5 
Elemental 
analysis 
--- --- 
Calcd.: C, 68.45; N, 7.60; H, 6.56; S, 8.70 
Found: C, 60.63; N, 6.55; H, 6.28; S, 7.01 
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Once more the 1H NMR of the crude showed a proton bonded to C1, nevertheless elemental 
analysis proved that the crude contains sulfur. Moreover, there is a difference, of more than 1 ppm, of 
the chemical shift of the H1 proton of the imidazolium 44 and the chemical shift of the same proton of 
the obtained crude X (10.62 and 9.37 ppm, respectively). Despite that, the chemical shifts of the C1 
carbon for both species are the same, 130.7 ppm. The obtained results by NMR spectroscopy suggest 
that the sulfur dioxide is present in the crude X by interaction with the imidazolium salt (perhaps by 
coordination with the nitrogen atoms -NCN- of the imidazolium salt). 
 
Unfortunately, all the attempts to isolate carbene∙SO2 were ineffective. Also, it was not possible 
to identify the structure of the formed reaction product(s).  
 
According to the literature, sulfur dioxide has the ability to insert between carbon-metal bonds 
(R-M).130 Sulfur dioxide insertion reactions may be represented by the equation: 
 
 
 
where M stands for a metal together with its ancillary ligands and R is an alkyl or a related σ-bonded 
carbon group. Thus, for future work, one way to isolate the SO2∙carbene adduct could consist on the 
trapping the sulfur dioxide via in a carbon-metal bond for further transfer to an aromatic moiety (scheme 
III.30). 
 
 
Scheme III.30 – Reaction of insertion of sulfur dioxide in a carbene-metal bond and further transfer to an 
aromatic moiety. 
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III.3 Conclusions 
An indole based library was synthesized and its ability to selectively inhibit COX-2 was 
evaluated. From the 19 new indole based compounds synthesized, the biological tests revealed that the 
presence of a sulfonamide was more favorable for interaction with both COXs, being more active than 
the corresponding methylsulfones. Compound 17d was found to be the most promising, showing 67 ± 
5% COX-2 inhibition at 50 µM, suggesting that fluorine seems to be crucial, as this inhibition percentage 
is close to the one of celecoxib (75 ± 8%) at 10 µM. STD-NMR studies performed with 17d highlighted 
that the sulfonamide group is indeed important to promote the interaction with COX-2 rather than with 
COX-1, supporting the observed selectivity in the inhibition evaluation and this fact was also confirmed 
by docking studies of compound 17d (figure III.23). 
 
 
Figure III.23 – Docking and chemical structure of compound 17d. 
 
During the preparation of the fluorinated compounds from the indole-based library, an unexpected 
reactivity was observed when compounds 12 and 18 were treated with indole sodium salt (21). A 
mechanism was proposed, based on DFT studies, which fully rationalizes the experimental data. The 
proposed mechanism identifies the importance of the metal ion and the reaction conditions on the final 
reaction outcome. 
 
The prepared and tested indole-based library required the presence of a sulfonamide or amethyl 
sulfone groups. Thus, several attempts were made to synthesize a new versatile reagent for the synthesis 
of sulfonamides. The first attempt consisted on the synthesis of sodium benzotriazole/benzimidazole 
sulfinates, by reaction of benzotriazole/benzimidazole with sulfuryl or tionyl chloride. The second 
attempt relied on the use of a carbene∙SO2 adduct. . Both approaches revealed to be ineffectual for the 
proposed goal, and further work must be performed to explore the metal-catalyzed approaches to 
generate a versatile sulfonylating reagent.  
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III.4 Experimental 
III.4.1 Synthesis, biological evaluation, docking and STD-NMR studies of an 
indole based library as COX-2 selective inhibitors 
III.4.1.1 General 
Melting points were determined on a Reichert Thermovar apparatus and are uncorrected. 1H- 
and 13C-NMR spectra were recorded in (CD3)2CO, DMSO or CDCl3 on a Bruker ARX 400 spectrometer 
at 400 and 100.62 MHz respectively. Chemical shifts are expressed in parts per million (ppm) relative 
to tetramethylsilane (TMS). The coupling constants (J) are reported in Hertz (Hz). High resolution mass 
spectra were recorded on an AutoSpecQ spectrometer. IR spectra were run on an FT PerkinElmer 683 
instrument, with absorption frequencies expressed in reciprocal centimeters. The progress of all reaction 
was monitored by thin-layer chromatography, which was performed on Merck silica gel 60 F254 plates. 
Flash column chromatography was carried out on Merck silica gel 60 (230-400 mesh). For preparative 
thin layer chromatography was used Merck silica gel 60 GF254 in 20x20 glass plates. Anhydrous solvents 
were dried as described131 and freshly distilled. All the tested compounds possess a purity of at least 
95% as determined by HPLC. Analytical HPLC was run on a Merck Hitachi system consisting of an L-
7100 pump, Rheodyne type injector, a D-7000 interface and an L-7450 diode array spectrometric 
detector, equipped with LiChrospher®100 RP-18 column. Eluent system was: 20% A (H2O/TFA pH 
2.5), 80% B (MeOH) to 10% A, 90% B; flow rate = 1 mL/min. 
A microplate reader (Synergy HT, BIO-TEK), was used to perform the spectrophotometric 
readings in COX-1 and COX-2 inhibition assays. The COX-1 and COX-2 assay kit was obtained from 
Cayman Chemical Co. 
The STD-NMR spectra were acquired at 37ºC in a Bruker Avance III spectrometer operating at 
600.13 MHz, with a 5 mm triple resonance cryogenic probehead. 
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III.4.1.2 Synthesis of 1-acetylindoline-5-sulfonyl chloride (2)84 
 
In a round bottom flask containing chlorosulfonic acid (1.1 mL, 15.5 mmol), cooled in an ice 
bath, was added N-acetylindoline (1) (500 mg, 3.1 mmol) portion wise. The mixture was warmed to 
room temperature and then to 70ºC for 45 min. After that time it was cooled and poured onto ice and 
the solid was collected by suction filtration, and washed several times with water. The solid was 
recrystallized from iPrOH giving 668.23 mg (83%) of 2 as a white solid. 
m.p. 163-165ºC (iPrOH) [lit.84 167-169ºC (iPrOH)] 
1H NMR (400 MHz, DMSO-d6) δ 7.92 (d, J = 8.2 Hz, 1H), 7.41 (s, 1H), 7.37 (d, J = 8.2 Hz, 
1H), 4.08 (t, J = 8.3, 2H), 3.11 (t, J = 8.3 Hz, 2H), 2.13 (s, 3H); 
IR (KBr) 1673, 1377, 1183 cm-1; 
Spectral data were in accordance with the literature.84 
 
III.4.1.3 Synthesis of 1-acetylindoline-5-sulfonamide (3)132 
 
To a solution of 2 (100 mg, 0.38 mmol), in THF (2.5 mL), was added a 25% ammonium 
hydroxide solution (0.4 mL) at room temperature. The mixture was stirred for 3 h. After that time the 
solvent was removed under vacuum and the crude recrystallized from MeOH affording 70.3 mg (76%) 
of 3 as a white solid. 
m.p. 225-229ºC (MeOH) [lit.132 228-229ºC (EtOH)] 
1H NMR (400 MHz, DMSO-d6) δ 8.10 (d, J = 8.0 Hz, 1H), 7.63-7.60 (m, 3H), 7.20 (s, 2H, 
NH2), 4.14 (t, J = 8.2, 2H), 3.20-3.16 (m, 2H), 2.17 (s, 3H); 
IR (KBr) 3294, 1668, 1396, 1183 cm-1. 
Spectral data were in accordance with the literature.132 
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III.4.1.4 Synthesis of indoline-5-sulfonamide (4)84 
 
To a suspention of 3 (500 mg, 2.1 mmol), in MeOH (4.7 mL), was added a 37% aqueous solution 
of HCl (0.4 mL). The mixture was refluxed for 1 h 30 min. After that time it was allowed to cool and 
the solvent was removed under reduced pressure. The crude was dissolved in water and the pH was 
adjusted to 7 with 1 N sodium hydroxide. The precipitate was collected by suction filtration, washed 
several times with water, affording 276.3 mg (67%) of 4 as a white solid. 
m.p. 155-160ºC (lit.132 163-165ºC) 
1H NMR (400 MHz, DMSO-d6) δ 7.38 (s, 1H), 7.34 (d, J = 8.2 Hz, 1H), 6.86 (s, 2H, NH2), 6.45 
(d, J = 8.2 Hz, 1H), 6.19 (s, 1H, NH), 3.49 (t, J = 8.5, 2H), 2.94 (t, J = 8.5, 2H); 
IR (KBr) 3321, 3257, 1309, 1140 cm-1. 
Spectral data were in accordance with the literature.132 
 
III.4.1.5 Synthesis of 1H-indole-5-sulfonamide (5)84 
 
To a solution of 4 (100 mg, 0.50 mmol), in MeOH (0.5 mL) was added Co(salen) hydrate (12.1 
mg, 0.03 mmol). Air was bubbled through the solution for 24 h, at room temperature. The solvent was 
removed under reduced pressure and the residue was purified by flash chromatography (EtOAc) 
affording 5 (77.2 mg, 78%) was a white solid. 
m.p. 200-205ºC (EtOAc) [lit.132 208ºC (acetone)] 
1H NMR (400 MHz, DMSO-d6) δ 11.49 (s, 1H, NH), 8.05 (s, 1H), 7.56-7.50 (m, 3H), 7.09 (s, 
2H, NH2), 6.59 (s,1H); 
IR (KBr) 3322, 3208, 1326, 1148 cm-1. 
Spectral data were in accordance with the literature.132 
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III.4.1.6 Synthesis of 5-(methylsulfonyl)-1H-indole (7)85 
 
In a sealed tube, containing a solution of 5-iodoindole (6) (1 g, 4.11 mmol), in dry DMSO (8.2 
mL), were added sodium methanesulfinate (546 mg, 5.35 mmol), copper iodide (157 mg, 0.82 mmol) 
and L-proline (189 mg, 1.64 mmol), under argon atmosphere. The mixture was stirred at 80ºC for 3 days. 
The reaction was quenched with saturated aqueous NH4Cl, diluted with distilled water and extracted 
with EtOAc. The combined organic layers were washed with water and brine, dried over Na2SO4, 
filtered and concentrated. The crude was purified by flash chromatography (EtOAc/n-hexane 1:1) 
affording 7 (738 mg, 92%) as a white solid. 
m.p. 166-170ºC (EtOAc/n-hexane);  
1H NMR [400 MHz, (CD3)2CO] δ 10.79 (s, 1H, NH), 8.22 (s, 1H), 7.68-7.63 (m, 2H), 7.56-7.55 
(m, 1H), 6.71-6.70 (m, 1H), 3.06 (s, 3H). 
IR (KBr) 1673, 1377, 1183 cm-1;  
Spectral data were in accordance with the literature.133 
 
III.4.1.7 Reaction of 5-(methylsulfonyl)-1H-indole (7) with p-chlorobenzyl bromide and n-
BuLi 
 
To a solution of 7 (50 mg, 0.26 mmol), in dry THF (0.5 mL), was added a 1.5 M solution of n-
BuLi in n-hexane (0.19 mL, 0.28 mmol), at -78ºC. The mixture was stirred at this temperature for 30 
min. After this time a solution of 4-chlorobenzyl bromide (57.9 mg, 0.28 mmol), in dry THF (0.2 mL) 
was added. The mixture was allowed to warm up to room temperature. The reaction was quenched with 
distilled water and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered 
and concentrated. The crude was purified by flash chromatography (EtOAc/n-hexane 1:1) affording 1-
(4-chlorobenzyl)-5-(methylsulfonyl)-1H-indole (9) (51.4 mg, 63%) was a white solid. 
m.p. 136-138ºC (EtOAc/n-hexane); 
1H NMR (400 MHz, DMSO-d6) δ 8.18 (s, 1H, H4), 7.76 (d, J = 3.1 Hz, 1H, H2), 7.71 (d, J = 
8.0 Hz, 1H, H7), 7.62 (d, J = 8.0 Hz, 1H, H6), 7.38 (d, J = 8.4 Hz, 2H, H12), 7.23 (d, J = 8.3 Hz, 2H, 
H11), 6.75 (d, J = 3.0 Hz, 1H, H3), 5.52 (s, 2H, H9), 3.15 (s, 3H, H8); 
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13C NMR (101 MHz, DMSO-d6) δ 137.6 (C7’), 136.7 (C10), 132.2 (CCl), 131.9 (C2), 131.8 
(C5), 128.9 (2 x C11), 128.6 (2 x C12), 127.7 (C3’), 120.8 (C4), 119.5 (C6), 110.9 (C7), 103.0 (C3), 
48.6 (C9), 44.4 (C8); 
IR (KBr) 2924, 1491, 1289, 1136, 972, 755 cm-1; 
HRMS (ESI) m/z 320.0509 [M+H]+ (calcd for C16H15ClNO2S 320.0512). 
 
III.4.1.8 Reaction of 5-(methylsulfonyl)-1H-indole (7) with p-chlorobenzyl bromide and 
Grignard reagents 
 
To a solution of 7 (50 mg, 0.26 mmol), in dry THF (0.5 mL), was added a 1 M solution of 
PhMgBr in THF (0.3 mL, 0.28 mmol) or a 3 M solution of MeMgI in Et2O (0.1 mL, 0.28 mmol), at -
78ºC. The mixture was stirred at this temperature for 30 min. After this time a solution of 4-chlorobenzyl 
bromide (57.9 mg, 0.28 mmol), in dry THF (0.2 mL) was added. The mixture was allowed to warm up 
to room temperature for the reaction with PhMgBr or up to 50ºC for the reaction with MeMgI, for 24 h. 
After TLC control no reaction was observed. 
 
III.4.1.9 General procedure for the preparation of 3-p-halo-benzylated indoles derivatives 
(11a-g) and 2,3-p-halo-benzylated indoles derivatives (17a-f)87 
Procedure A: To a solution of 1H-indole-5-sulfonamide (5)/5-(methylsulfonyl)-1H-indole (7) 
(2 equiv.), Zn(OTf)2 (1.2 equiv.) and TBAI (1 equiv.) in dry toluene (ca. 3 mL per mmol of indole) was 
added DIPEA (2.2 equiv.) under argon. The reaction mixture was heated at 50ºC for 30 min, followed 
by addition of the p-halo-benzyl bromide (1 equiv.). The mixture was stirred overnight at 50ºC under 
argon. The reaction was quenched with saturated aqueous NH4Cl, diluted with distilled water and 
extracted with EtOAc. The combined organic layers were washed with water and brine, dried over 
Na2SO4, filtered and concentrated. The samples were further purified by flash chromatography followed 
by PTLC. 
Procedure B: To a solution of 1H-indole-5-sulfonamide (5)/5-(methylsulfonyl)-1H-indole (7) 
(1 equiv.), Zn(OTf)2 (1.2 equiv.) and TBAI (1 equiv.) in dry toluene (ca. 3 mL per mmol of indole) was 
added DIPEA (2.2 equiv.) under argon. The reaction mixture was heated at 70ºC for 30 min, followed 
by addition of the p-halo-benzyl bromide (3 equiv.). The mixture was stirred overnight at 70ºC under 
argon. The reaction was quenched with saturated aqueous NH4Cl, diluted with distilled water and 
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extracted with EtOAc. The combined organic layers were washed with water and brine, dried over 
Na2SO4, filtered and concentrated. The samples were further purified by flash chromatography. 
 
III.4.1.9.1 Synthesis of 3-(4-fluorobenzyl)-5-(methylsulfonyl)-1H- indole (11a) 
 
Procedure A: Purified by flash chromatography (gradient CH2Cl2; CH2Cl2/EtOAc 9:1) 
followed by PTLC (EtOAc/n-hexane 1:1) affording 11a as a white solid in 47% yield. 
m.p. 136-136ºC (EtOAc/n-hexane); 
1H NMR [400 MHz, (CD3)2CO] δ 10.65 (s, 1H,NH), 8.13 (s, 1H, H4), 7.67 (d, J = 8.5 Hz, 1H, 
H6), 7.62 (d, J = 8.5 Hz, 1H, H7), 7.42-7.28 (m, 3H, H2 and H11), 7.03 (t, J = 8.7 Hz, 2H, H12), 4.17 
(s, 2H, H9), 3.04 (s, 3H, H8); 
13C NMR [101 MHz, (CD3)2CO] δ 162.1 (d, J = 240 Hz, CF), 139.9 (C7’), 138.0 (C10), 132.6 
(C5), 131.0 (d, J = 7 Hz, 2 x C11), 127.7 (C3 )́, 126.7 (C2), 120.7 (C6), 120.1 (C4), 117.3 (C3), 115.7 
(d, J = 21 Hz, 2 x C12), 112.9 (C7), 45.1 (C8), 30.8 (C9); 
IR (KBr) 3370, 2928, 1283, 1132, 1090 cm-1; 
HRMS (ESI) m/z 304.0802 [M+H]+ (calcd for C16H15FNO2S 304.0808); 
Purity 97% 
 
III.4.1.9.2 Synthesis of 3-(4-chlorobenzyl)-5-(methylsulfonyl)-1H- indole (11b) 
 
Procedure A: Purified by flash chromatography (gradient CH2Cl2; CH2Cl2/EtOAc 9:1) 
followed by PTLC (EtOAc/n-hexane 1:1) affording 11b as a white solid in 41% yield. 
m.p. 155-157ºC (EtOAc/n-hexane); 
1H NMR [400 MHz, (CD3)2CO] δ 10.67 (s, 1H, NH), 8.12 (s, 1H, H4), 7.66 (d, J = 8.6 Hz, 1H, 
H6), 7.62 (d, J = 8.6 Hz, 1H, H7), 7.38 (s, 1H, H2), 7.34 (d, J = 8.5 Hz, 2H, H12), 7.30 (d, J = 8.5 Hz, 
2H, H11), 4.19 (s, 2H, H9), 3.03 (s, 3H, H8);  
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13C NMR [101 MHz, (CD3)2CO] δ 141.0 (C10), 139.9 (C7’), 132.7 (C5), 131.9 (CCl), 131.0 (2 
x C11), 129.1 (2 x C12), 126.8 (C2 and C3’), 120.8 (C6), 120.1 (C4), 116.8 (C3), 112.9 (C7), 45.1 (C8), 
30.9 (C9); 
IR (KBr) 3308, 2926, 1281, 1141, 1130, 1094, 763 cm-1;  
HRMS (ESI) m/z 320.0507 [M+H]+ (calcd for C16H15ClNO2S 320.0512); 
Purity 95% 
 
III.4.1.9.3 Synthesis of 3-(4-bromobenzyl)-5-(methylsulfonyl)-1H-indole (11c) 
 
Procedure A: Purified by flash chromatography (gradient CH2Cl2; CH2Cl2/EtOAc 9:1) 
followed PTLC (EtOAc/n-hexane 1:1) affording 11c as a white solid in 50% yield. 
  m.p. 169-171ºC (EtOAc/n-hexane);  
  1H NMR [400 MHz, (CD3)2CO] δ 10.69 (s, 1H, NH), 8.11 (s, 1H, H4), 7.66 (d, J = 8.3 Hz, 1H, 
H6), 7.61 (d, J = 8.3 Hz, 1H, H7), 7.45 (d, J = 7.6 Hz, 2H, H12), 7.38 (s, 1H, H2), 7.29 (d, J = 7.6 Hz, 
2H, H11), 4.18 (s, 2H, H9), 3.03 (s, 3H, H8);  
  3C NMR [101 MHz, (CD3)2CO] δ 141.4 (C10), 139.8 (C7’), 132.7 (C5), 132.1 (2 x C12), 131.4 
(2 x C11), 127.6 (C3’), 126.8 (C2), 120.8 (C6), 120.0 (C4 and CBr), 116.8 (C3), 112.9 (C7), 45.1 (C8), 
31.0 (C9);  
  IR (KBr) 3307, 2926, 1278, 1140, 1095, 764 cm-1; 
  HRMS (ESI) m/z 364.0001 [M+H]+ (calcd for C16H15BrNO2S 364.0007); 
Purity 98% 
 
III.4.1.9.4 Synthesis of 3-(4-fluorobenzyl)-1H- indole-5-sulfonamide (11d) 
 
  Procedure A: Purified by flash chromatography (CHCl3; CHCl3/MeOH 2 to 10%) followed by 
PTLC (EtOAc/n-hexane 3:2) affording 11d as a white solid in 39% yield. 
  m.p. 153-155ºC (EtOAc/n-hexane);  
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  1H NMR [400 MHz, (CD3)2CO] δ 10.53 (s, 1H, NH), 8.09 (s, 1H, H4), 7.66 (d, J = 8.3 Hz, 1H, 
H6), 7.53 (d, J = 8.3 Hz, 1H, H7), 7.41-7.25 (m, 3H, H2 and H10), 7.02 (t, J = 8.0 Hz, 2H, H11), 6.33 
(s, 2H, NH2), 4.14 (s, 2H, H8);  
  13C NMR [101 MHz, (CD3)2CO] δ 162.1 (d, J = 240 Hz, CF), 139.1 (C7’), 138.2 (C9), 135.7 
(C5), 131.0 (d, J = 7 Hz, 2 x C10), 127.3 (C3’), 126.2 (C2), 120.2 (C6), 118.5 (C4), 116.9 (C3), 115.7 
(d, J = 21 Hz, 2 x C11), 112.5 (C7), 30.8 (C8);  
  IR (KBr) 3379, 3291, 1313, 1147, 1096 cm-1; 
  HRMS (ESI) m/z 305.0755 [M+H]+ (calcd for C15H14FN2O2S 305.0760); 
Purity 99% 
 
III.4.1.9.5 Synthesis of 3-(4-chlorobenzyl)-1H-indole-5-sulfonamide (11e) 
 
Procedure A: Purified by flash chromatography (CHCl3; CHCl3/MeOH 2 to 10%) followed by 
PTLC (EtOAc/n-hexane 3:2) affording 11e  as a white solid in 46% yield. 
m.p. 205-206ºC (EtOAc/n-hexane);  
1H NMR [400 MHz, (CD3)2CO] δ 10.55 (s, 1H, NH), 8.08 (s, 1H, H4), 7.66 (d, J = 8.4 Hz, 1H, 
H6), 7.53 (d, J = 8.4 Hz, 1H, H7), 7.38-7.23 (m, 5H, H2, H10 and H11), 6.32 (s, 2H, NH2), 4.15 (s, 2H, 
H8);  
13C NMR [101 MHz, (CD3)2CO] δ 141.1 (C9), 139.1 (C7’), 135.8 (C5), 131.9 (CCl), 131.0 (2 
x C10), 129.1 (2 x C11), 127.3 (C3’), 126.3 (C2), 120.2 (C6), 118.5 (C4), 116.4 (C3), 112.5 (C7), 32.0 
(C8); 
IR (KBr) 3336, 3267, 1324, 1154, 1090, 806 cm-1;  
HRMS (ESI) m/z 321.0459 [M+H]+ (calcd for C15H14ClN2O2S 321.0465); 
Purity 99% 
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III.4.1.9.6 Synthesis of 3-(4-bromobenzyl)-1H-indole-5-sulfonamide (11f) 
 
Procedure A: Purified by flash chromatography (CHCl3; CHCl3/MeOH 2 to 10%) followed by 
PTLC (EtOAc/n-hexane 3:2) affording 11f as a white solid in 42% yield. 
m.p. 220-221ºC (EtOAc/n-hexane);  
1H NMR [400 MHz, (CD3)2CO] δ 10.57 (s, 1H, NH), 8.08 (s, 1H, H4), 7.66 (d, J = 8.5 Hz, 1H, 
H6), 7.54 (d, J = 8.5 Hz, 1H, H7), 7.44 (d, J = 8.1 Hz, 2H, H11), 7.34 (s, 1H, H2), 7.26 (d, J = 8.1 Hz, 
2H, H10), 6.33 (s, 2H, NH2), 4.14 (s, 2H, H8);  
13C NMR [101 MHz, (CD3)2CO] δ 141.7 (C9), 139.1 (C7’), 135.8 (C5), 132.1 (2 x C11), 131.4 
(2 x C10), 127.3 (C3’), 126.4 (C2), 120.2 (C6 and CBr), 118.5 (C4), 116.3 (C3), 112.5 (C7), 32.0 (C8);  
IR (KBr) 3331, 3266, 1323, 1153, 1099, 803 cm-1; 
HRMS (ESI) m/z 364.9954 [M+H]+ (calcd for C15H14BrN2O2S 364.9959); 
Purity 97% 
 
III.4.1.9.7 Synthesis of 4-[(5-bromo-1H-indol-3-yl)methyl]benzenesulfonamide (11g) 
 
  Procedure A: The reaction was performed at room temperature. Purified by flash 
chromatography (EtOAc/n-hexane 1:1) affording 11g as a white solid in 79% yield.  
  m.p. 157-159ºC (EtOAc/n-hexane);  
  1H NMR [400 MHz, (CD3)2CO] δ 10.36 (s, 1H, NH), 7.80 (d, J = 7.4 Hz, 2H, H11), 7.62 (s, 
1H, H4), 7.48 (d, J = 7.4 Hz, 2H, H10), 7.38 (d, J = 8.4 Hz, 1H, H7), 7.29 (s, 1H, H2), 7.21 (d, J = 8.4 
Hz, 1H, H6), 6.49 (s, 2H, NH2), 4.19 (s, 2H, H8);  
  13C NMR [101 MHz, (CD3)2CO] δ 146.9 (C9), 142.7 (CSO2NH2), 136.5 (C7’), 130.0 (C5), 
129.7 (2 x C10), 127.0 (2 x C11), 125.8 (C2), 124.9 (C6), 121.8 (C4), 114.3 (C3’), 114.1 (C7), 112.5 
(C3), 31.6 (C9); 
  IR (KBr) 3401, 2923, 1325, 1158, 1095, 882 cm-1;  
  HRMS (ESI) m/z 364.9954 [M+H]+ (calcd for C15H14BrN2O2S 364.9959); 
Purity 99% 
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III.4.1.9.8 Synthesis of 2,3-bis(4-fluorobenzyl)-5-(methylsulfonyl)-1H-indole (17a) 
 
  Procedure A: Purified by flash chromatography (gradient CH2Cl2; CH2Cl2/EtOAc 9:1) 
followed by PTLC (EtOAc/n-hexane 1:1) affording 17a as a white solid in 9% yield.  
  m.p. 165-168ºC (EtOAc/n-hexane);  
  1H NMR [400 MHz, (CD3)2CO] δ 10.61 (s, 1H, NH), 8.02 (s, 1H, H4), 7.60 (d, J = 8.5 Hz, 1H, 
H6), 7.50 (d, J = 8.5 Hz, 1H, H7), 7.29-7.18 (m, 4H, H12 and H12’), 7.09-6.89 (m, 4H, H11 and H11’), 
4.24 (s, 4H, H9 and H9’), 3.01 (s, 3H, H8);  
  13C NMR [101 MHz, (CD3)2CO] δ 162.4 (d, J = 240 Hz, CF), 162.1 (d, J = 239 Hz, CF), 139.3 
(C7’), 138.4 (C10 or C10’), 138.2 (C2), 135.9 (C10 or C10’), 132.9 (C5), 131.2 (d, J = 7 Hz, 2 x C11 
or C11’), 130.8 (d, J = 7 Hz, 2 x C11 or C11’), 129.0 (C3’), 120.5 (C6), 119.7 (C4), 115.9 (m, 4 x C12 
and C12’), 113.0 (C3), 112.2 (C7), 45.2 (C8), 32.0 (C9 or C9’), under the solvent peak (C9 or C9’);  
  IR (KBr) 3320, 2929, 1291, 1222, 1140 cm-1; 
  HRMS (ESI) m/z 412.1177 [M+H]+ (calcd for C23H20F2NO2S 412.1183); 
Purity 95% 
 
III.4.1.9.9 Synthesis of 2,3-bis(4-chlorobenzyl)-5-(methylsulfonyl)-1H-indole (17b) 
 
  Procedure A: Purified by flash chromatography (gradient CH2Cl2; CH2Cl2/EtOAc 9:1) 
followed by PTLC (EtOAc/n-hexane 1:1) affording 17b as a white solid in 7% yield.  
  m.p. 210-211ºC (EtOAc/n-hexane);  
  1H NMR [400 MHz, (CD3)2CO] δ 10.61 (s, 1H, NH), 8.03 (s, 1H, H4), 7.61 (d, J = 8.4 Hz, 1H, 
H6), 7.51 (d, J = 8.4 Hz, 1H, H7), 7.35-7.12 (m, 8H, H11, H11’, H12 and H12’), 4.25 (s, 4H, H9 and 
H9’), 3.01 (s, 3H, H8);  
  13C NMR [101 MHz, (CD3)2CO] δ 141.1 (C10 or C10’), 139.2 (C7’), 138.7 (C2), 138.5 (C10 
or C10’), 132.9 (C5), 132.6 (CCl or CCl’), 131.9 (CCl or CCl’), 131.2 (2 x C11 or C11’), 130.8 (2 x 
C11 or C11’), 129.3 (2 x C12 or C12’), 129.1 (2 x C12 or C12’), 128.9 (C3’), 120.6 (C6), 119.6 (C4), 
112.8 (C3), 112.2 (C7), 45.2 (C8), 32.1 (C9 or C9’), under the solvent peak (C9 or C9’); 
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  IR (KBr) 3310, 2918, 1290, 1142, 765 cm-1;  
  HRMS (ESI) m/z 444.0586 [M+H]+ (calcd for C23H20Cl2NO2S 444.0592); 
Purity 95% 
 
III.4.1.9.10 Synthesis of 2,3-bis(4-chlorobenzyl)-5-(methylsulfonyl)-1H-indole (17c) 
 
  Procedure A: Purified by flash chromatography (gradient CH2Cl2; CH2Cl2/EtOAc 9:1) 
followed by PTLC (EtOAc/n-hexane 1:1) affording 17c as a white solid in 15% yield.  
  m.p. 189-193ºC (EtOAc/n-hexane);  
  1H NMR [400 MHz, (CD3)2CO] δ 10.77 (s, 1H, NH), 8.03 (s, 1H, H4), 7.60 (d, J = 8.5 Hz, 1H, 
H6), 7.52 (d, J = 8.5 Hz, 1H, H7), 7.43-7.37 (m, 4H, H12 and H12’), 7.20-7.13 (m, 4H, H11 and H11’), 
4.23 (s, 4H, H9 and H9’), 3.01 (s, 3H, H8);  
  13C NMR [101 MHz, (CD3)2CO] δ 141.6 (C10 or C10’), 139.2 (C7’ and C10 or C10’), 138.4 
(C2), 132.9 (C5), 132.3 (2 x C12 or C12’), 132.1 (2 x C12 or C12’), 131.5 (2 x C11 or C11’), 131.2 (2 
x C11 or C11’), 128.9 (C3’), 120.5 (C6 and 2 x CBr), 119.5 (C4), 112.6 (C3), 112.2 (C7), 45.1 (C8), 
32.1 (C9 or C9’), under the solvent peak (C9 or C9’);  
  IR (KBr) 3316, 2922, 1289, 1142, 1072, 1011, 765 cm-1; 
  HRMS (ESI) m/z 531.9576 [M+H]+ (calcd for C23H20Br2NO2S 531.9581); 
Purity 96% 
 
III.4.1.9.11 Synthesis of 2,3-bis(4-fluorobenzyl)-1H-indole-5-sulfonamide (17d) 
 
  Procedure A: Purified by flash chromatography (CHCl3; CHCl3/MeOH 2 to 10%) followed by 
PTLC (EtOAc/n-hexane 3:2) affording 17d as a white solid in 11% yield.  
  m.p. 183-185ºC (EtOAc/n-hexane);  
  1H NMR [400 MHz, (CD3)2CO] δ 10.46 (s, 1H, NH), 8.01 (s, 1H, H4), 7.61 (d, J = 8.4 Hz, 1H, 
H6), 7.43 (d, J = 8.4 Hz, 1H, H7), 7.22 (m, 4H, H10 and H10’), 7.08-6.91 (m, 4H, H11 and H11’), 6.29 
(s, 2H, NH2), 4.22 (s, 2H, H8 or H8’), 4.20 (s, 2H, H8 or H8’);  
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  13C NMR [101 MHz, (CD3)2CO] δ 162.4 (d, J = 240 Hz, CF), 162.0 (d, J = 239 Hz, CF), 138.3 
(C7’, C9 or C9’ and C2), 135.9 (C5 and C9 or C9’), 131.2 (d, J = 6 Hz, 2 x C10 or C10’), 130.7 (d, J = 
7 Hz, 2 x C10 or C10’), 128.6 (C3’), 119.9 (C6), 118.1 (C4), 116.0-115.6 (m, 4 x C11 and C11’), 112.6 
(C3), 111.8 (C7), under the solvent peak (2 x C8 and C8’); 
  IR (KBr) 3396, 3267, 2926, 1327, 1217, 1154 cm-1;   
  HRMS (ESI) m/z 413.1130 [M+H]+ (calcd for C22H18F2N2O2S 413.1135); 
Purity 95% 
 
III.4.1.9.12 Synthesis of 2,3-bis(4-chlorobenzyl)-1H- indole-5-sulfonamide (17e) 
 
  Procedure A: Purified by flash chromatography (CHCl3; CHCl3/MeOH 2 to 10%) followed by 
PTLC (EtOAc/n-hexane 3:2) affording 17e  as a white solid with 15% yield.  
  m.p. 172-173ºC (EtOAc/n-hexane);  
  1H NMR [400 MHz, (CD3)2CO] δ 10.48 (s, 1H, NH), 8.01 (s, 1H, H4), 7.62 (d, J = 8.4 Hz, 1H, 
H6), 7.44 (d, J = 8.4 Hz, 1H, H7), 7.33-7.12 (m, 8H, H10, H10’, H11 and H11’), 6.31 (s, 2H, NH2), 
4.23 (s, 2H, H8 or H8’), 4.20 (s, 2H, H8 or H8’);  
  13C NMR [101 MHz, (CD3)2CO] δ 141.2 (C9 or C9’), 138.8 (C9 or C9’), 138.4 (C7’), 137.9 
(C2), 135.9 (C5), 132.5 (CCl or CCl’), 131.8 (CCl or CCl’), 131.1 (2 x C10 or C10’), 130.7 (2 x C10 or 
C10’), 129.3 (2 x C11 or C11’), 129.0 (2 x C11 or C11’), 128.5 (C3’), 119.9 (C6), 118.0 (C4), 112.3 
(C3), 111.8 (C7), 32.0 (C8 or C8’), under the solvent peak (C8 or C8’); 
  IR (KBr) 3317, 2909, 1317, 1156, 1014, 800 cm-1;  
  HRMS (ESI) m/z 467.0358 [M+Na]+ (calcd for C22H18Cl2N2NaO2S 467.0364); 
Purity 95% 
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III.4.1.9.13 Synthesis of 2,3-bis(4-bromobenzyl)-1H- indole-5-sulfonamide (17f) 
 
Procedure B: Purified by flash chromatography (CHCl3; CHCl3/MeOH 2 to 10%) affording 
17f as a white solid in 89% yield.  
m.p. 213-216ºC (EtOAc/n-hexane);  
1H NMR [400 MHz, (CD3)2CO] δ 10.49 (s, 1H, NH), 8.01 (s, 1H, H4), 7.62 (d, J = 8.3 Hz, 1H, 
H6), 7.48-7.34 (m, 5H, H7, H11 and H11’), 7.15 (d, J = 7.3 Hz, 4H, H10 and H10’), 6.30 (s, 2H, NH2), 
4.21 (s, 2H, H8 or H8’), 4.19 (s, 2H, H8 or H8’).;  
13C NMR [101 MHz, (CD3)2CO] δ 141.6 (C9 or C9’), 139.3 (C7’), 138.4 (C2), 137.8 (C9 or 
C9’), 135.9 (C5), 132.3 (2 x C11 or C11’), 132.0 (2 x C11 or C11’), 131.5 (2 x C10 or C10’), 131.1 (2 
x C10 or C10’), 128.5 (C3’), 120.6 (2 x CBr), 119.9 (C6), 118.0 (C4), 112.3 (C3), 111.8 (C7), 32.1 (C8 
or C8’), under the solvent peak (C8 or C8’); 
IR (KBr) 3336, 3270, 2924, 1320, 1157, 1011, 802 cm-1; 
HRMS (ESI) m/z 554.9348 [M+Na]+ (calcd for C22H18Br2N2NaO2S 554.9353); 
Purity 96% 
 
III.4.1.10 Reaction of (E)-4,4,4-trifluorobut-2-en-1-ol with 3-(4-bromobenzyl)-5-
(methylsulfonyl)-1H-indole (11c) 
 
III.4.1.10.1 Classical Mitsunobu reaction92 
To a solution of 11c (44 mg, 0.14 mmol), in a dry MeCN (1.3 mL), was added (E)-4,4,4-
trifluorobut-2-en-1-ol (23.7 mg, 0.19 mmol) and PPh3 (60.7 mg, 0.23 mmol), under argon atmosphere. 
The mixture was allowed to stir at room temperature for 10 min and then cooled in an ice bath followed 
by addition of DEAD (70 µL, 0.16 mmol). The ice bath was removed and the mixture was stirred at 
room temperature, under argon, for 24 h. After TLC control no reaction was observed. 
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III.4.1.10.2 Modified Mitsunobu reaction93 
III.4.1.10.2.1 Synthesis of cyanomethyltrimethylphosphonium chloride134 
 
A solution of 1 M PMe3 in THF (6.6 mL, 6.60 mmol) was slowly added to chloroacetonitrile 
(0.5 mL, 7.92 mmol). The reaction was maintained at ca 40ºC by cooling (water bath). The reaction 
mixture was stirred at room temperature for 2 days during which a white precipitate was formed. The 
solid was recrystallized from iPrOH and collected by filtration affording 
cyanomethyltrimethylphosphonium chloride in quantitative yield. 
m.p. 288-290ºC (decomp.) (iPrOH) [lit.132208-253ºC (decomp.) (iPrOH)]; 
1H NMR (400 MHz, DMSO-d6) δ 4.47 (d, J = 16.8 Hz, 2H), 2.12 (d, J = 15.4 Hz, 9H); 
IR (KBr) 2970, 2887, 2251, 1634, 1292, 975 cm-1. 
Spectral data were in accordance with the literature.134 
 
In a dried ACE pressure tube under an argon atmosphere, containing a solution of 
cyanomethyltrimethylphosphonium chloride (62.2 mg, 0.41 mmol), in dry THF (1.8 mL), was added 
KH (14.5 mg, 0.36 mmol). The mixture was stirred for 2 h at room temperature. Then 11c (50 mg, 0.16 
mmol) and (E)-4,4,4-trifluorobut-2-en-1-ol (41.4 mg, 0.33 mmol) were added. The reaction mixture was 
stirred at 100°C, for 24 h. After TLC control no reaction was observed. 
 
III.4.1.11 Synthesis of (E)-4,4,4-trifluorobut-2-en-1-yl methanesulfonate (12) 
 
To a solution of (E)-4,4,4-trifluorobut-2-en-1-ol (1 g, 7.93 mmol), in dry DCM (4.4 mL), cooled 
with an ice bath, was added TEA (1.2 mL, 1.72 mmol). The mixture was stirred for 10 min at this 
temperature, then methanesulfonyl chloride (0.67 mL, 1.72 mmol) was added. The reaction was stirred 
for 30 min at 0ºC and the ice bath was removed and the mixture was stirred for 1 h, at room temperature. 
The reaction was quenched with distilled water and extracted with EtOAc. The combined organic layers 
were dried over Na2SO4, filtered and concentrated. The crude was purified by flash chromatography 
(Et2O/n-hexane 3:2) affording 12 (1.39 mg, 86%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 6.47-6.42 (m, 1H, H2), 6.05-5.95 (m, 1H, H3), 4.83-4.82 (m, 
2H, H1), 3.08 (s, 3H, H4); 
13C NMR (101 MHz, CDCl3) δ 132.1 (q, J = 6.5 Hz, C2), 122.2 (q, J = 269.7 Hz, CF3), 121.6 
(q, J = 34.7 Hz, C3), 65.9 (C1), 38.0 (C4); 
IR (KBr) 2920, 1312, 1118, 936 cm-1; 
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MS (FI) m/z 204.00 [M]+ (calcd for C5H7F3O3S 204.01). 
 
III.4.1.12 Reaction of 3-(4-chlorobenzyl)-5-(methylsulfonyl)-1H-indole (11b) with (E)-4,4,4-
trifluorobut-2-en-1-yl methanesulfonate (12) 
 
To a solution of 11b (22.6 mg, 0.07 mmol), in dry DMF (1 mL), was added NaH (1.7 mg, 0.07 
mmol) at 0ºC, under argon. The reaction mixture was stirred at that temperature for 45 min. Then 
compound 12 (14.4 mg, 0.07 mmol) was added and mixture was stirred, at 0ºC under argon, for 1 h. The 
reaction was quenched with distilled water and extracted with EtOAc. The combined organic layers 
were washed with water and brine, dried over Na2SO4, filtered and concentrated. The crude was purified 
by PTLC (toluene/EtOAc 4:1) affording a mixture of compounds 14(Z/Z) and 14(Z/E) (1:0.5) as light 
yellow oils in 27% yield (9.7 mg). These compounds were separated by HPLC. 
 
(1Z,3Z)-4-[3-(4-chlorobenzyl)-5-(methylsulfonyl)-1H-indol-1-yl]-4-fluorobuta-1,3-dien-1-yl 
methanesulfonate [14(Z/Z)] 
 
1H NMR (400 MHz, CDCl3) δ 8.14 (s, 1H, H4), 7.85 (d, J = 8.7 Hz, 1H, H6), 7.72 (d, J = 8.7 
Hz, 1H, H7), 7.30 (d, J = 8.3 Hz, 2H, H12), 7.21 (d, J = 8.3 Hz, 2H, H11), 7.05 (s, 1H, H2), 6.63 (d, J 
= 5.9 Hz, 1H, H16), 6.07 (dd, J = 11.1, 5.9 Hz, 1H, H15), 5.88 (dd, J = 28.5, 11.2 Hz, 1H, H14), 4.09 
(s, 2H, H9), 3.13 (s, 3H, H17), 3.06 (s, 3H, H8); 
13C NMR (101 MHz, CDCl3) δ 148.4 (d, J = 267 Hz, C13), 138.8 (C7’), 137.3 (C10), 134.7 
(C16), 134.2 (C5), 132.6 (CCl), 130.1 (2 x C12), 129.0 (2 x C11), 128.4 (C3’), 125.9 (C2), 122.8 (C6), 
120.3 (C3 and C4), 113.1 (C7), 108.1 (C15), 90.5 (d, J = 18.5 Hz, C14), 45.2 (C8), 38.1 (C17), 30.6 
(C9). 
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(1Z,3E)-4-[3-(4-chlorobenzyl)-5-(methylsulfonyl)-1H-indol-1-yl]-4-fluorobuta-1,3-dien-1-yl 
methanesulfonate [14(Z/E)] 
 
1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1H, H4), 7.85 (d, J = 8.7 Hz, 1H, H6), 7.46 (d, J = 8.6 
Hz, 1H, H7), 7.30 (d, J = 8.4 Hz, 2H, H12), 7.21 (d, J = 8.4 Hz, 2H, H11), 7.01 (s, 1H, H2), 6.55 (d, J 
= 6.0 Hz, 1H, H16), 6.33 (dd, J = 11.5, 6.0 Hz, 1H, H15), 5.27 (dd, J = 11.5, 6.1 Hz, 1H, H14), 4.10 (s, 
2H, H9), 3.16 (s, 3H, H17), 3.07 (s, 3H, H8); 
13C NMR (101 MHz, CDCl3) δ 148.0 (d, J = 267 Hz, C13), 138.8 (C7’), 137.3 (C10), 135.9 
(C16), 134.2 (C5), 132.6 (CCl), 130.1 (2 x C12), 129.0 (2 x C11), 128.4 (C3’), 127.1 (C2), 122.7 (C6), 
120.4 (C3), 120.2 (C4) 112.4 (C7), 108.3 (C15), 95.9 (d, J = 39 Hz, C14), 45.2 (C8), 38.2 (C17), 30.6 
(C9); 
MS (EI) m/z 483.03 [M]+ (calcd for C21H19ClFNO5S2 483.04). 
 
III.4.1.13 General procedure for the preparation of 1-[3-(4-halobenzyl)-5-(methylsulfonyl)-
1H-indol-1-yl]-4,4,4-trifluorobutan-2-ol (15a-c) 
To a solution of 3-p-halo-benzylated-5-(methylsulfonyl)indole 11a-c (1 equiv.), in dry THF (ca 
8 mL per mmol of indole derivative), was added NaH (0.9 equiv.), at 0ºC under argon. The reaction 
mixture was stirred at that temperature for 45 min then (2,2,2-trifluoro-ethyl)-oxirane (1.1 equiv.) was 
added and mixture was refluxed for 2 h. The reaction was quenched with distilled water and extracted 
with EtOAc. The combined organic layers were washed with water and brine, dried over Na2SO4, 
filtered and concentrated. The crude was purified by PTLC (CH2Cl2/MeOH 2%) affording compounds 
15a-c. 
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III.4.1.13.1 Synthesis of 1-[3-(4-fluorobenzyl)-5-(methylsulfonyl)- indol-1-yl]-4,4,4-
trifluorobutan-2-ol (15a) 
 
  White solid; 62% yield;  
  m.p. 75-79 ºC; 
  1H NMR [400 MHz, (CD3)2CO] δ 8.10 (s, 1H, H4), 7.77-7.63 (m, 2H, H6 and H7), 7.36 (m, 
3H, H2 and H11), 7.05-7.01 (m, 2H, H12), 4.53-4.37 (m, 2H, H13), 4.37-4.25 (m, 1H, H14), 4.18 (s, 
2H, H9), 3.04 (s, 3H, H8), 2.68-2.36 (m, 2H, H15);  
  13C NMR [101 MHz, (CD3)2CO] δ 162.2 (d, J = 240 Hz, CF), 140.2 (C7’), 137.9 (C10), 132.8 
(C5), 131.1 (d, J = 7 Hz, 2 x C11), 130.9 (C2), 128.2 (C3’), 120.7 (C6), 120.2 (C4), 116.9 (C3), 115.7 
(d, J = 21 Hz, 2 x C12), 111.5 (C7), 66.1 (C14), 52.7 (C13), 45.1 (C8), 39.1-38.8 (m, C15), 30.7 (C9);  
  IR (KBr) 3481, 1510, 1292, 1148, 1132 cm-1; 
  HRMS (ESI) m/z 430.1095 [M+H]+ (calcd for C20H20F4NO3S 430.1100); 
 Purity 99% 
 
III.4.1.13.2 Synthesis of 1-[3-(4-chlorobenzyl)-5-(methylsulfonyl)- indol-1-yl]-4,4,4-
trifluorobutan-2-ol (15b) 
 
  White solid; 46% yield;  
  m.p. 115-117 ºC;  
  1H NMR [400 MHz, (CD3)2CO] δ 8.10 (s, 1H, H4), 7.72 (d, J = 8.4 Hz, 1H, H6), 7.69 (d, J = 
8.4 Hz, 1H, H7), 7.46-7.22 (m, 5H, H2, H11 and H12), 4.53-4.37 (m, 2H, H13), 4.37-4.25 (m, 1H, H14), 
4.18 (s, 2H, H9), 3.04 (s, 3H, H8), 2.74-2.30 (m, 2H, H15);  
  13C NMR [101 MHz, (CD3)2CO] δ 140.8 (C10), 140.1 (C7’), 132.8 (C5), 132.1 (CCl), 131.1 (2 
x C11), 131.0 (C2), 129.1 (2 x C12), 128.1 (C3’), 120.8 (C6), 120.2 (C4), 116.5 (C3), 111.5 (C7), 66.1 
(C14), 52.7 (C13), 45.1 (C8), 39.1-38.8 (m, C15)), 30.8 (C9); 
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  IR (KBr) 3484, 2926, 1741, 1408, 1290, 1148 cm-1; 
  HRMS (ESI) m/z 446.0799 [M+H]+ (calcd for C20H20ClF3NO3S 446.0805); 
 Purity 97% 
 
III.4.1.13.3 Synthesis of 1-[3-(4-bromobenzyl)-5-(methylsulfonyl)- indol-1-yl]-4,4,4-
trifluorobutan-2-ol (15c) 
 
  White solid; 49% yield;  
  m.p. 139-141 ºC;  
  1H NMR [400 MHz, (CD3)2CO] δ 8.11 (s, 1H, H4), 7.74-7.67 (m, 2H, H6 and H7), 7.44 (d, J 
= 8.0 Hz, 2H, H12), 7.37 (s, 1H, H12), 7.29 (d, J = 8.0 Hz, 2H, H11), 4.54-4.37 (m, 2H, H13), 4.37-
4.24 (m, 1H, H14), 4.16 (s, 2H, H9), 3.05 (s, 3H, H8), 2.76-2.35 (m, 2H, H15);  
  13C NMR [101 MHz, (CD3)2CO] δ 141.3 (C10), 140.1 (C7’), 132.7 (C5), 132.1 (2 x C12), 131.5 
(2 x C11), 131.0 (C2), 128.1 (C3’), 120.7 (C6), 120.2 (C4 and CBr), 116.3 (C3), 111.5 (C7), 66.5 (C14), 
52.7 (C13), 45.0 (C8), 39.0 (q, J = 26.7 Hz, C15), 30.9 (C9);  
  IR (KBr) 3486, 2928, 1290, 1146, 1133 cm-1; 
  HRMS (ESI) m/z 490.0294 [M+H]+ (calcd for C20H20BrF3NO3S 490.0299); 
 Purity 98% 
 
III.4.1.14 General Procedure for the preparation of 3-(4-halobenzyl)-5-(methylsulfonyl)-1-
(4,4,4-trifluorobut-1-en-1-yl)-1H-indole (16a-c) 
  To a solution of previous compounds 15a-c, in dry THF (ca. 7 mL per mmol of indole 
derivative), TEA (2 equiv.) and mesyl chloride (1.3 equiv.) were added at 0ºC under argon. The mixture 
was stirred at that temperature for 30 min and then allowed to warm at room temperature and stirred for 
another 1 h 30 min. The solvent was removed under reduced pressure and the residue was dissolved in 
EtOAc, washed with distilled water, dried over Na2SO4, filtered and concentrated.  
 The crude was dissolved in dry THF, and DBU (1.3 equiv.) was added at room temperature 
under argon. The reaction mixture was refluxed for 30 min. After this time work-up was performed as 
described above. The crude was purified by silica flash chromatography (CH2Cl2) affording compounds 
16a-c. 
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III.4.1.14.1 Synthesis of 3-(4-fluorobenzyl)-5-(methylsulfonyl)-1-(4,4,4-trifluorobut-1-en-
1-yl)indole (16a) 
 
  White solid; 66% yield (0.6:0.4, Z/E);  
  m.p. 83-86 ºC;  
  1H NMR [400 MHz, (CD3)2CO] δ 8.15 (s, 2H, H4), 7.84-7.78 (m, 3H, H6 and H13E), 7.62 (d, 
J = 8.7 Hz, 2H, H7), 7.51 (s, 2H, H2), 7.42-7.31 (m, 5H, H11 and H13Z), 7.08-7.00 (m, 4H, H12), 6.01-
5.87 (m, 1H, H14E), 5.67-5.59 (m, 1H, H14Z), 4.21 (s, 4H, H9), 3.44-3.29 (m, 2H, H15Z), 3.30-3.15 
(m, 2H, H15E), 3.07 (s, 6H, H8);  
  13C NMR [101 MHz, (CD3)2CO] δ 162.2 (d, J = 240 Hz, 2 x CF), 139.7 (2 x C7’), 137.3 (2 x 
C10), 134.4 (2 x C5), 131.1 (4 x C11), 128.7 (2 x C2 and C13Z), 128.3 (2 x C3’), 125.3 (C13E), 122.1 
(2 x C6), 120.5 (2 x C4), 119.5 (2 x C3), 115.8 (d, J = 21 Hz, 4 x C12), 112.1 (C14Z), 111.7 (2 x C7), 
103.6 (C14E), 45.0 (2 x C8), 38.3 (q, J = 29 Hz, C15E), 32.7 (q, J = 30 Hz, C15Z), 30.6 (2 x C9);  
  IR (NaCl) 2928, 1674, 1509, 1303, 1137, 759 cm-1; 
  HRMS (ESI) m/z 412.0989 [M+H]+ (calcd for C20H18F4NO2S 412.0994); 
 Purity 98% 
 
III.4.1.14.2 Synthesis of 3-(4-chlorobenzyl)-5-(methylsulfonyl)-1-(4,4,4-trifluorobut-1-en-
1-yl)indole (16b)  
 
  White solid; 83% yield (0.6:0.4, Z/E);  
  m.p. 97-100ºC;  
  1H NMR [400 MHz, (CD3)2CO] δ 8.15 (s, 2H, H4), 7.86-7.77 (m, 3H, H6 and H13E), 7.64 (d, 
J = 8.6 Hz, 2H, H7), 7.54 (s, 2H, H2), 7.45-7.27 (m, 9H, H11, H12 and H13Z), 5.97-5.90 (m, 1H, H14E), 
5.68-5.58 (m, 1H, H14Z), 4.23 (s, 4H, H9), 3.46-3.28 (m, 2H, H15Z), 3.28-3.16 (m, 2H, H15E), 3.07 (s, 
6H, H8);  
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  13C NMR [101 MHz, (CD3)2CO] δ 140.3 (2 x C10), 140.0 (2 x C7’), 134.5 (2 x C5), 132.3 (2 x 
CCl), 131.1 (4 x C11), 129.3 (4 x C12), 128.8 (2 x C2), 128.7 (C13Z), 128.4 (2 x C3’), 125.5 (C13E), 
122.1 (2 x C6), 120.5 (2 x C4), 119.0 (2 x C3), 112.2 (C14Z), 111.8 (2 x C7), 103.7 (C14E), 44.9 (2 x 
C8), 35.1 (q, J = 29 Hz, C15E), 32.7 (q, J = 30 Hz, C15Z), 30.7 (2 x C9); 
  IR (NaCl)  2928, 1301, 1136 cm-1; 
  HRMS (ESI) m/z 428.0693 [M+H]+ (calcd for C20H18ClF3NO2S 428.0699); 
 Purity 99% 
 
III.4.1.14.3 Synthesis of 3-(4-bromobenzyl)-5-(methylsulfonyl)-1-(4,4,4-trifluorobut-1-en-
1-yl)indole (16c)  
 
White solid; 69% yield (0.6:0.4, Z/E);  
m.p. 94-97ºC;  
1H NMR [400 MHz, (CD3)2CO] δ 8.15 (s, 2H, H4), 7.85-7.77 (m, 3H, H6 and H13E), 7.63 (d, 
J = 8.6 Hz, 2H, H7), 7.54 (s, 1H, H2), 7.44 (d, J = 7.2 Hz, 4H, H12), 7.34-7.30 (m, 5H, H11 and H13Z), 
6.04-5.87 (m, 1H, H14E), 5.69-5.58 (m, 1H, H14Z), 4.20 (s, 4H, H9), 3.45-3.29 (m, 2H, H15Z), 3.23 
(m, 2H, H15E), 3.07 (s, 6H, H8); 
13C NMR [101 MHz, (CD3)2CO] δ 140.8 (2 x C10), 139.7 (2 x C7’), 134.5 (2 x C5), 132.2 (4 x 
C12), 131.5 (4 x C11), 128.8 (2 x C2), 128.7 (C13Z), 128.2 (2 x C3’), 125.5 (C13E), 122.1 (2 x C6), 
120.5 (2 x C4), 120.3 (2 x CBr), 118.9 (2 x C3), 112.3 (C14Z), 111.8 (2 x C7), 103.7 (C14E), 45.0 (2 x 
C8), 34.9 (q, J = 29 Hz, C15E), 32.7 (q, J = 29 Hz, C15Z), 30.8 (2 x C9);  
IR (NaCl) 2925, 1301, 1136 cm-1; 
HRMS (ESI) m/z 472.0188 [M+H]+ (calcd for C20H18BrF3NO2S 472.0194); 
Purity 98% 
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III.4.1.15 COXs inhibition tests 
The inhibition of COX-1 (ovine) and COX-2 (human recombinant), by the synthesized 
compounds was determined in a cell-free system by quantifying the levels of PGF 2α, produced by 
catalysis of arachidonic acid, using an Enzyme Immunoassay (EIA) kit (COX Inhibitor Screening 
Assay) supplied by Cayman Chemical Co. The known COX inhibitors indomethacin and celecoxib were 
used as positive controls. The results are expressed as the percent inhibition of control COX-1 or COX-
2 activity. For each experimental condition, were performed at least four independent assays, in 
duplicate. 
 
III.4.1.16 Docking studies 
For all docking calculations Autodock 4.2135 (Release 4.2.2.1 in combination with Autogrid 
4.2.2.) was used for the flexible ligand docking into two X-ray crystal structures 2AYL136 and 3PGH20 
for COX-1 and COX-2, respectively. 
 
III.4.1.17 NMR studies 
The STD-NMR spectra were acquired with a standard pulse sequence from the Bruker library 
with a spin-lock (T1) for protein background suppression and water suppression with excitation 
sculpting with gradients. 1024 transients were acquired in a matrix of 32 k data points in t2 using a 
spectral window of 12019 Hz centered at 2812.4 Hz. A 2 kHz spin lock filter with a length of 20 ms 
was used. Selective saturation of protein resonances was performed by irradiating at -300 Hz (on 
resonance spectrum) using a series of 51 Eburp2.1000 shaped 90º pulses (50 ms, 1 ms delay between 
pulses), for a total saturation time of 2.5 s. For the off resonance spectrum irradiation was performed at 
20,000 Hz. All data was processed with Bruker Topspin 2.1 and the STD spectra were obtained after 
subtraction of the on-resonance spectra from the off-resonance spectra. The relative STD effect for a 
given hydrogen -(ISTD/I0) x 100, where I0 and ISTD are the intensities of the reference (off resonance) and 
difference (STD-NMR) spectra respectively e was normalized using the highest intensity STD response 
as a reference for every spectrum. 
COX-1 from ram seminal vesicles and COX-2 from sheep placenta were purchased from 
Cayman Chemical Co. The proteins are supplied in 80 mM TriseHCl, pH 8.0, 0.1% Tween 20 and 300 
mM diethyldithiocarbamate and were used as such. Stock solutions of compounds 14d and 15d (2 mM) 
were prepared in DMSO-d6. The samples for STD-NMR experiments were prepared by adding the 
appropriate amount of ligand stock solution to a 3 mm NMR tube containing the enzyme. Final 
concentrations were in the range of 3 mM of COX and 300 mM of ligand(s) in a total volume of 300 
mL, when necessary volumes were corrected with 80 mM TriseHCl buffer at pH 8.0.  
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III.4.2 Mechanistic investigation of the reaction of indole with 
trifluoromethylated olefins 
III.4.2.1 General 
Melting points were determined on a Reichert Thermovar apparatus and are uncorrected. 1H-, 
13C- and 19F-NMR spectra were recorded in CDCl3 on a Bruker ARX 400 spectrometer at 400, 101.62 
and 377 MHz respectively.Chemical shifts are expressed in parts per million (ppm) relative to 
tetramethylsilane (TMS). The coupling constants (J) are reported in Hertz (Hz). High resolution mass 
spectra were recorded on an AutoSpecQ spectrometer. GC-FID spectra were recorded on a Konik 
HRGC 4000B spectrometer equipped with a DB-WAX column (30 m; 0.32 I.D.; 0.25 µm film). GC-
TOF-MS spectra were recorded on a Micromass GCT spectrometer. IR spectra were run on an FT 
PerkinElmer 683 instrument, with absorption frequencies expressed in reciprocal centimeters. The 
progress of all reaction was monitored by thin-layer chromatography, which was performed on Merck 
silica gel 60 F254 plates. Flash column chromatography was carried out on Merck silica gel 60 (230-
400 mesh). For preparative thin layer chromatography was used Merck silica gel 60 GF254 in 20x20 
glass plates. Anhydrous solvents were dried as described131 and freshly distilled. Semi-preparative 
HPLC was run on a Merck Hitachi system consisting of an L-7100 pump, Rheodyne type injector, a D-
7000 interface and an L-7450 diode array spectrometric detector, equipped with LiChrospher®100 RP-
18 column. Eluent system was: 20% A (H2O/TFA pH 2.5), 80% B (MeOH) to 10% A, 90% B; flow rate 
= 1 mL/min. 
DFT calculations were performed with Gaussian 09, Revision. B.01.113 
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III.4.2.2 Reaction of indole (20) with (E)-4,4,4-trifluorobut-2-en-1-yl methanesulfonate(12) 
 
General procedure  (table III.9, entry 1): 
To a solution of 20 (20 mg, 0.17 mmol) in dry DMF (1.3 mL) was added NaH (6.8 mg, 0.17 
mmol) at 0ºC under argon. The reaction mixture was stirred at that temperature for 45 min. 12 (38.3 mg, 
0.19 mmol) was added and mixture was stirred, at 0ºC under argon, for 1 h. The reaction was quenched 
with distilled water and extracted with EtOAc. The combined organic layers were washed with water 
and brine, dried over Na2SO4, filtered and concentrated. The crude was purified by flash chromatography 
(n-hexane/Et2O 4:1 to 3:2) affording 24.4 mg a mixture of compounds 22 (Z/Z)(Z/E) and 23 (1:0.6:0.6). 
Isomers 22(Z/Z)(Z/E) were later separated by HPLC. Compound 23 could not be isolated. 
 
Table III.9 – Reaction conditions. 
Entry Solvent Base (equiv.) Products Yield (%) Observations 
1 DMF NaH (1) 
22(Z/Z)(Z/E) (1:0.6) 
23 
38 
16 
--- 
2 DMF NaH (0.25) 22(Z/Z)(Z/E) (1:0.6) 12 --- 
3 DMF NaH (0.5) 22(Z/Z)(Z/E) (1:0.6) 22 --- 
4 DMF NaH (2) 22(Z/Z)(Z/E) (1:0.5) 83 2 equiv. of 20 were used 
5 DMF NaH (1) 
22(Z/Z)(Z/E) (1:0.6) 
23 
47 
1 
5x diluted 
6 DMF NaH (1) 
22(Z/Z)(Z/E) (1:0.5) 
23 
32 
40 
inversion of reagents addition 
7 MeCN NaH (1) 22(Z/Z)(Z/E) (1:0.5) 31 --- 
8 MeCN NaH (1) 
22(Z/Z)(Z/E) (1:0.6) 
23 
40 
7 
addition of crown ether (1 mol%) 
9 THF NaH (1) 
22(Z/Z)(Z/E) (1:0.6) 
23 
3 
9 
--- 
10 THF NaH (1) 
22(Z/Z)(Z/E) (1:0.6) 
23 
25 
19 
addition of crown ether (1 mol%)  
11 THF tBuOK (1) 
22(Z/Z)(Z/E) (1:0.6) 
23 
29 
6 
addition of crown ether (1 mol%)  
12 THF n-BuLi (1) --- --- no reaction occurred 
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(1Z,3Z)-4-fluoro-4-(indol-1-yl)buta-1,3-dien-1-yl methanesulfonate [22(Z/Z)] 
 
Isolated as a pale yellow oil;  
1H NMR (400 MHz, CDCl3) δ 7.65-7.58 (m, 2H, H2 and H5), 7.35-7.28 (m, 1H, H6), 7.26-7.20 
(m, 2H, H4 and H7), 6.66 (d, J = 3.4 Hz, 1H, H3), 6.59 (d, J = 5.9 Hz, 1H, H11), 6.11 (ddd, J = 11.2, 
5.9 Hz, 1H, H10), 5.86 (dd, J = 28.9, 11.2 Hz, 1H, H9), 3.11 (s, 3H, H12);  
13C NMR (101 MHz, CDCl3) δ 149.7 (d, J = 267.3 Hz, C8), 135.1 (C7’), 133.7 (d, J = 4.8 Hz, 
C11)), 129.7 (C3’), 125.4 (C2), 124.0 (C6), 122.2 (C5), 121.6 (C4), 112.1 (C7), 109.2 (d, J = 1.8 Hz, 
C10), 106.8 (C3), 88.5 (d, J = 19.1 Hz, C9), 37.9 (C12); 
19F NMR (377 MHz, CDCl3) δ -93.01 (d, J = 28.9 Hz);  
IR (NaCl) 2926, 1688, 1633, 1456, 1367, 1182, 967 cm-1; 
HRMS (HPLC-ESI-TOF) m/z 282,0595 [M+H]+ (calcd for C13H13FNO3S 282,06002). 
 
(1Z,3E)-4-fluoro-4-(indol-1-yl)buta-1,3-dien-1-yl methanesulfonate [22(Z/E)] 
 
Isolated as a pale yellow oil;  
1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 7.9 Hz, 1H, H4), 7.37 (d, J = 7.9 Hz, 1H, H7), 7.30 
(t, J = 7.5 Hz, 1H, H6), 7.23 (t, J = 7.5 Hz, 1H, H5), 7.19 (d, J = 3.4 Hz, 1H, H2), 6.69 (d, J = 3.4 Hz, 
1H, H3), 6.51 (d, J = 6.0 Hz, 1H, H11), 6.25 (dd, J = 11.4, 6.0 Hz, 1H, H9), 5.42 (dd, J = 11.4, 6.0 Hz, 
1H, H10), 3.14 (s, 3H, H12);  
13C NMR (101 MHz, CDCl3) δ 149.6 (d, J = 268.5 Hz, C8), 136.0 (C7’), 135.0 (d, J = 10.8 Hz, C11), 
129.0 (C3’), 127.0 (C2), 123.8 (C6), 122.1 (C5), 121.4 (C4), 111.5 (C7), 109.6 (d, J = 4.5 Hz, C10), 
106.5 (C3), 94.3 (d, J = 40.5 Hz, C9), 38.1 (C12);  
19F NMR (377 MHz, CDCl3) δ -81.86 (d, J = 6.0 Hz); 
IR (NaCl) 2925, 1687, 1629, 1456, 1367, 1182, 964 cm-1; 
HRMS (HPLC-ESI-TOF) m/z 282,0595 [M+H]+ (calcd for C13H13FNO3S 282,06002). 
 
 
 
 
Chapter III   New indole derivatives as cyclooxygenase inhibitors 
140 
 
(Z)-5,5,5-trifluoropent-1-en-1-yl methanesulfonate (23) 
 
1H NMR (400 MHz, CDCl3) δ 6.78 (d, J = 5.7 Hz, 1H), 5.14 (dd, J = 13.6, 7.3, 1H), 3.10 (s, 
3H), 3.06-2.95 (m, 2H). 
 
III.4.2.3 Synthesis of (E)-4,4,4-trifluorobut-1-en-1-yl 4-methylbenzenesulfonate (18) 
 
To a solution of (E)-4,4,4-trifluorobut-2-en-1-ol (500 mg, 3.96 mmol), in dry DCM (5 mL), was 
added TEA (0.6 mL, 4.36 mmol), in an ice bath. The mixture was stirred for 10 min at this temperature, 
and then tosyl chloride (831.7 mg, 4.36 mmol) was added. The reaction was stirred for 30 min at 0ºC 
and the ice bath was removed and the mixture was stirred for 1 h, at room temperature. The reaction was 
quenched with distilled water and extracted with EtOAc. The combined organic layers were dried over 
Na2SO4, filtered and concentrated. The crude was purified by flash chromatography (n-hexane/Et2O 4:1) 
affording 18 (712.1 mg, 64% yield) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.1 Hz, 2H), 6.35-6.25 (m, 
1H), 5.95-5.82 (m, 1H), 4.65-4.63 (m, 2H), 2.46 (s, 3H). 
 
III.4.2.4 Reaction of indole (20) with (E)-4,4,4-trifluorobut-1-en-1-yl 4-
methylbenzenesulfonate (18) 
 
To a solution of 20 (20 mg, 0.17 mmol) in dry DMF (1.3 mL) was added NaH (6.8 mg, 0.17 
mmol) at 0ºC under argon. The reaction mixture was stirred at that temperature for 45 min. Then 18 
(38.3 mg, 0.19 mmol) was added and mixture was stirred, at 0ºC under argon, for 1 h. The reaction was 
quenched with distilled water and extracted with EtOAc. The combined organic layers were washed 
with water and brine, dried over Na2SO4, filtered and concentrated. The crude was purified by flash 
column chromatography (hexane/Et2O 4:1 to 3:2) affording a mixture of compounds 24(Z/Z)(Z/E) 
(1:0.3) (10.3 mg,17% yield) and compound 25 (18.8 mg, 51% yield). 
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(4-fluoro-4-(5-(methylsulfonyl)-1H-indol-1-yl)buta-1,3-dien-1-yl 4-methylbenzenesulfonate 
[24(Z/Z)(Z/E)] 
 
1H NMR (400 MHz, CDCl3) δ 7.89-7.76 (m, 4H), 7.61 (d, J = 7.4 Hz, 2H), 7.50-7.32 (m, 6H), 
7.32-7.17 (m, 4H), 7.14 (d, J = 3.5 Hz, 1H), 7.09 (d, J = 3.4 Hz, 1H), 6.66-6.61 (m, 2H), 6.47 (d, J = 5.4 
Hz, 1H for Z/Z), 6.38 (d, J = 6.0 Hz, 1H for E/Z), 6.07 (dd, J = 11.4, 6.1 Hz, 1H for E/Z), 5.98 (dd, J = 
11.0, 5.6 Hz, 1H for Z/Z), 5.64 (dd, J = 29.2, 11.2 Hz, 1H for Z/Z), 5.32-5.24 (m, 1H for E/Z), 2.50-2.40 
(m, 6H). 
 
(Z)-4,4,4-trifluorobut-1-en-1-yl 4-methylbenzenesulfonate (25) 
 
1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 8.2 Hz, 2H, H5), 7.36 (d, J = 8.1 Hz, 2H, H6), 6.64 
(d, J = 5.9 Hz, 1H, H1), 5.00 (dd, J = 13.6, 7.1 Hz, 1H, H2), 2.91-2.72 (m, 2H, H3), 2.45 (s, 3H, H8). 
13C NMR (101 MHz, CDCl3) δ 146.0 (C7), 139.0 (C1), 132.3 (C4), 130.2 (2 x C5), 128.0 (C6), 
125.3 (q, J = 276.7 Hz, CF3), 106.0 (C2), 29.6 (q, J = 31.2 Hz, C3), 21.77 (C8); 
IR (NaCl) 1377, 1193, 1181, 1056, 984 cm-1 
MS (EI) m/z 280.02 [M]+ (calcd for C11H11F3O3S 280.04). 
 
III.4.2.5 Synthesis of but-2-en-1-yl methanesulfonate (26) 
 
To a solution of but-2-en-1-ol (200 mg, 2.77 mmol), in dry DCM (2 mL), was added TEA (0.4 
mL, 3.05 mmol), in an ice bath. The mixture was stirred for 10 min, at this temperature, and then mesyl 
chloride (0.2 mL, 3.05 mmol) was added. The reaction was stirred for 30 min at 0ºC, then the ice bath 
was removed and the mixture was stirred for 1 h, at room temperature. The reaction was quenched with 
distilled water and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered 
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and concentrated. The crude was purified by flash chromatography (n-hexane/Et2O 4:1) affording 26 
(332.8 mg, 80% yield) was a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 5.94-5.85 (m, 1H), 5.64-5.56 (m, 1H), 4.61 (d, J = 6.6 Hz, 2H), 
2.95 (s, 3H), 1.72 (d, J = 6.1 Hz, 2H). 
Spectral data were in accordance with the literature.137 
 
III.4.2.6 Reaction of indole (20) with but-2-en-1-yl methanesulfonate (26) 
 
III.4.2.6.1 In DMF using NaH as base 
To a solution of 20 (20 mg, 0.17 mmol) in dry DMF (1.3 mL) was added NaH (6.8 mg, 0.17 
mmol) at 0ºC under argon. The reaction mixture was stirred at that temperature for 45 min. Then 26 
(28.2 mg, 0.19 mmol) was added and mixture was stirred, at 0ºC under argon, for 1 h. The reaction was 
quenched with distilled water and extracted with EtOAc. The combined organic layers were washed 
with water and brine, dried over Na2SO4, filtered and concentrated. The crude was purified by flash 
chromatography (n-hexane/Et2O 3:2) affording 27, as a colorless oil, in 34% yield (10mg). 
 
III.4.2.6.2 In THF using n-BuLi as base  
The same procedure, as described above, was performed in THF (1.3 mL), using a 1.5 M 
solution of n-BuLi in n-hexane (0.1 mL, 0.17 mmol) as base. Product 27 was obtained in 18% yield (5.3 
mg). 
 
1-(but-2-en-1-yl)-1H-indole (27) 
 
1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 7.9 Hz, 1H), 7.41 (d, J = 7.9 Hz, 1H), 7.28 (t, J = 
7.5 Hz, 1H), 7.20-7.16 (m, 2H), 6.58 (d, J = 2.6 Hz, 1H), 5.77-5.64 (m, 2H), 4.71 (s, 2H), 1.77 (s, 3H). 
Spectral data were in accordance with the literature.138 
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III.4.2.7 Reaction of cyclohexylmanine with (E)-4,4,4-trifluorobut-2-en-1-yl 
methanesulfonate (12) 
 
To a solution cyclohexylamine (150 mg, 1.51 mmol) in dry THF (6 mL), was added 12 (102.9 
mg, 0.50 mmol) and the mixture was stirred, at room temperature under argon, for 24 h. The reaction 
was quenched with distilled water and extracted with DCM. The combined organic layers were washed 
with water and brine, dried over Na2SO4, filtered and concentrated. The crude was purified by flash 
chromatography (n-hexane/Et2O 1:1) affording 28, as a colorless oil, in 72% yield (74.6 mg). 
 
(E)-N-(4,4,4-trifluorobut-2-en-1-yl)cyclohexanamine (28) 
 
1H NMR (400 MHz, CDCl3) δ 6.45-6.39 (m, 1H, H2), 5.84-5.75 (m, 1H, H3), 3.37-3.35 (m, 
2H, H1), 2.44-2.37 (m, 1H, H4), 1.86-1.83 (m, 2H, H5 and H9), 1.72-1.69 (m, 2H, H6 and H8), 1.60-
1.57 (m, 1H, H7), 1.25-0.99 (m, 5H, H5, H6, H7, H8 and H9); 
13C NMR (101 MHz, CDCl3) δ 139.7 (q, J = 6.2 Hz, C2), 123.3 (q, J = 269.1 Hz, CF3), 118.6 
(q, J = 33.6 Hz, C3), 56.4 (C4), 46.8 (C1), 33.7 (C5 and C9), 26.2 (C7), 25.0 (C6 and C8). 
 
III.4.2.8 Mass spectrometry studies 
III.4.2.8.1 GC-MS studies 
The temperature program used was: 60ºC (2 min), 10ºC/min till 250ºC (10 min); Tinjector: 250ºC; 
Splitless time of 1 min; Tinterface: 250ºC; Solvent delay of 5 min; Vinjected: 1µL. 
Three assays were performed in GC-MS: a) reaction crude without work-up; b) reaction crude 
after work-up but without purification and; c) reaction products isolated by PTLC.  
The procedure used is described above in section III.4.3.1, using the conditions mentioned in 
table III.9, entry 9. 
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Table III.10 – GC-MS studies. 
  Relative intensity (%)  
Retention time (min) [M]+ (FI) a) b) c)* Fragmentations (EI) 
11.77 203.99 
49 64 
100 126.02; 78.97 
11.83 183.99 --- 105.01 
12.79 204.00 15 12 24 126.03; 108.99; 78.98 
13.31** 204.00; 184.00 17 22 --- 125.01; 109.01; 78.97; 64.96 
15.63 225.04 28 13 --- 156.08; 116.05 
16.15 225.06 32 27 --- 156.08 
17.93*** 117.06 100 100 --- 90.02; 63.01; 58.52 
20.21 195.05 11 8 --- 116.04 
20.77 225.08 5 --- --- --- 
*Between 20-28 min there is a broad peak that corresponds to a compound with a MW of 281.05. This 
observation is due to the retention of the compound in the column. 
**Corresponds to compound 12. Co-elution with a compound with MW of 184.00. 
***Corresponds to compound 20. 
 
III.4.2.8.2 MS studies 
The crudes a) and b) as well as the reaction products isolated by PTLC (c)) previously analyzed 
by GC-MS (section III.4.3.7.1) were submitted to MS analysis. The assays were carried out without 
heating on probe and also with temperature on probe = 50ºC. 
 
Table III.11 – MS studies. 
 Relative intensity (%) 
 Without Δ Tprobe = 50ºC 
[M]+ a) b) c) a) b) c) 
      1st spectrum 2nd spectrum 
117.06 100 100 --- 4 1 --- --- 
184.00 4 15 --- 1 ---   
195.04 14 1 --- 14 ---   
203.99 25 34 100 7 5 100 5 
225.08 45 8 --- 7 --- --- --- 
281.05 --- --- --- 100 100 --- 100 
301.06 --- --- --- 12 3 --- 5 
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III.4.3 Studies towards a new methodology for the synthesis of sulfonyl-
containing compounds 
III.4.3.1 General 
Melting points were determined on a Reichert Thermovar apparatus and are uncorrected. 1H- 
and 13C-NMR spectra were recorded in DMSO, CDCl3, d8-THF or C6D6 on a Bruker ARX 400 
spectrometer at 400 and 100.62 MHz respectively. Chemical shifts are expressed in parts per million 
(ppm) relative to tetramethylsilane (TMS). The coupling constants (J) are reported in Hertz (Hz). High 
resolution mass spectra were recorded on an AutoSpecQ spectrometer. Elemental analysis spectra were 
recorded on a Thermo Finnigan-CE Instruments, model Flash EA 1112 CHNS series. IR spectra were 
run on an FT PerkinElmer 683 instrument, with absorption frequencies expressed in reciprocal 
centimeters. Anhydrous solvents were dried as described131 and freshly distilled and degassed. All the 
air-sensitive reactions were performed or prepared in a glovebox. 
 
III.4.3.2 Synthesis of 1,1'-sulfonylbis(benzotriazole) (33)117 
 
To a solution of 1-(trimethylsilyl)-1H-benzotriazole (32) (1.4 mL, 7.84 mmol), in dry toluene 
(2 mL), cooled with an ice bath, was slowly added SO2Cl2 (0.32 mL, 3.92 mmol), under argon 
atmosphere. The mixture was allowed to warm to room temperature and was stirred for 24 h. After that 
time the solid was filtered and washed with Et2O, affording 33 with 48% yield (1.13 g) as a white solid.  
m.p. 110-113ºC (Et2O) [lit.
115 165-166ºC (dec.) (Et2O)]; 
1H NMR (400 MHz, CDCl3) δ 8.24 (d, J = 8 Hz, 2H), 8.09 (d, J = 8.0 Hz, 2H), 7.80-7.76 (m, 
2H), 7.57-7.53 (m, 2H); 
IR (KBr) 1442, 1204, 905, 751 cm-1; 
Spectral data were in accordance with the literature.117 
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III.4.3.3 Reaction of 1,1'-sulfonylbis(benzotriazole) (33) with sodium sulfite and sodium 
hydrogenoarbonate118 
 
A solution of Na2SO3 (29.4 mg, 0.23 mmol), in H2O (0.3 mL), was stirred for 10 min at room 
temperature. Then NaHCO3 (39.2 mg, 0.46 mmol) was added and the mixture was stirred at 50ºC for 1 
h. Compound 33 (70 mg, 0.23 mmol) was added and the reaction mixture was stirred for 3 h at 50ºC. 
The solvent was removed under reduced pressure, redissolved in MeOH and the solid was filtered. This 
reaction afforded a complex mixture of products that were not possible to identify. 
 
III.4.3.4 Reactions of 1-(trimethylsilyl)-1H-benzotriazole (32) with an excess of sulfuryl 
chloride 
 
III.4.3.4.1 In toluene, using 1.1 equivalents of sulfuryl chloride 
To a solution of 1-(trimethylsilyl)-1H-benzotriazole (32) (0.19 mL, 1.04 mmol), in dry toluene 
(0.4 mL), cooled with an ice bath, was slowly added SO2Cl2 (93.2 µL, 1.15 mmol), under argon 
atmosphere. The mixture was allowed to warm to room temperature and was stirred for 24 h. After that 
time the solid was filtered and washed with Et2O, affording 33 with 41% yield (129.3 mg) as a white 
solid. 
m.p. 105-110ºC (Et2O) [lit.
117 165-166ºC (dec.) (Et2O)]; 
1H NMR (400 MHz, CDCl3) δ 8.24 (d, J = 8.1 Hz, 2H), 8.09 (d, J = 8.1 Hz, 2H), 7.78 (t, J = 
7.5 Hz, 2H), 7.55 (t, J = 7.6 Hz, 2H); 
IR (KBr) 1442, 1205, 905, 752 cm-1. 
 
III.4.3.4.2 Neat conditions, using 5 equivalents of sulfuryl chloride 
In a round bottom flask containing SO2Cl2 (0.42 mL, 5.23 mmol), cooled with an ice bath, was 
slowly added 1-(trimethylsilyl)-1H-benzotriazole (32) (0.19 mL, 1.04 mmol), under argon atmosphere. 
Then the ice bath was removed and the mixture was stirred for 24 h. After this time Et2O was added and 
the solid was filtered and washed with Et2O, affording benzotriazole (31) in 75% yield (93.7 mg) as a 
white solid. 
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m.p. 95-97ºC (lit.139 96-99ºC); 
1H NMR (400 MHz, CDCl3) δ 7.95-7.92 (m, 2H), 7.43-7.40 (m, 2H); 
IR (KBr) 3085, 2800, 1212, 743 cm-1. 
 
III.4.3.5 Reaction of benzimidazole (35) with tionyl chloride119 
 
To a solution of 35 (250 mg, 2.12 mmol), in dry DCM (2 mL), was slowly added SOCl2 (38.5 
µL, 0.53 mmol), under argon atmosphere. The mixture was stirred at room temperature for 30 min. After 
that time the solution was filtered, under argon, and the solid was washed with dry DCM (5 mL). SOCl2 
(16.2 µL, 0.22 mmol) was slowly added to the solution. The mixture was stirred for 10 min then NaH 
(17.8 mg, 0.44 mmol) and H2O (8 µL, 0.44 mmol) were added. The solid was filtered and washed with 
dry DCM, affording benzimidazole sodium salt, as a white solid. 
1H NMR (400 MHz, DMSO-d6) δ 8.10 (s, 1H), 7.54-7.51 (m, 2H), 7.10-7.08 (m, 2H); 
IR (KBr) 2930, 1458, 1410, 1246, 744 cm-1. 
Data are in accordance with authentic sample. 
 
III.4.3.6 Studies towards SO2 capture using NHCs 
III.4.3.6.1 Reaction of 1,3-di-tert-butylimidazol-2-ylidene (37) with SO2 
 
III.4.3.6.1.1 Neat conditions 
In a dried schlenk containing 37 (20 mg, 0.11 mmol), cooled at -20ºC, fitted with a condenser, 
cooled at -78ºC, was introduced SO2 gas till the solid was complete covered with SO2 liquid. The sulfur 
dioxide flow was stopped and the flask allowed to warm up to -10ºC and left stirring for 1h. The cooling 
baths were removed and a flow of argon was introduced in the system, till complete evaporation of SO2, 
affording 15 mg of a white solid that was analyzed without further purification. 
m.p. 145-150ºC; 
1H NMR (400 MHz, CDCl3) δ 10.17 (s, < 1H, H1), 9.59 (s, < 1H, H1’), 7.56 (s, 2H, H2), 1.71 
(s, 18H, H4); 
13C-NMR (101 MHz, CDCl3) δ 134.2 (C1), 120.2 (C2), 60.9 (C3), 30.1 (C4); 
IR (KBr) 3055, 2974, 1547, 1377, 1205, 1136, 1041, 968, 782 cm-1; 
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Elemental analysis Calcd.: C, 54.07; N, 11.46; H, 8.25; S, 13.12; Found: C, 47.11; N, 9.62; 
H, 6.88; S, 10.50. 
 
III.4.3.6.1.2 Reaction in solution 
General: In a dried schlenk containing a 0.1 M solution of 37, cooled at -20ºC, was bubbled 
SO2 gas, for 5 min. The sulfur dioxide flow was stopped and the mixture was left stirring for 1 h. The 
cooling baths were removed and a flow of argon was introduced in the system, till complete evaporation 
of SO2. Then the solvent was removed under vacuum and the solid collected was analyzed without 
further purification. 
 
In toluene 
m.p. hygroscopic; 
1H NMR (400 MHz, DMSO-d6) δ 9.88 (s, < 1H, H1), 9.17 (s, <1 H, H1’), 9.06 (s, < 1H, H1’’), 
8.07 (s, 2H, H2), 1.61 (s, 18H, H4); 
1H NMR (400 MHz, DMSO-d6+D2O) δ 8.95 (s, 1H, H1), 7.96 (s, 2H, H2), 1.58 (s, 18H, H4) 
13C-NMR (101 MHz, DMSO-d6) δ 132.2 (C1), 120.4 (C2), 59.6 (C3), 29.1 (C4); 
IR (KBr) 3432 (br), 2978, 1640, 1545, 1379, 1203, 1124, 1096, 970 cm-1. 
 
In diethyl ether 
m.p. 199-204ºC; 
1H NMR (400 MHz, DMSO-d6) δ 9.88 (s, < 1H, H1), 9.05 (s, <1 H, H1’), 8.07 (s, 2H, H2), 
1.61 (s, 18H, H4); 
13C-NMR (101 MHz, DMSO-d6) δ 132.3 (C1), 120.5 (C2), 59.6 (C3), 29.1 (C4); 
IR (KBr) 3055, 1205, 1124, 968, 810 cm-1; 
Elemental analysis Calcd.: C, 54.07; N, 11.46; H, 8.25; S, 13.12; Found: C, 49.20; N, 10.13; 
H, 7.33; S, 11.27. 
 
III.4.3.6.2 Synthesis of 1,3-di-tert-butylimidazolidine-2-ylidene (39) 
 
To a solution of 1,3-bis(tert-butyl)ylimidazolinium chloride (200 mg, 0.91 mmol), in dry 
toluene (2.7 mL), was added KHMDS (182.4 mg, 0.91 mmol). The mixture was stirred for 2 h at room 
temperature. After this time the crude was filtered under celite. The solvent was removed under vacuum, 
affording 39, in 80% yield (132.4 mg) as a beige solid. 
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1H NMR (400 MHz, C6D6) δ 3.03 (s, 4H, H2), 1.36 (s, 18H, H4); 
13C NMR (101 MHz, C6D6) δ 218.3 (C1), 54.0 (C2), 44.5 (C3), 30.0 (C4); 
Spectral data were in accordance with the literature.140 
 
III.4.3.6.3 Reaction of 1,3-di-tert-butylimidazolidine-2-ylidene (39) with SO2 
 
In a dried schlenk containing 39 (100 mg, 0.55 mmol), in dry THF (2 mL), was bubbled SO2 
gas, for 5 min. The sulfur dioxide flow was stopped and the mixture was left stirring for 20 min. A flow 
of argon was introduced in the system, till complete evaporation of SO2. Then the solvent was removed 
under vacuum, affording 103.1 mg of a white solid that was analyzed without further purification. 
m.p. hygroscopic 
1H NMR (400 MHz, DMSO-d6) δ 8.15 (s, 1H, H1), 3.92 (s, 4H, H2), 1.35 (s, 18H, H4); 
IR (KBr) 2972, 1634, 1210, 1173, 972 cm-1. 
 
III.4.3.6.4 Synthesis of 1,3-bis-(2,6-di-iso-propylphenyl)imidazolin-2-ylidene (41) 
 
To a solution of 1,3-bis(2,6-di-iso-propylphenyl)imidazolinium chloride (43) (200 mg, 0.47 
mmol), in dry toluene (2.5 mL), was added KHMDS (133.5 mg, 0.47 mmol). The mixture was stirred 
for 2 h at room temperature. After this time the crude was filtered under celite and the solvent was 
removed under vacuum, affording 41, in 52% yield (96 mg) as a beige solid. 
1H NMR (400 MHz, C6D6) δ 7.31-7.28 (m, 2H, H6), 7.16 (4H, H5, under the solvente peak), 
6.61 (s, 2H, H2), 2.61-2.47 (m, 6H, H7), 1.28 (d, J = 7 Hz, 12H, H8), 1.18 (d, J = 7 Hz, 12H, H9); 
13C NMR (101 MHz, C6D6) δ 220.4 (C1), 146.1 (C4), 138.8 (C3), 128.8 (C6), 123.5 (C5), 121.4 
(C2), 28.6 (C7), 24.6 (C8), 23.5 (C9). 
Spectral data were in accordance with the literature.141 
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III.4.3.6.5 Reaction of 1,3-bis-(2,6-di-iso-propylphenyl)imidazolin-2-ylidene (41) with 
SO2 
 
III.4.3.6.5.1 Neat conditions 
In a dried schlenk containing 41 (80 mg, 0.20 mmol) cooled at -20ºC, fitted with a condenser 
cooled at -78ºC, was introduced SO2 gas till the solid was complete covered with SO2 liquid. The sulfur 
dioxide flow was stopped and the flask allowed to warm up to -10ºC and left stirring for 1 h. The cooling 
baths were removed and a flow of argon was introduced in the system, till complete evaporation of SO2, 
affording 49.2 mg of a white solid that was analyzed without further purification. 
m.p. 289-300ºC (dec.); 
1H NMR (400 MHz, d8-THF) δ 10.60 (s, 1H, H1), 8.23 (s, 2H, H2), 7.54 (t, J = 7.7 Hz, 2H, 
H6), 7.39 (d, J = 7.7 Hz, 4H, H5), 2.61-2.47 (m, 6H, H7), 1.26-1.25 (m, 24H, H8 and H9); 
13C-NMR (101 MHz, d8-THF) δ 146.4 (C4), 141.7 (C1), 132.4 (C6), 131.9 (C3), 127.5 (C2), 
125.2 (C5), 30.0 (C7), 24.8 (C8), 24.1 (C9); 
IR (KBr) 2965, 1545, 1199, 1177, 1059 cm-1; 
 
III.4.3.6.5.2 Reaction in solution 
In a dried schlenk containing 41 (45 mg, 0.12 mmol), in dry THF (2 mL), was bubbled SO2 gas, 
for ca 5 min. The sulfur dioxide flow was stopped and the mixture was left stirring for 1 h. A flow of 
argon was introduced in the system, till complete evaporation of SO2. Then the solvent was removed 
under vacuum, affording 52.6 mg of a beige solid. 1H-NMR spectrum of this solid showed a complex 
mixture of products that was no further investigated. 
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III.4.3.6.6 Reaction of 1,3-bis(2,6-di-iso-propylphenyl)imidazolinium chloride (43) with 
SO2 
 
In a dried schlenk containing 43 (100 mg, 0.23 mmol), in dry THF (2 mL), was added a 1 M 
solution of LiHMDS (0.26 mL, 0.26 mmol). The solution was stirred for 2 h at room temperature. After 
that time, the mixture was cooled at -50ºC and SO2 was bubbled for ca 5 min, then stirred for 10 min, 
then SO2 was bubbled for another 5 min. The reaction was stirred for 30 min. The cooling bath was 
removed, and a flow of argon was introduced till complete evaporation of SO2. The solvent was removed 
under vacuum and the solid washed with dry Et2O, affording 89.3 mg a beige solid that was analyzed 
without further purification. 
m.p. 278-285ºC 
1H NMR (400 MHz, DMSO-d6) δ 10.16 (s, 1H, H1), 8.55 (s, 2H, H2), 7.68 (t, J = 7.6 Hz, 2H, 
H6), 7.52 (d, J = 7.6 Hz, 4H, H5), 2.36-2.32 (m, 4H, H7), 1.25 (d, J = 6.8 Hz, 12H, H8), 1.15 (d, J = 6.8 
Hz, 12H, H9); 
IR (KBr) 2969, 1537, 948, 810 cm-1. 
 
III.4.3.6.7 Synthesis of 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene (42) 
 
To a solution of 1,3-bis(2,4,6-trimethylphenyl)imidazolinium chloride (44) (200 mg, 0.59 
mmol), in dry toluene (2.5 mL), was added KHMDS (133.5 mg, 0.59 mmol). The mixture was stirred 
for 2 h at room temperature. After this time the crude was filtered under celite and the solvent was 
removed under vacuum, affording 42 as a beige solid, in 57% yield (103.2 mg). 
 1H NMR (400 MHz, C6D6) δ 6.81 (s, 4H, H5), 6.49 (s, 2H, H2), 2.16 (s, 18H, H7 and H8); 
13C NMR (101 MHz, C6D6) δ 219.2 (C1), 139.3 (C6), 137.3 (C3), 135.4 (C4), 129.1 (C5), 120.6 
(C2), 21.1 (C7), 18.1 (C8). 
 Spectral data were in accordance with the literature.142 
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III.4.3.6.8 Reaction of 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene (42) with SO2 
 
In a dried schlenk containing 42 (80 mg, 0.26 mmol), was added dry THF (8 mL). The schlenk 
was sealed and connected to a vacuum line. Then it was connected to the SO2 system and the schlenk 
was filled with this gas. The solution was stirred for 24 h at room temperature. After that time, a flow 
of argon was introduced till complete evaporation of SO2. The solvent was removed under vacuum, till 
1/3 of the initial volume, then pentane was added. The solid were washed with pentane and dried under 
vacuum, affording a beige solid (52.3 mg) that was analyzed without further purification. 
m.p. > 300ºC (dec.) 
1H NMR (400 MHz, CDCl3) δ 9.37 (s, 1H, H1), 7.67 (s, 2H, H2), 6.99 (s, 4H, H5), 2.31 (s, 6H, 
H7), 2.10 (s, 12H, H8); 
13C NMR (101 MHz, CDCl3) δ 141.4 (C3), 138.2 (C6), 134.3 (C4), 130.7 (C1), 129.9 (C5), 
125.3 (C2), 21.3 (C7), 17.5 (C8); 
IR (KBr) 3432, 2923, 1541, 1230, 1035 cm-1; 
Elemental analysis Calcd.: C, 68.45; N, 7.60; H, 6.56; S, 8.70; Found: C, 60.63; N, 6.55; H, 
6.28; S, 7.01. 
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IV.1 Introduction 
Tuberculosis (TB) is a contagious and deadly disease that spreads through air, and has reached 
pandemic proportions.1 
TB is caused predominantly by the bacillus Mycobacterium tuberculosis (M.tb), which is an 
aerobic pathogenic bacterium that establishes its infection preferentially to the pulmonary system. It is 
a weak Gram-positive rod-shaped bacterium that has no flagellum, does not form spores nor produces 
toxins and it has no capsule. Currently, there are 60 known species among the Mycobacterium genera 
and a minority of these species are pathogenic to humans, causing TB (M. tuberculosis, M. bovis and 
M. africanum) and leprosy (M. leprae).2 Mycobacteria produce an extremely uncommon cell wall 
structure. Its peptidoglycan contains N-glycolylmuramic acid instead of the usual N-acetylmuramic acid. 
Another distinctive feature is that up to 60% of the mycobacterial cell wall is composed of lipids that 
consists almost of unusually long-chain fatty acids with 60 to 90 carbons, the mycolic acids. Mycolic 
acids are branched fatty acids that have a short and a long branch, with 22 to 24 and 40 to 64 carbons, 
respectively. They are covalently bonded to the polysaccharide that composes the cell wall, the 
arabinogalactan, which is bonded to peptidoglycan by a phosphodiester link. Approximately 10% of the 
arabinose residues in the arabinogalactan are substituted by mycolic acids. The cell wall also contains 
several other lipids that are not covalently bonded to this basal skeleton (the mycolycarabinogalactan-
peptodoglycan complex). Although mycobacteria have several cell wall lipid types, some are limited to 
specific species, such as sulfolipids, only present in M.tb and being involved in its pathogenicity (figure 
IV.1).3-5 
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Figure IV.1 – Schematic representation of the mycobacterial cell envelope (adapted from Gokhale, 2007).6 
 
The unique structure of the cell wall of M.tb allows it to lie dormant for many years as a latent 
infection, particularly as it can grow readily inside macrophages, hiding it from the host immune system. 
It usually affects lungs (pulmonary TB), but in about 25% of cases (immunosuppressed people and 
young children) the bacteria enters the blood and infects other parts of the body, such as pleura, 
meninges, lymphatic system, genitourinary system and bones and joints.2 
TB occurs in every part of the world. According to the World Health Organization (WHO), in 
2012, 8.6 million people fell ill with TB and 1.3 million died from this disease. Over 95% of TB deaths 
occur in low- and middle-income countries, and it is among the top three causes of death for women 
aged 15 to 44. The largest number of new TB cases occurred in Asia, accounting for 60% of new cases 
globally. However, sub-Saharan Africa carried the greatest proportion of new cases per population with 
over 255 cases per 100 000 population in 2012. (figure IV.2).1 
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Figure IV.2 – Estimated TB incidence rates in 2012.1 
 
Prior to the explosive spread of human immunodeficiency virus (HIV), TB held the distinction 
of being the single most deadly pathogen for the most part of the 20th century. By the time HIV surpassed 
TB in the late 1990s, the synergy among these two pathogens was apparent: HIV and TB form a lethal 
combination, each speeding the other's progress. Someone who is infected with HIV and TB is much 
more likely to become sick with active TB. In 2012 about 320 000 people died of HIV-associated TB. 
Almost 25% of deaths among people with HIV are due to TB. There were an estimated 1.1 million new 
cases of HIV-positive/TB, 75% of whom living in Africa.1  
The current first-line TB drug regimen is more than 40 years old and consists of rifampicin, 
isoniazid, pyrazinamide and ethambutol (figure IV.3). These antibiotics are effective in active, drug-
susceptible TB, provided that patients complete the course. There is, however, poor patient compliance 
due to the cost of drugs, adverse effects, the long time required for full treatment and the required number 
of drug doses. Non-compliance has contributed to the appearance of multi-drug resistant (MDR) and 
extensively drug resistant (XDR) TB strains. Infection by MDR-TB strains is resistant to second-line 
drugs such as kanamycin, amikacin, capreomycin, p-aminosalicylate, fluoroquinolones (e.g., 
levofloxacin), ethionamide, and cycloserine (figure IV.3). Thus, XDR-TB exhibits resistance to both 
first and second-lines drugs and is virtually incurable.7,8 
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Figure IV.3 – Currently prescribed antitubercular drugs (adapted from Bewley, 2008).8 
 
Globally, in 2012, an estimated 450 000 people developed MDR-TB and there was an estimated 
170 000 death toll. The number of people diagnosed with MDR-TB nearly doubled between 2011 and 
2012, and reached 94 000 worldwide. At least one case of XDR-TB has been reported by 92 countries 
by the end of 2012. On average, an estimated 9.6% of MDR-TB cases have XDR-TB.1 The incidence 
of MDR- and XDR-TB demands renewed efforts in the development of new classes of anti-TB drugs. 
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Table IV.1 summarizes some of the most important attributes that a new drug must have to 
contribute to a future regimen. 
 
Table IV.1 – Important attributes that new TB drug candidates should have and their therapeutic 
objectives (adapted from Wang, 2010).9 
 Desired attributes Therapeutic objectives  
Mechanism of 
action 
Novel mode of 
action 
Active against MDR and XDR 
TB 
Potency and 
efficacy 
Active against both 
replicating and non-
replicating M.tb 
Shorten treatment; effective 
against latent infection, and prevent 
development of resistance to co-
administered drugs 
Drug-drug 
interaction 
Reduced interaction 
with P450 enzymes 
Co-administration with 
antiretroviral drugs 
Pharmacokinetics 
Orally bioavailable, 
acceptable pharmacokinetic 
and pharmacodynamic 
profiles 
Suitable for oral, once daily or 
less frequent administration 
Safety and 
tolerability 
Improved safety 
and tolerability profiles 
Acceptable for treatment of 
drug-susceptible and drug-resistant 
TB, including acceptability for 
treatment of children and pregnant 
women 
Cost Low cost Ensure affordability 
 
At present, there are several drugs being evaluated in clinical trials.9,10 Some of these represent 
novel chemical entities, such as TMC207 and PA824, whereas others are approved drugs being 
redeveloped or repurposed for TB (rifapentine, gatifloxin) (figure IV.4). 
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Figure IV.4 – Compounds in clinical development for the treatment of active TB. 
 
The United States Food and Drug Administration (FDA) agency recently approved TMC20711 
for the treatment of MDR-TB (including XDR-TB) in adults when no other treatment options are 
effective. This is the first antitubercular drug to be approved by FDA in the last four decades. 
Unfortunately, like other known second-line antitubercular drugs, it has been reported to possess 
unwanted side effects. A singular FDA approval in 40 years coupled with the staggering volume of 
mortality from TB stimulate the impetus for the discovery and development of new TB 
chemotherapeutics. 
For the development of a new class of anti-TB drugs the choice of a scaffold and its substitution 
pattern are of almost importance. When considering the vast amount of work published concerning new 
antitubercular agents, several heterocyclic scaffolds have been investigated, such as benzopyranones, 
thiadiazoles, oxadiazoles, triazoles, hydroxyquinolines, pyrimidines, pyrazoles, and nitrofurans (figure 
IV.5).12,13 
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Figure IV.5 – Several scaffolds proposed as antitubercular agents. 
 
Although the indole ring being considered a privileged structure and an attractive scaffold for 
drug discovery, it has been scarcely explored as antitubercular agents (figure IV.6). Moreover, these 
works have been published mostly on the last five years.14-21 Thus, further investigation should be carried 
on that direction. The aim of this work was the development of novel compounds with antitubercular 
activity and indole was selected as scaffold for that purpose. 
 
 
Figure IV.6 – Chemical structures of some indole derivatives reported in literature possessing 
antitubercular activity. 
 
A QSAR approach was used to develop classification and regression models to assist in the 
design and selection of new potentially antitubercular agents. Several QSAR models were built using 
Random Forests (RFs) and Associative Neural Networks (AsNNs) as machine learning techniques, and 
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different types of descriptors.22 Several different training and test sets were built from publicly available 
data sets of compounds, including recent data deposited in the PubChem database. 
Therefore, an indole-based library was synthesized involving the substitution patterns proposed 
by the previously QSARs studies. 
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IV.2 Results and discussion 
The most relevant structural features responsible for the compounds’ biological activities were 
identified after a careful analysis of the literature.12,13 Therefore, a set of virtual molecules was 
computationally generated as a combinatorial library, which comprised analogues of 1355 with distinct 
substitution patterns (the set of generated structures was comprised in the general formula of figure IV.7 
but not all possible structures were generated). The molecular structures were produced by in-house 
developed software that combines SMILES strings of molecular fragments. The data set of the 
compounds was screened by the developed classification and regression models (studies performed by 
the group of Prof. J. Aires de Sousa, from FCT-UNL). 
 
 
Figure IV.7 – Proposed structures submitted for computational screening. 
 
The proposed structures were encoded and their minimum inhibitory concentration (MIC) 
values were predicted. Further, the compounds were divided into two classes, active (MIC ≤ 5 µM) and 
inactive (MIC > 5 µM) compounds. From those, only compounds with low predicted MIC values were 
suggested for further evaluation. Subsequently, the synthetic strategies required for each compound 
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were analysed and five different compounds were considered, based on their predicted MIC and 
synthetic feasibility and promptitude (figure IV.8). 
 
 
Figure IV.8 – Chemical structures of the proposed compounds, chosen for further synthesis and 
antitubercular activity analysis. 
 
The compounds substituted at N-1 and C-5 (figure IV.8, pattern A) were readily synthesized 
from the reaction of the 5-(benzyloxy)-1H-indole (1) sodium salt with 4-fluorobenzyl bromide or 2-
(bromomethyl)pyridine hydrobromide, all commercially available (scheme IV.1). 5-(Benzyloxy)-1-(4-
fluorobenzyl)-1H-indole (2) and 5-(benzyloxy)-1-(pyridin-2-ylmethyl)-1H-indole (3) were obtained in 
97% and 84% yield, respectively. 
 
 
Scheme IV.1 – Synthesis of compounds 2 and 3. 
 
The compounds possessing a 4-chlorobenzene at position C-2 (figure IV.8, pattern B) can be 
achieved by two main pathways: functionalization of the indole ring by direct C-2 arylation or; by indole 
ring assembly using a precursor possessing the aryl group in its structure (e.g. Fischer indolization). 
A procedure described in the literature by Larrosa et al.,23 for the direct C-2 arylation of indole 
with aryl iodides, was applied. For the synthesis of 5-(benzyloxy)-2-(4-chlorophenyl)-1H-indole (4), 5-
(benzyloxy)-1H-indole (1) was treated with 1-chloro-4-iodobenzene, in an organic media catalyzed by 
palladium(II) acetate, silver (I) oxide and o-nitrobenzoic acid. Unfortunately no products formation was 
observed by TLC control, after 48 h. This result can be explained by the lower reactivity of free N-H 
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indoles, under these reaction conditions, observed by the authors. In fact, when the reaction of indole 
with iodobenzene was performed, higher temperature and reaction time was required, 50ºC for 38 h 
instead of 25ºC for 15 h, and the product was obtained only in moderate yield.23 
Next, a procedure reported by Djakovitch et al.,24 that consists on the direct and site-selective 
C-H arylation of (NH)-indoles catalyzed by palladium, was applied. Thus, indole derivative 1 was 
treated with 1-chloro-4-iodobenzene, in the presence of palladium(II) acetate, 1,1-
bis(diphenylphosphino)methane (dppm) and potassium acetate, and compound 4 was obtained in 56% 
yield (scheme IV.2). 
 
 
Scheme IV.2 – Synthesis of 5-(benzyloxy)-2-(4 -chlorophenyl)-1H-indole (4). 
 
For the synthesis of the other C-2 substituted indole derivative, N-benzyl-2-(4-chlorophenyl)-
1H-indol-5-amine (5), the same conditions were applied. However, no reaction occurred during the 
treatment of N-benzyl-1H-indol-5-amine (6) with 1-chloro-4-iodobenzene, in the presence of 
palladium(II) acetate, dppm and potassium acetate (scheme IV.3). 
 
 
Scheme IV.3 – Reaction of N-benzyl-1H-indol-5-amine (6) with 1-chloro-4-iodobenzene. 
 
Since direct C-2 arylation of indole compound 6 was not well succeeded, the next approach to 
synthesize compound 5 consisted on a Fischer indole synthesis. Indole derivative 5 has two substituted 
position, C-2 and C-5, thus the retrosynthetic analysis of this molecule was evaluated in order to select 
the easiest, faster and less expensive pathway. Three different and conceivable approaches are depicted 
on scheme IV.4. 
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Scheme IV.4 – Retrosynthetic analysis of compound 5. 
 
Pathway a consists on a C-N disconnection at position C-5, leading to 5-bromo-2-(4-
chlorophenyl)-1H-indole (7), followed by a C-N/C-C disconnection. This disconnection leads to the 
reagents required for the Fischer indolization, a phenyl hydrazine and a ketone. Both (4-
bromophenyl)hydrazine (9) and 4-chloroacetophenone (10) are commercially available. The first 
disconnection of pathway b results on the indole derivative 11 which, through a functional group 
interconversion (FGI), leads to 2-(4-chlorophenyl)-5-nitro-1H-indole (13). Next, two different 
disconnection are possible: the C-N disconnection at C-5, leading to indole derivative 14 which can be 
prepared by a Fischer indolization by reaction of phenylhydrazine (15) and 4-chloroacetophenone (10) 
(pathway d); and the disconnection at C-N/C-C bonds, resulting in two commercially available reagents: 
(4-nitrophenyl)hydrazine (16) and 4-chloroacetophenone (10) (pathway e). Pathway b/d consists in four 
synthetic steps whereas pathway b/e can afford the desired indole 5 in three synthetic steps. A C-N/C-
C disconnection of indole 5 (pathway c) results in the N-benzyl-4-hydrazinylaniline (17) and 4-
chloroacetophenone (10). A FGI leads 17 to the corresponding aniline, the N-benzylbenzene-1,4-
Chapter IV   New indole derivatives as antitubercular agents: synthetic studies 
171 
 
diamine (18). This compound can be acquired from a few chemical suppliers, however it is offered at 
high costs. Thus, a FGI results in the, also commercially available, N-benzyl-4-nitroaniline (19), 
however, this reagent is also very expensive. To prepare 19, a C-N disconnection leads to the affordable 
4-nitroaniline (20). 
Pathway a was the first choice to synthesize indole derivative 5 due to its simplicity and 
readiness. Scheme IV.5 depicts the synthetic route proposed for the preparation of compound 5 through 
pathway a. 
 
 
Scheme IV.5 – Synthetic route proposed for the preparation of compound 5 through pathway a. 
 
Treatment of (4-bromophenyl)hydrazine hydrochloride (9) with 4-chloroacetophenone (10), in 
polyphosphoric acid (PPA) afforded 5-bromo-2-(4-chlorophenyl)-1H-indole (7) in 85% yield. Next, the 
C-N coupling reaction was attempted. Indole 7 was treated with benzylamine (8), in the presence of 
copper (I) iodide, L-proline and potassium carbonate, under the conditions described by Ma et al.25 
However no product formation resulted from this reaction. Therefore, the reaction conditions reported 
for the Pd-catalyzed amination reactions of heterocycles, described by Buchwald et al.26 were tested. 
These involve the reaction of indole derivative 7 with benzylamine (8) using a BrettPhos based catalyst 
system and lithium hexamethyldisilazide (LiHMDS) in THF as the base. Despite the fact that several 
examples for the C-N coupling of different halo-indoles with varied amines are stated under these 
conditions, no reaction occurred between indole 7 and amine 8. 
Since the compound 7 could not be accomplished through this synthetic route, pathway b/e 
(scheme IV.4) was then considered. This involves three synthetic steps: a Fisher indolization by reaction 
of (4-nitrophenyl)hydrazine (16) with 4-chloroacetophenone (10), next a reduction of the nitro group 
and lastly a reductive amination reaction of compound 11 with benzaldehyde (12) (scheme IV.6). 
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Scheme IV.6 – Proposed synthetic route for the preparation of compound 5 through pathway b/e. 
 
The (4-nitrophenyl)hydrazine hydrochloride (16) was treated with 4-chloroacetophenone (10), 
in PPA. Unfortunately, no reaction took place under these conditions. In fact, only one report was found 
in the literature describing a Fischer indolization reaction of hydrazine 16 with acetophenone.27 The 
conditions described herein were then applied. However, treatment of hydrazine 16 with ketone 10, in 
the presence of phosphomolybdic acid, did not afford any product.  
Probably, the observed absence of reactivity is due to the presence of the nitro group, which is 
a strongly deactivator group, at para-position. For that reason, it was envisaged that the presence of the 
benzylamine group, an activator group, at para-position, would improve the reactivity of the hydrazine 
and the desired product would be successful afforded through the Fischer indole synthesis (scheme IV.4, 
pathway c). The first requirement of this route is to synthesize N-benzyl-4-hydrazinylaniline (17). The 
synthesis of compound 17 can be accomplished from the reductive amination reaction of the 4-
nitroaniline (20) with benzaldehyde (12), followed by reduction of the nitro group, affording N-
benzylbenzene-1,4-diamine (18), and finally conversion of the amine to hydrazine (scheme IV.7). 
Lastly, the desired compound 5 can be obtained from the reaction of the synthesized hydrazine 17 with 
4-chloroacetophenone (10) via a Fischer indolization reaction (scheme IV.7). 
 
 
Scheme IV.7 - Proposed synthetic route for the preparation of compound 5 through pathway c. 
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Synthesis of N-benzyl-4-nitroaniline (19) was performed in 89% yield using solvent-free 
conditions, by grounding 4-nitroaniline (20), benzaldehyde (12), sodium borohydride and silica-gel-
supported sulfuric acid (SSA). Then, compound 19 was reduced, using a Fe/NH4Cl system, affording 
N-benzylbenzene-1,4-diamine (18) in 95% yield. Treatment of aniline 18 with sodium nitrite in aqueous 
HCl, gave the corresponding aryl diazonium salt that was readily converted in the aryl hydrazine 
hydrochloride 17, in the presence of tin (II) chloride and aqueous HCl, in 40% yield. The next step 
consisted on the reaction of 17 with 4-chloroacetophenone (10), in PPA. However, this reaction did not 
afford the desired indole derivative 5, instead decomposition of starting material 17 was observed. 
Since it was not possible to perform a Fischer indolization reaction neither with the nitro group 
nor with the benzilamine group at para-position of the hydrazine, due to its low reactivity or instability, 
respectively, under these reaction conditions, pathway b/d (scheme IV.4) was then considered. This 
route consists in four steps: a Fisher indolization by reaction of phenylhydrazine (15) with 4-
chloroacetophenone (10), followed by a regioselective nitration of position C-5 of 14, affording 2-(4-
chlorophenyl)-5-nitro-1H-indole (13), subsequent reduction of the nitro group, and lastly a reductive 
amination reaction of compound 11 with benzaldehyde (scheme IV.8). 
 
 
Scheme IV.8 - Proposed synthetic route for the preparation of compound 5 through pathway b/d. 
 
The synthesis of 2-phenylindole as well as its regioselective nitration at C-5 position is described 
by Smith et al.28 Therefore, reaction of the phenylhydrazine (15) with 4-chloroacetophenone (10), in 
PPA afforded 2-(4-chlorophenyl)-1H-indole (14) in 66% yield. 2-(4-chlorophenyl)-5-nitro-1H-indole 
(13) was obtained in 82% yield, by treatment of indole 15 with a solution of sodium nitrate in sulfuric 
acid. The next step consisted on the reduction of the nitro group present in compound 13, using a Pd/C, 
H2 system. A mixture of the desired indole derivative 11 along with the dechlorinated product was 
obtained. Therefore, a Fe/NH4Cl system was used, affording exclusively 2-(4-chlorophenyl)-1H-indol-
5-amine (11), in 59% yield. For the reductive amination reaction, the indole derivative 11 was treated 
with benzaldehyde, in the presence of NaBH3CN, affording N-benzyl-2-(4-chlorophenyl)-1H-indol-5-
amine (5) in 78% yield. 
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Concerning the preparation of the ethyl 5-({[5-(benzyloxy)-1H-indol-3-
yl]amino}methyl)tetrahydrofuran-2-carboxylate (21), two different substituents were required: the 
benzyloxy group at C-5, and an alkyl amine derivative at C-3 (figure IV.8, pattern C). The substitution 
at C-5 did not require any synthetic studies since 5-(benzyloxy)-1H-indole (1) is commercially available. 
Thus, only the introduction of the alkyl amine derivative at C-3 position was considered for the 
retrosynthetic analysis of compound 21 (scheme IV.9). 
 
 
Scheme IV.9 - Retrosynthetic analysis of compound 21 for the introduction of the alkyl amine derivative 
at C-3. 
 
Two different approaches were considered. Pathway a consists on the C-N coupling of the 3-
bromo or iodo indole derivative 22 with the alkyl amine derivative 23. Compound 22 can be obtained 
from the C-3 halogenation of 5-(benzyloxy)-1H-indole (1). A FGI of compound 23 results on the 
corresponding furan derivative 24, which can be attained from the 5-(chloromethyl)furan-2-carboxylate 
(25), that is commercially available. Pathway b comprises a SN2 reaction of the 3-aminoindole derivative 
26 with 5-(halomethyl)furan-2-carboxylate derivative 28. A FGI of indole 26 leads to the corresponding 
Chapter IV   New indole derivatives as antitubercular agents: synthetic studies 
175 
 
3-nitroindole derivative 27, which can be afforded from the C-3 nitration of 5-(benzyloxy)-1H-indole 
(1). A FGI to compound 28 leads to compound 25. 
Despite the existence of several procedures in the literature describing C-N coupling reactions 
of aryl halides with amines,26,29,30 amides,31-33 or carbamates,34,35 by catalysis of either copper or 
palladium complexes, no report of the C-N coupling at C-3 position of the indole ring was described to 
date. Therefore, the first attempt to synthesize indole derivative 21 relied on pathway b (scheme IV.9) 
since it was envisaged that would be a more straightforward route. 
The synthetic approach required to synthesize indole derivative via pathway b, consists in a 
convergent synthetic route, as depicted on scheme IV.10. Thus, the 3-aminoindole derivative 26 can be 
afforded from the regioselective nitration reaction at position C-3 of the 5-(benzyloxy)-1H-indole (1), 
followed by reduction of the nitro group present in the indole derivative 27. The desired product 21 can 
be obtained from a SN2 reaction of indole derivative 26 with compound 28, that can be prepared from 
hydrogenation of 25 (scheme IV.10). 
 
 
Scheme IV.10 - Proposed synthetic route for the preparation of compound 21 via pathway b. 
 
Concerning to the nitration reaction, indole was tested as a model molecule, since it is cheaper 
than 5-(benzyloxy)-1H-indole (1) and this reaction is described in the literature.36,37 The nitration of C-
3 position of the indole ring was attempted from two different conditions: reaction of indole with a 
reactive intermediate specie, generated in situ, from chlorodiphenylphosphine (CDP), molecular iodine 
and silver nitrate36, or from silver nitrate and benzoyl chloride37. Both approaches afforded a slurry 
mixture of products which was not possible to separate. 
In 2008, Chang et al.38 firstly reported a procedure for the Cu-catalyzed amination of aryl halides 
using ammonium salts (ammonium chloride or aqueous ammonia) as the nitrogen source. Further, other 
methodologies were published employing aqueous ammonia as the nitrogen source for the amination of 
aryl halides.39-42 Thus, it was envisaged that 5-(benzyloxy)-1H-indol-3-amine (26) could be afforded 
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from the amination reaction of the tert-butyl 5-(benzyloxy)-3-iodo-1H-indole-1-carboxylate (29) 
(scheme IV.11). 
 
 
Scheme IV.11 – Alternative approach for the synthesis of compound 26. 
 
Treatment of indole 1 with potassium hydroxide and molecular iodine afforded the 
corresponding 3-iodoindole derivative that was then treated with Boc anhydride, in the presence of 
triethylamine and DMAP, affording tert-butyl 5-(benzyloxy)-3-iodo-1H-indole-1-carboxylate (29) in 
80% yield. Two different experiments were carried attempting the synthesis of compound 26. The 
reaction of indole 29 with aqueous ammonia catalyzed by: a copper (I) oxide/NMP system41, and an iron 
(III) oxide/copper (I) iodide system42. The first catalytic system did not afford any product and from the 
second only the product resulting from the removal of the Boc group was observed. Unfortunately, 
despite the good yields reported for the amination reaction of aryl halides, these reactions conditions 
could not be applied for the tested substrate. 
Due to the difficulties in synthesizing compound 26, pathway b was abandoned and pathway a 
was then considered. Pathway a also consists in a convergent synthetic route which involves the 
preparations of the alkyl amine 23 and the indole derivative 22 (scheme IV.9, pathway a). 
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Scheme IV.12 – Synthetic approach for synthesis of the amine 23. 
 
The synthesis of compound 23 consisted on the treatment of ethyl 5-(chloromethyl)furan-2-
carboxylate (25) with sodium azide, affording the azide derivative 30, in 90% yield. Subsequent, 
reduction of the azide to amine 24 with PPh3/H2O, followed by protection of the amino group with Boc 
anhydride, afforded compound 31, in 56% yield (two steps). Next step involved the hydrogenation of 
the furan ring, with Pd(OH)2/C under H2 atmosphere ,affording compound 32 in 91% yield. Subsequent, 
treatment of 32 with a 4 M solution of HCl in dioxane afforded ethyl 5-(aminomethyl)tetrahydrofuran-
2-carboxylate hydrochloride (33), in 92% yield. Since the free alkyl amine derivative 23 is not very 
stable, this was prepared and immediately used in the next step (scheme IV.12). 
Collot et al.43 described a procedure to synthetize 3-aminoindazoles derivatives, in moderate to 
good yields, via Buchwald-Hartwig C-N coupling reaction, using a palladium(II) acetate/Xantphos 
catalytic system (scheme IV.13). 
 
 
Scheme IV.13 – Synthesis of 3-aminoindazoles derivatives via Buchwald-Hartwig C-N coupling reaction, 
described by Collot et al.43 
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Thus, the first attempt to synthesize indole derivative 21 consisted on the C-N coupling reaction 
of tert-butyl 5-(benzyloxy)-3-bromo-1H-indole-1-carboxylate (34) with ethyl 5-
(aminomethyl)tetrahydrofuran-2-carboxylate (23), catalyzed by palladium(II) acetate/Xantphos in the 
presence of cesium carbonate. Indole derivative 34 was obtained after protecting the indolic nitrogen 
atom with Boc anhydride, followed by the bromination at C-3 with N-bromosuccinimide (NBS), in 67% 
yield (scheme IV.14). 
 
 
Scheme IV.14 – Proposed synthetic approach of compound 21. 
 
Unfortunately, only the product of debromination of the starting material 34 was observed by 
TLC control, after 24 h of reaction. Same conditions were applied on the reaction of tert-butyl 5-
(benzyloxy)-3-bromo-1H-indole-1-carboxylate (34) with N-Boc alkyl amine derivative 32. In this 
experiment a product was formed, however by analysis of the 1H-NMR spectra it was possible to 
conclude that the amine moiety was not present. This product could not be identified due to its 
instability. 
Alternative reaction conditions for the amination reaction towards heterocyclic compounds 
functionalization, reported by Buchwald et al.,26 were then adopted. The authors performed a C-N 
coupling at C-4 or C-5 positions of the indole ring, using a BrettPhos based catalystic system. Thus, the 
3-bromoindole derivative 34 was treated with ethyl 5-(aminomethyl)tetrahydrofuran-2-carboxylate 
(23), in the presence of the BrettPhos, chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′, 6′-
triisopropyl-1,1′-biphenyl][2-(2-aminoethyl)phenyl]palladium(II) (BrettPhos precatalyst) and 
LiHMDS. However, only removal of the Boc group from the starting 34 was observed by TLC control. 
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Due to the difficulties in performing the C-N coupling reaction of the indole derivative 34 with 
the alkyl amine derivative 23 via palladium catalysis, a copper catalysis was then considered to attempt 
the synthesis of compound 21. 
Several Ulmman-type C-N coupling reactions are mediated by a copper (I)/α-amino acid44 or 
copper (I)/diamine45 catalytic systems. Therefore, two different experiments were performed envisaging 
the synthesis of ethyl 5-({[5-(benzyloxy)-1H-indol-3-yl]amino}methyl)tetrahydrofuran-2-
carboxylate (21). It consisted on the treatment of tert-butyl 5-(benzyloxy)-3-iodo-1H-indole-1-
carboxylate (29) with ethyl 5-(aminomethyl)tetrahydrofuran-2-carboxylate (23) catalyzed by: a CuI/L-
proline; or a CuI/DMEDA catalytic systems. Under the first conditions only the product of de-iodination 
and removal of the Boc group of the starting material 34 was observed by TLC, while when the second 
conditions were tested the C-N coupling product was afforded. However, hydrolysis of the ethyl ester 
occurred and 5-({[5-(benzyloxy)-1-(tert-butoxycarbonyl)-1H-indol-3-yl]amino}methyl) 
tetrahydrofuran-2-carboxylic acid (35) was isolated in 56% yield (scheme. IV.15). 
 
 
Scheme IV.15 – Reaction of indole derivative 29 with the alkyl amine derivative 23. 
 
Despite all efforts, such as the use of dry dioxane as solvent, or the use of potassium phosphate 
as base, it was not possible to avoid the ester hydrolysis. Nevertheless, due to the structural similarity of 
compounds 21 and 35, indole derivative 35 was also submitted for biological evaluation together with 
compounds 2, 3, 4 and 5. 
The biological tests are being performed at Instituto de Higiene e Medicina Tropical in 
collaboration with Faculdade de Ciências da Universidade de Lisboa under the supervision of Prof. 
Filomena Martins. 
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IV.3 Conclusions 
Five indole-based compounds, predicted by computational methods, were synthesized to be 
evaluated as potential antitubercular agents. These compounds were divided in three different 
substitution patterns (figure IV.8): pattern A, C-5 and N-1 substitution (compounds 2 and 3); pattern B, 
C-5 and C-2 substitution (compounds 4 and 5); and pattern C, C-5 and C-3 substitution (compound 21). 
Several approaches and methodologies were applied for the synthesis of these compounds 
(scheme IV.16).  
 
 
Scheme IV.16 – Summary of the synthetic approaches performed towards compounds 2, 3, 4, 5 and 21.  
Chapter IV   New indole derivatives as antitubercular agents: synthetic studies 
181 
 
The synthesis of compounds 2 and 3 (pattern A) consisted on the N-alkylation reactions of the 
indole sodium salt of compound 1 with the corresponding alkyl bromide, via a SN2 reaction. 
Concerning the synthesis of compound 4 (pattern B), a direct C-2 arylation of 1 with an 
arylhalide was performed, via a palladium catalysis. Due to the impossibility to synthesize compound 5 
using the same procedure used to prepare compound 4, a Fischer indolization reaction was attempted, 
followed by a regioselective nitration at position C-5 and subsequent reduction of the nitro group and 
lastly a reductive amination. 
In relation to compound 21, a C-N coupling reaction, at C-3 position of indole, catalyzed by 
copper, was performed. Despite all efforts to avoid the ester hydrolysis, the indole derivative 35 was 
also submitted for biological evaluation due to its structural similarity with compound 21. 
Overall new compounds were synthetized trough useful synthetic routes in order to achieve 
functionalized indole derivatives. The choice of the substitution patterns was based on preliminary 
computational studies upon analysis of several known antitubercular agents. Thus, it is expected that the 
biological evaluation of the synthesized indole derivatives along with the QSARs studies will allow the 
validation of this strategy, opening a new path to the design of new antitubercular agents with improved 
activity. 
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IV.4 Experimental 
IV.4.1 General 
Melting points were determined on a Reichert Thermovar apparatus and are uncorrected. 1H- 
and 13C-NMR spectra were recorded in (CD3)2CO, DMSO-d6 or CDCl3 on a Bruker ARX 400 
spectrometer at 400 and 100.62 MHz respectively. Chemical shifts are expressed in parts per million 
(ppm) relative to tetramethylsilane (TMS). The coupling constants (J) are reported in Hertz (Hz). High 
resolution mass spectra were recorded on an AutoSpecQ spectrometer. IR spectra were run on an FT 
PerkinElmer 683 instrument, with absorption frequencies expressed in reciprocal centimeters. The 
progress of all reaction was monitored by thin-layer chromatography, which was performed on Merck 
silica gel 60 F254 aluminum plates. Flash column chromatography was carried out on Merck silica gel 
60 (230-400 mesh). For preparative thin layer chromatography was used Merck silica gel 60 GF254 in 
20x20 glass plates. Anhydrous solvents were dried as described and freshly distilled.46 All the tested 
compounds possess a purity of at least 94% as determined by HPLC. Analytical HPLC was run on a 
Merck Hitachi system consisting of an L-7100 pump, Rheodyne type injector, a D-7000 interface and 
an L-7450 diode array spectrometric detector, equipped with LiChrospher®100 RP-18 column. Eluent 
system was: 50% A (H2O/TFA pH 2.5), 70% B (MeOH) to 30% A, 100% B; flow rate = 1 mL/min. 
 
IV.4.2 Synthesis of 5-(benzyloxy)-1-(4-fluorobenzyl)-1H-indole (2) 
 
To a solution 5-(benzyloxy)-1H-indole (1) (100 mg, 0.45 mmol) in dry DMF (1.2 mL) was 
added NaH (21.5 mg, 0.54 mmol) at 0ºC under argon. The reaction mixture was stirred at that 
temperature for 45 min. 4-Fluorobenzyl bromide (67 µL, 0.54 mmol) was added and the mixture was 
stirred, from 0ºC to room temperature, under argon, for 3 h. The reaction was quenched with distilled 
water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried 
over Na2SO4 anhydrous, filtered and concentrated. The crude was purified by flash chromatography (n-
hexane/Et2O 7:3) affording compound 2 in 97% yield (144.6 mg) as a white solid. 
m.p. 75-76ºC (n-hexane/Et2O) (lit.
47 77-78ºC); 
1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 7.2 Hz, 2H), 7.39 (t, J = 7.2 Hz, 2H), 7.32 (t, J = 7.2 
Hz, 1H), 7.20 (d, J = 2.3 Hz, 1H), 7.14 (d, J = 8.9 Hz, 1H), 7.09 (d, J = 3.1 Hz, 1H), 7.08-7.05 (m, 2H), 
6.98 (t, J = 8.6 Hz, 2H), 6.93 (dd, J = 8.9, 2.3 Hz, 1H), 6.47 (d, J = 3.1 Hz, 1H), 5.25 (s, 2H), 5.11 (s, 
2H); 
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 13C NMR (101 MHz, CDCl3) δ 162.3 (d, J = 246.0 Hz, CF), 153.5, 137.8, 133.4 (d, J = 3.2 Hz), 
131.8, 129.3, 128.8, 128.6 (2 x CH), 128.5 (d, J = 8.1 Hz), 127.9, 127.7 (2 x CH), 115.8 (d, J = 21.6 
Hz), 112.9, 110.5, 104.4, 101.6, 71.0, 49.8; 
IR (KBr) 1487, 1240, 1017, 810 cm-1; 
Purity 94% 
Spectral data were in accordance with the literature.47 
 
IV.4.3 Synthesis of 5-(benzyloxy)-1-(pyridin-2-ylmethyl)-1H-indole (3) 
 
To a solution 5-(benzyloxy)-1H-indole (1) (100 mg, 0.45 mmol) in dry DMF (1.2 mL), was 
added NaH (21.5 mg, 0.54 mmol) at 0ºC under argon. The reaction mixture was stirred at that 
temperature for 45 min. 2-(Bromomethyl)pyridine hydrobromide (135.9 mg, 0.54 mmol) was added and 
the mixture was stirred, from 0ºC to room temperature, under argon, for 24 h. The reaction was quenched 
with distilled water and extracted with EtOAc. The combined organic layers were washed with water 
and brine, dried over Na2SO4 anhydrous, filtered and concentrated. The crude was purified by flash 
chromatography (n-hexane/Et2O 2:3) affording compound 3 in 84% yield (117.8 mg), as a white solid. 
m.p. 115-117ºC (n-hexane/Et2O);  
1H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 4.0 Hz, 1H, H15), 7.52 (t, J = 7.7, 1H, H17), 7.47 
(d, J = 7.3 Hz, 2H, H10), 7.39 (t, J = 7.3 Hz, 2H, H11), 7.32 (t, J = 7.3 Hz, 1H, H12), 7.20 (d, J = 2.3 
Hz, 1H, H4), 7.18 (d, J = 3.2 Hz, 1H, H2), 7.17-7.15 (m, 2H, H7 and H16), 6.92 (dd, J = 8.9, 2.3 Hz, 
1H, H6), 6.67 (d, J = 7.8 Hz, 1H, H18), 6.51 (d, J = 3.2 Hz, 1H, H3), 5.43 (s, 2H, H13), 5.10 (s, 2H, 
H8); 
13C NMR (101 MHz, CDCl3) δ 157.8 (C14), 153.6 (C5), 149.5 (C15), 137.8 (C9), 137.2 (C17), 
131.8 (C7’), 129.3 (C3’), 129.2 (C2), 128.6 (2 x C11), 127.9 (C12), 127.7 (2 x C10), 122.6 (C16), 120.8 
(C18), 113.0 (C6), 110.6 (C7), 104.4 (C4), 101.9 (C3), 71.0 (C8), 52.4 (C13); 
IR (KBr) 3444, 1484, 1237, 1019 cm-1; 
HRMS (ESI) m/z 315.1495 [M+H]+ (calcd for C21H19N2O 315.1497); 
Purity 100% 
 
 
 
Chapter IV   New indole derivatives as antitubercular agents: synthetic studies 
184 
 
IV.4.4 Synthesis of 5-(benzyloxy)-2-(4-chlorophenyl)-1H-indole (4) 
 
 
IV.4.4.1 Reaction catalyzed by palladium(II) acetate, silver(I) oxide and 2-nitrobenzoic 
acid23 
A solution of 1 (50.0 mg, 0.22 mmol), Pd(OAc)2 (2.5 mg, 0.01 mmol), Ag2O (38.9 mg, 0.17 
mmol), 2-nitrobenzoic acid (56.1 mg, 0.33 mmol) and 1-chloro-4-iodobenzene (106.8 mg, 0.45 mmol), 
in dry DMF (0.45 mL), was stirred under argon, at 50ºC, for 48 h. No product formation was observed 
after TLC control. 
 
IV.4.4.2 Reaction catalyzed by palladium(II) acetate, dppm and potassium acetate24 
In a dried ACE pressure tube, containing 1 (100.0 mg, 0.45 mmol), 1-chloro-4-iodobenzene 
(128.2 mg, 0.54 mmol), Pd(OAc)2 (5.0 mg, 0.02 mmol), dppm (8.6 mg, 0.02 mmol) and KOAc (131.9 
mg, 1.34 mmol), was added degassed H2O (1 mL), under an argon atmosphere. The mixture was stirred 
for 24 h at 100ºC. After this time, the reaction was quenched with 1 M HCl and extracted with EtOAc. 
The combined organic layers were washed with water and brine, dried over Na2SO4 anhydrous, filtered 
and concentrated. The crude was purified by flash chromatography (n-hexane/EtOAc 5 to 20%) 
affording compound 4 in 56% yield (83.7 mg), as a white solid. 
m.p. 180-182ºC (n-hexane/EtOAc);  
1H NMR [400 MHz, (CD3)2CO] δ 10.60 (s, 1H, NH), 7.83 (d, J = 8.7 Hz, 2H, H15), 7.50 (d, J 
= 7.5 Hz, 2H, H10), 7.46 (d, J = 8.7 Hz, 2H, H14), 7.39 (t, J = 7.5 Hz, 2H, H11), 7.36-7.27 (m, 2H, H7 
and H12), 7.17 (d, J = 2.3 Hz, 1H, H4), 6.88 (dd, J = 8.8, 2.3 Hz, 1H, H6), 6.84 (s, 1H, H3), 5.13 (s, 2H, 
H8); 
13C NMR [101 MHz, (CD3)2CO] δ 154.4 (C5), 139.1 (C9), 138.1 (C13), 133.8 (C7’), 133.7 
(CCl), 133.2 (C2), 130.5 (C3’), 129.8 (2 x C14), 129.2 (2 x C11), 128.4 (C12), 128.3 (2 x C10), 127.3 
(2 x C15), 114.1 (C6), 112.8 (C7), 104.3 (C4), 100.5 (C5), 71.0 (C8); 
IR (KBr) 3436, 1215, 1096, 731 cm-1; 
HRMS (ESI) m/z 334.0982 [M+H]+ (calcd for C21H17ClNO 334.0999); 
Purity 98% 
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IV.4.5 Reaction of N-benzyl-1H-indol-5-amine (6) with 1-chloro-4-
iodobenzene, catalyzed by palladium(II) acetate, dppm and potassium 
acetate24 
 
In a dried ACE pressure tube, containing 6 (50.0 mg, 0.22 mmol), 1-chloro-4-iodobenzene (64.1 
mg, 0.27 mmol), Pd(OAc)2 (2.8 mg, 0.01 mmol), dppm (4.8 mg, 0.01 mmol) and KOAc (66.4 mg, 0.67 
mmol), was added degassed H2O (0.5 mL), under an argon atmosphere. The mixture was stirred for 24 
h at 100ºC. No product formation was observed after TLC control. 
 
IV.4.6 Synthesis of 5-bromo-2-(4-chlorophenyl)-1H-indole (7)28 
 
In a two-neck round bottom flask, equipped with a thermometer, was added (4-
bromophenyl)hydrazine hydrochloride (9) (200 mg, 0.84 mmol) and 4-chloroacetophenone (10) (0.12 
mL, 0.84 mmol). The mixture was stirred for 5 min. Then PPA (ca. 1 g) was added and the reaction 
mixture was gently warmed to 110ºC. After 2 h stirring at that temperature, the reaction was poured 
onto ice. A solution of 2 M NaOH was added till pH ≈ 7. The solid was filtered by suction and purified 
by flash chromatography (n-hexane/Et2O 7:3) affording compound 7 in 85% yield (233.7 mg), as a white 
solid. 
m.p. 190-192ºC (n-hexane/Et2O 7:3);  
1H NMR [400 MHz, CD3)2CO] δ 10.96 (s, 1H, NH), 7.91-7.83 (m, 2H, H10), 7.74 (d, J = 1.8 
Hz, 1H, H4), 7.53-7.46 (m, 2H, H9), 7.38 (d, J = 8.6 Hz, 1H, H7), 7.23 (dd, J = 8.6, 1.8 Hz, 1H, H6), 
6.92 (s, 1H, H3); 
13C NMR [101 MHz, CD3)2CO] δ 139.1 (C8), 137.1 (C7’), 133.9 (CCl), 131.9 (C2 or C5), 131.8 
(C2 or C5), 129.9 (2 x C9), 127.7 (2 x C10), 125.5 (C6), 123.5 (C4), 113.9 (C7), 113.4 (C3’), 100.1 
(C3); 
IR (KBr) 3437, 1440, 1097, 831, 792 cm-1; 
HRMS (ESI) m/z 305.9662 [M+H]+ (calcd for C14H10BrClN 305.9685). 
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IV.4.7 Reaction of 5-bromo-2-(4-chlorophenyl)-1H-indole (7) with 
benzylamine (8) 
 
IV.4.7.1 Via copper catalysis25 
In a dried ACE pressure tube, containing 7 (50 mg, 0.16 mmol), CuI (3.1 mg, 0.016 mmol), L-
proline (3.8 mg, 0.032 mmol), K2CO3 (45.1 mg, 0.32 mmol) and benzylamine (8) (26.7 µL, 0.24 mmol), 
was added dry DMSO (0.1 mL), under an argon atmosphere. The mixture was stirred for 96 h at 80ºC. 
No product formation was observed after TLC control. 
 
IV.4.7.2 Via palladium catalysis26 
Compound 7 (100 mg, 0.33 mmol), BrettPhos (1.7 mg, 0.003 mmol) and chloro[2-
(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′, 6′-triisopropyl-1,1′-biphenyl][2-(2-aminoethyl)phenyl] 
palladium(II) (BrettPhos precatalyst) (2.6 mg, 0.003 mmol) were added in a dried ACE pressure tube. 
The vial was evacuated and backfilled with argon, then a 1 M solution of LiHMDS (0.8 mL, 0.79 mmol) 
in THF, and benzylamine (8) (42.7 µL, 0.39 mmol) were added. The mixture was stirred at 65ºC for 48 
h. No product formation was observed after TLC control. 
 
IV.4.8 Synthesis of (4-nitrophenyl)hydrazine hydrochloride (16)48 
 
To a solution of 4-nitroaniline (20) (500 mg, 3.62 mmol), in HCl (6.3 mL), cooled with an ice 
bath, was added dropwise a solution of NaNO2 (265.6 mg, 3.85 mmol), in H2O (1.5 mL), also cooled in 
an ice bath. Then, a solution of SnCl2·2H2O (1.81 g, 8.02 mmol), in HCl (1.8 mL) was added, dropwise. 
The solution was stirred for 2 h. The resulting solid was filtered by suction and washed with Et2O, 
affording compound 16 in 81% yield (555.6 mg) as an orange solid. 
m.p. 199-201ºC (Et2O) [lit.
49 201-202ºC (EtOAc)];  
1H NMR (400 MHz, DMSO-d6) δ 10.64 (s, 3H, NH3
+), 9.57 (s, 1H, NH), 8.16 (d, J = 9.1 Hz, 
2H), 7.06 (d, J = 9.1 Hz, 2H); 
IR (KBr) 3326, 2880, 2677, 1601, 1336, 1112, 851 cm-1; 
Spectral data were in accordance with the literature.49 
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IV.4.9 Reaction of (4-nitrophenyl)hydrazine hydrochloride (16) with 4-
chloroacetophenone (10) 
 
IV.4.9.1 With polyphosphoric acid28 
In a two-neck round bottom flask, equipped with a thermometer, was added compounds 16 (200 
mg, 1.05 mmol) and 10 (0.14 mL, 1.05 mmol). The mixture was stirred for 5 min. Then PPA (ca. 1 g) 
was added and the reaction mixture was gently warmed to 110ºC, for 5 h. No product formation was 
observed after TLC control. 
 
IV.4.9.2 With phosphomolybdic acid27 
To a solution of 4-chloroacetophenone (10) (0.14 mL, 1.05 mmol), in dry CHCl3 (0.5 mL), was 
added phosphomolybdic acid (385.1 mg, 0.21 mmol). Compound 16 (200 mg, 1.05 mmol) was then 
slowly added, at room temperature. The reaction mixture was heated to 60ºC, for 24 h. No product 
formation was observed after TLC control. 
 
IV.4.10 Preparation of silica-gel-supported sulfuric acid (SSA)50 
To a flask containing silica gel (1 g) was slowly added chlorosulfonic acid (0.22 mL). The 
mixture was shacked for 30 min, affording SSA, which was used without purification directly on the 
next step. 
 
IV.4.11 Synthesis of N-benzyl-4-nitroaniline (19)51 
 
In a mortar was added 4-nitroaniline (20) (50 mg, 0.36 mmol), NaBH4 (13.7 mg, 0.36 mmol), 
SSA (72.4 mg) and benzaldehyde (12) (36.9 µL, 0.36 mmol). The mixture was grounded for 10 min, 
then was filtered through celite and washed with EtOAc. The crude was purified by flash 
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chromatography (n-hexane/EtOAc 3:2) affording compound 19 in 89% yield (73.6 mg) as a yellow 
solid. 
m.p. 147-148ºC (n-hexane/EtOAc) [lit.52 146-147ºC (EtOAc/petroleum ether)];  
1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 9.2 Hz, 2H), 7.42-7.28 (m, 5H), 6.58 (d, J = 9.2 Hz, 
2H), 4.70 (s, 1H, NH), 4.43 (s, 2H); 
IR (KBr) 3366, 1604, 1282, 1106 cm-1. 
Spectral data were in accordance with the literature.52 
 
IV.4.12 Synthesis of N-benzylbenzene-1,4-diamine (18)53 
 
To a solution of NH4Cl (70.3 mg, 1.31 mmol), in H2O (0.9 mL), was added Fe (73.4 mg, 1.31 
mmol), under argon atmosphere. A solution of 19 (100 mg, 0.44 mmol), in acetone (2.2 mL), was slowly 
added. The reaction was refluxed overnight. The mixture was diluted in EtOAc, washed with a saturated 
solution of NaHCO3 and then brine, dried over Na2SO4 anhydrous, filtered and concentrated. The crude 
was purified by flash chromatography (DCM/MeOH 1 to 2%) affording compound 18 in 95% yield 
(82.8 mg) as beige solid. 
1H NMR (400 MHz, CDCl3) δ 7.40-7.27 (m, 5H), 6.62 (d, J = 8.4 Hz, 2H), 6.55 (d, J = 8.4 Hz, 
2H), 4.27 (s, 2H), 3.27 (s, 3H, NH and NH2); 
IR (KBr) 3409, 3340, 1516 cm-1. 
Spectral data were in accordance with the literature.54 
 
IV.4.13 Synthesis of N-benzyl-4-hydrazinylaniline hydrochloride (17) 
 
To a solution of 18 (122.7 mg, 0.62 mmol), in HCl (1.1 mL), cooled with an ice bath, was added 
dropwise a solution of NaNO2 (45.3 mg, 0.66 mmol), in H2O (0.3 mL), also cooled in an ice bath. Then, 
a solution of SnCl2·2H2O (310.0 mg, 1.37 mmol), in HCl (0.3 mL) was added, dropwise. The solution 
was stirred for 2 h. The resulting solid was filtered by suction and washed with Et2O, affording 17 in 
40% yield (62.4 mg) as beige solid. 
m.p. 173-175ºC (Et2O);  
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1H NMR (400 MHz, DMSO-d6) δ 10.02 (s, 3H, NH3
+), 7.36 (d, J = 7.2 Hz, 2H), 7.31 (t, J = 7.2 
Hz, 2H), 7.22 (t, J = 7.2 Hz, 1H), 7.09 (d, J = 8.4 Hz, 2H), 6.71 (d, J = 8.4 Hz, 2H), 4.29 (s, 2H), 3.40 
(s, NH, under the solvent water peak ); 
13C NMR (101 MHz, DMSO-d6) δ132.2, 131.3, 129.5, 129.2, 128.3, 127.6, 126.9, 123.5, 47.1; 
IR (KBr) 3435, 2836, 1508 cm-1. 
 
IV.4.14 Reaction of N-benzyl-4-hydrazinylaniline hydrochloride (17) with 4-
chloroacetophenone (10) 
 
In a two-neck round bottom flask, equipped with a thermometer, was added 17 (55 mg, 0.22 
mmol) and 10 (28.6 µL, 0.22 mmol). The mixture was stirred for 5 min. Then PPA (ca. 150 mg) was 
added and the reaction mixture was gently warmed to 110ºC. Decomposition of the starting material 
was observed and no reaction product was formed by TLC control. 
 
IV.4.15 Synthesis of 2-(4-chlorophenyl)-1H-indole (14)28 
 
In a two-neck round bottom flask, equipped with a thermometer, was added phenylhydrazine 
hydrochloride (15) (500 mg, 3.46 mmol) and 4-chloroacetophenone (10) (0.44 mL, 3.39 mmol). The 
mixture was stirred for 5 min. Then PPA (ca. 2 g) was added and the reaction mixture was gently warmed 
to 110ºC. After 1 h stirring at that temperature, the reaction was poured onto ice. A solution of 2 M 
NaOH was added till pH ≈ 7. The solid was filtered by suction and recrystallized from Et2O/pentane 
affording compound 13 in 66% yield (512.1 mg) as white solid. 
m.p. 208-210ºC (Et2O/pentane) [lit.
55 208-210ºC (EtOAc/n-hexane)];  
1H NMR (400 MHz, DMSO-d6) δ 11.58 (s, 1H, NH), 7.88 (d, J = 8.5 Hz, 2H), 7.56-7.49 (m, 
3H), 7.40 (d, J = 7.7 Hz, 1H), 7.11 (t, J = 7.7 Hz, 1H), 7.00 (t, J = 7.7 Hz, 1H), 6.93 (s, 1H); 
IR (KBr) 3433, 1426, 1094, 798 cm-1. 
Spectral data were in accordance with the literature.55 
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IV.4.16 Synthesis of 2-(4-chlorophenyl)-5-nitro-1H-indole (13)28 
 
To a solution of 14 (190 mg, 0.83 mmol), in H2SO4 (5.4 mL), cooled with an ice bath, was 
added, dropwise, a solution of NaNO3 (75.5 mg, 0.89 mmol), in H2SO4 (2.7 mL), also cooled in an ice 
bath. The mixture was stirred, at 0ºC, for 5 min. Then, was poured onto ice and a solution of 2 M NaOH 
was added till pH ≈ 7. The solid was filtered by suction, redissolved in EtOAc, washed with distilled 
water and brine, dried over Na2SO4 anhydrous, filtered and concentrated. The resulting solid was 
recrystallized from EtOAc/pentane affording 13 in 82% yield (185.6 mg) as a yellow solid. 
m.p. 292-294ºC (EtOAc/pentane);  
1H NMR (400 MHz, DMSO-d6) δ 12.34 (s, 1H, NH), 8.53 (s, 1H, H4), 8.01 (dd, J = 9.0, 2.1 Hz, 
1H, H6), 7.92 (d, J = 8.4 Hz, 2H, H10), 7.62-7.52 (m, 3H, H7 and H9), 7.21 (s, 1H, H3); 
13C NMR (101 MHz, DMSO-d6) δ 141.1 (C5), 140.4 (C7’ or C8), 140.2 (C7’ or C8), 133.0 
(C2), 129.9 (CCl), 129.1 (2 x C9), 127.8 (C3’), 127.1 (2 x C10), 117.2 (C6), 117.1 (C4), 111.7 (C7), 
101.5 (C3); 
IR (KBr) 3333, 1471, 1334 cm-1; 
HRMS (ESI) m/z 273.0408 [M+H]+ (calcd for C14H10ClN2O2 273.0431). 
 
IV.4.17 Synthesis 2-(4-chlorophenyl)-1H-indol-5-amine (11) 
 
IV.4.17.1 Reduction with Pd/C, H256 
To a solution of 13 (50 mg, 0.18 mmol), in EtOH (7 mL), was added 10% Pd/C (12.9 mg, 0.01 
mmol). The mixture was stirred at room temperature under H2 atmosphere. After 2 h, the reaction 
mixture was filtered through celite and concentrated under reduce pressure. The crude was purified by 
flash chromatography (CHCl3/MeOH 2 to 4%) affording a mixture of 1:0.6 of compounds 11 and the 
dechlorinated product. 
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IV.4.17.2 Reduction with Fe/NH4Cl53 
To a solution of NH4Cl (98.1 mg, 1.83 mmol), in H2O (1.2 mL), was added Fe (102.4 mg, 1.83 
mmol), under argon atmosphere. A solution of 13 (100 mg, 0.37 mmol), in THF (1.8 mL), was slowly 
added. The reaction was refluxed overnight. The mixture was diluted in EtOAc, washed with a saturated 
solution of NaHCO3 and then brine, dried over Na2SO4 anhydrous, filtered and concentrated. The crude 
was purified by flash chromatography (CHCl3; CHCl3/MeOH 2%) affording compound 15 in 59% yield 
(52.7 mg) as a beige solid. 
m.p. 249-251ºC (EtOAc/pentane);  
1H NMR [400 MHz, (CD3)2CO] δ 10.30 (s, 1H, NH), 7.79 (d, J = 8.6 Hz, 2H, H10), 7.43 (d, J 
= 8.6 Hz, 2H, H9), 7.14 (d, J = 8.5 Hz, 1H, H7), 6.81 (s, 1H, H4), 6.67 (s, 1H, H3), 6.62 (dd, J = 8.5, 
2.2 Hz, 1H, H6), 4.15 (s, 2H, NH2); 
13C NMR [101 MHz, (CD3)2CO] δ 142.6 (C5), 137.3 (C8), 132.9 (CCl), 132.8 (C7’), 131.1 
(C2), 129.7 (2 x C9), 127.1 (2 x C10), 114.1 (C6), 112.3 (C7), 112.2 (C3’), 104.7 (C4), 99.5 (C3); 
IR (KBr) 3420, 1458, 830, 762 cm-1; 
HRMS (ESI) m/z 243.0686 [M+H]+ (calcd for C14H12ClN2 243.0684). 
 
IV.4.18 Synthesis of N-benzyl-2-(4-chlorophenyl)-1H-indol-5-amine (5) 
 
To a solution of 11 (70 mg, 0.29 mmol), in dry MeOH (2.2 mL), was added benzaldehyde (29.4 
µL, 0.29 mmol), one drop of glacial acetic acid and NaBH3CN (18.1 mg, 0.29 mmol). The mixture was 
stirred, at room temperature, under argon atmosphere, overnight. The reaction was quenched with 
distilled water, extracted with EtOAc, dried over Na2SO4 anhydrous, filtered and concentrated. The 
crude was purified by flash chromatography (n-hexane/EtOAc 4:1) affording compound 5 in 78% yield 
(75.2 mg) as white solid. 
m.p. 189-191ºC (n-hexane/EtOAc);  
1H NMR [400 MHz, (CD3)2CO] δ 10.32 (s, 1H, NH), 7.79 (d, J = 8.7 Hz, 2H, H15), 7.45-7.41 
(m, 4H, H10 and H14), 7.31 (t, J = 7.4 Hz, 2H, H11), 7.22 (t, J = 7.4 Hz, 1H, H12), 7.17 (d, J = 8.4 Hz, 
1H, H7), 6.72-6.68 (m, 3H, H3, H4 and H6), 5.01 (s, 1H, NH), 4.37 (s, 2H, H8); 
13C NMR [101 MHz, (CD3)2CO] δ 144.0 (C5), 141.9 (C9), 137.1 (C13), 132.9 (CCl), 132.7 
(C7’), 132.5 (C2), 131.0 (C3’), 129.7 (2 x C14), 129.1 (2 x C11), 128.2 (2 x C10), 127.4 (C12), 127.1 
(2 x C15), 113.6 (C6), 112.5 (C7), 101.9 (C4), 99.9 (C3), 49.4 (C8); 
IR (KBr) 3432, 1458, 1239, 833 cm-1; 
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HRMS (ESI) m/z 333.1148 [M+H]+ (calcd for C21H18ClN2 333.1159); 
Purity 100% 
 
IV.4.19 Synthetic studies toward C-3 nitration of indole 
 
IV.4.19.1 Reaction with chlorodiphenylphosphine and silver nitrate36 
To a solution of Ph2PCl (42.6 µL, 0.24 mmol) and I2 (60.2 mg, 0.24 mmol), in dry DCM (1.1 
mL), was added AgNO3 (73.9 mg, 0.47 mmol), at room temperature. Indole (50 mg, 0.43 mmol) was 
then added to the reaction mixture. The reaction afforded a complex mixture of products, observed by 
TLC control and no isolation was attempted due to the complexity of the mixture. 
 
 
IV.4.19.2 Reaction with benzoyl chloride and silver nitrate37 
To a solution AgNO3 (87 mg, 0.51 mmol), in dry MeCN (0.3 mL), cooled with ice bath, was 
slowly added a solution of benzoyl chloride (54.5 µL, 0.47 mmol), in dry MeCN (0.2 mL). The resulting 
mixture was added to a solution of indole (50 mg, 0.43 mmol), in dry MeCN (0.5 mL), cooled ate -10ºC. 
The reaction mixture was stirred ate this temperature for 1 h and then was allowed to warm to room 
temperature. The reaction afforded a complex mixture of products, observed by TLC control and no 
isolation was attempted due to the complexity of the mixture. 
 
IV.4.20 Synthesis of tert-butyl 5-(benzyloxy)-3-iodo-1H-indole-1-carboxylate 
(29)57 
 
To a solution of 5-(benzyloxy)-1H-indole (1) (100 mg, 0.45 mmol), in dry DMF (0.8 mL), was 
added KOH (62.8 mg, 1.12 mmol), under argon atmosphere. The solution was stirred at room 
temperature for 20 min. After that time, a solution of I2 (114.8 mg, 0.45 mmol), in dry DMF (0.8 mL), 
was slowly added. The reaction was stirred for 45 min. The solution was poured onto ice and water 
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containing ammonia (0.5%) and sodium metabisulphite (0.1%), the precipitate was filtered and washed 
with cold water, affording 5-(benzyloxy)-3-iodo-1H-indole in 98% yield (152.9 mg) as a white solid. 
To a solution of 5-(benzyloxy)-3-iodo-1H-indole (152.9 mg, 0.44 mmol), in dry DCM (10.2 
mL), was added Boc2O (105.13 mg, 0.48 mmol), TEA (0.18 mL, 1.31 mmol) and DMAP (5.3 mg, 0.04 
mmol). The mixture was stirred for 30 min, under argon atmosphere, at room temperature. The reaction 
mixture was then washed with a 5% aqueous solution of sodium metabisulphite, dried over MgSO4 and 
concentrated. The crude was purified by flash chromatography (n-hexane/Et2O 4:1) affording compound 
29 in 82% yield (161 mg), as a white solid. 
m.p. 109-112ºC (n-hexane/Et2O);  
1H NMR (400 MHz, CDCl3) δ 8.03-8.01 (m, 1H, H7), 7.70 (s, 1H, H2), 7.49 (d, J = 7.2 Hz, 2H, 
H10), 7.40 (t, J = 7.2 Hz, 2H, H11), 7.34 (t, J = 7.2 Hz, 1H, H12), 7.05 (dd, J = 9.0, 2.5 Hz, 1H, H6), 
6.95 (d, J = 2.5 Hz, 1H, H4), 5.14 (s, 2H, H8), 1.66 (s, 9H, 3 x H15); 
13C NMR (101 MHz, CDCl3) δ 155.8 (C5), 148.8 (C13), 137.1 (C9), 133.1 (C7’), 130.8 (C2), 
129.7 (C3’), 128.7 (2 x C11), 128.1 (C12), 127.8 (2 x C10), 116.1 (C7), 115.2 (C6), 105.3 (C4), 84.3 
(14), 70.7 (C8), 65.3 (C3), 28.3 (3 x C15); 
IR (KBr) 1720, 1358, 1271, 1154 cm-1; 
HRMS (ESI) m/z 450.0557 [M+H]+ (calcd for C20H21INO3 450.0566). 
 
IV.4.21 Synthetic studies towards C-3 amination of tert-butyl 5-(benzyloxy)-3-
iodo-1H-indole-1-carboxylate (29) 
 
IV.4.21.1 Reaction with NH4OH and Cu2O41 
In an ACE pressure tube containing a solution of 29 (100 mg, 0.22 mmol) and Cu2O (1.6 mg, 
0.01 mmol), in NMP (0.2 mL), was added a 25% aqueous solution of NH3 (0.17 mL, 2.23 mmol). The 
reaction mixture was heated to 80ºC, for 16 h. No product formation was observed after TLC control.  
 
IV.4.21.2 Reaction with NH4OH, CuI and Fe2O342 
In an ACE pressure tube containing a solution of 29 (100 mg, 0.22 mmol), in EtOH (0.4 mL), 
were added CuI (4.2 mg, 0.02 mmol) and Fe2O3 (3.5 mg, 0.02 mmol). A 25% aqueous solution of NH3 
(83.3 µL, 1.11 mmol) and NaOH (17.8 mg, 0.44 mmol) were then added. The reaction mixture was 
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heated to 90ºC for 24 h. only the product resulting from the hydrolysis of the tert-butylcarboxylate group 
compound 29 was observed by TLC. 
 
IV.4.22 Synthesis of ethyl 5-(azidomethyl)furan-2-carboxylate (30)58 
 
To a solution of ethyl 5-(chloromethyl)furan-2-carboxylate (25) (300 mg, 1.59 mmol), in dry 
DMF (1.1 mL), was added NaN3 (124.1 mg, 1.91 mmol), under argon atmosphere. The mixture was 
heated to 70ºC and was stirred for 3 h. After that time the reaction was quenched with distilled water, 
extracted with EtOAc, dried over Na2SO4, filtered and the solvent removed. The crude was purified by 
flash chromatography (n-hexane/Et2O 4:1 to 3:2) affording compound 30 in 90% yield (299.6 mg) as 
colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.14 (d, J = 3.4 Hz, 1H), 6.46 (d, J = 3.4 Hz, 1H), 4.37-4.46 (m, 
4H, 2 x CH2), 1.38 (t, J = 7.1 Hz, 3H, CH3); 
IR (NaCl) 2100, 1723, 1300 cm-1. 
Spectral data were in accordance with the literature.59 
 
IV.4.23 Synthesis of ethyl 5-(aminomethyl)furan-2-carboxylate (24)58 
 
To a solution of 30 (300 mg, 1.54 mmol), in dry THF (2.1 mL), was added a solution of PPh3 
(427.3 mg, 1.63 mmol), in dry THF (1.2 mL), under argon atmosphere. The mixture was heated to 50ºC, 
for 2 h. After that time, H2O (61 µL) was added. The reaction was stirred at 50ºC for 1 h. Then it was 
allowed to cool to room temperature and was stirred overnight. The THF was removed under reduced 
pressure and the crude was purified by flash chromatography (CHCl3; CHCl3/MeOH 1 to 10%) affording 
compound 24 in 88% yield (228.1 mg) as yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.09 (d, J = 3.4 Hz, 1H, H4), 6.26 (d, J = 3.4 Hz, 1H, H3), 4.33 
(q, J = 7.1 Hz, 2H, H7), 3.88 (s, 2H, H1), 1.70 (s, 2H, NH2), 1.35 (t, J = 7.1 Hz, 3H, H8); 
13C NMR (101 MHz, CDCl3) δ 161.1 (C2), 159.0 (C6), 143.9 (C5), 118.9 (C4), 107.6 (C3), 
61.0 (C7), 39.6 (C1), 14.5 (C8); 
IR (NaCl) 3371, 1715, 1302 cm-1; 
 HRMS (ESI) m/z 170.0815 [M+H]+ (calcd for C8H12NO3 170.0812). 
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IV.4.24 Synthesis of ethyl 5-{[(tert-butoxycarbonyl)amino]methyl}furan-2-
carboxylate (31) 
 
To a solution of 24 (656 mg, 3.88 mmol), in dry DCM (5.2 mL), was added Boc2O (931.6 mg, 
4.27 mmol), TEA (1.1 mL, 7.76 mmol) and DMAP (47.4 mg, 0.39 mmol), under argon atmosphere. The 
mixture was stirred for 2 h at room temperature. After that time the mixture was washed with distilled 
water and brine, the organic layers were dried over MgSO4, filtered and the solvent removed. The crude 
was purified by flash chromatography (n-hexane/Et2O 7:3) affording compound 31 in 64% yield (670 
mg) as yellow oil.  
1H NMR (400 MHz, CDCl3) δ 7.08 (d, J = 3.4 Hz, 1H, H4), 6.33-6.32 (m, 1H, H3), 5.02 (s, 1H, 
NH), 4.34-4.33 (m, 4H, H1 and H7), 1.43 (s, 9H, H11), 1.35 (t, J = 7.1 Hz, 3H, H8); 
13C NMR (101 MHz, CDCl3) δ 158.9 (C6), 156.7 (C2), 155.6 (C9), 144.2 (C5), 119.0 (C4), 
109.2 (C3), 80.1 (C10), 61.1 (C7), 37.9 (C1), 28.4 (C11), 14.5 (C8); 
  IR (NaCl) 3351, 1712, 1519, 1300, 1138 cm-1; 
HRMS (ESI) m/z 292.1155 [M+Na]+ (calcd for C13H19NNaO5 292.1161). 
 
IV.4.25 Synthesis of ethyl 5-{[(tert-butoxycarbonyl)amino]methyl} 
tetrahydrofuran-2-carboxylate (32) 
 
To a solution of 31 (633 mg, 2.35 mmol), in dry EtOH (3 mL), was added 20% Pd(OH)2/C 
(165.1 mg, 0.23 mmol). The mixture was stirred at room temperature under H2 atmosphere, overnight. 
The reaction mixture was filtered through celite and concentrated under reduce pressure. The crude was 
purified by flash chromatography (n-hexane/Et2O 3:2) affording compound 32 in 91% yield (582.2 mg) 
as pale yellow oil. 
1H NMR (400 MHz, CDCl3) δ 5.55 (s, 1H, NH), 4.46 (dd, J = 8.8, 4.2 Hz, 1H, H5), 4.25-4.15 
(m, 3H, H2 and H7), 3.45-3.37 (m, 1H, H1), 3.30-3.22 (m, 1H, H1), 2.34-2.22 (m, 1H, H4), 2.11-2.03 
(m, 1H, H4), 1.97-1.87 (m, 1H, H3), 1.79-1.69 (m, 1H, H3), 1.43 (s, 9H, H11), 1.29 (t, J = 7.1 Hz, 3H, 
H8); 
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13C NMR (101 MHz, CDCl3) δ 173.9 (C6), 156.5 (C9), 80.3 (C2), 79.2 (C10), 77.4 (C5), 61.3 
(C7), 43.7 (C1), 30.9 (C4), 28.5 (C11), 27.2 (C3), 14.3 (C8); 
IR (KBr) 3352, 2977, 1714, 1514, 1172 cm-1; 
HRMS (ESI) m/z 296.1470 [M+Na]+ (calcd for C13H23NNaO5 296.1474). 
 
IV.4.26 Synthesis of ethyl 5-(aminomethyl)tetrahydrofuran-2-carboxylate 
hydrochloride (33)60 
 
To a solution of 32 (425 mg, 1.56 mmol), in dry DCM (1.3 mL), was added a 4 M solution of 
HCl in dioxane (1.6 mL, 6.35 mmol). The reaction mixture was stirred at room temperature, under argon 
atmosphere, for 4 h. The solvent was removed under reduced pressure. The solid was washed with Et2O 
affording compound 33 in 92% yield (326.1 mg) as white solid. 
m.p. 111-113ºC (Et2O); 
1H NMR (400 MHz, CDCl3) δ 8.54 (s, 3H, NH3
+), 4.59-4.41 (m, 2H, H2 and H5), 4.27-4.10 (m, 
2H, H7), 3.46-3.14 (m, 2H, H1), 2.44-2.26 (m, 1H, H4), 2.19-2.02 (m, 2H, H4 and H3), 2.04-1.84 (m, 
1H, H3), 1.27 (t, J = 7.1 Hz, 3H, H8); 
13C NMR (101 MHz, CDCl3) δ 175.6 (C6), 77.0 (C2 or C5), 76.6 (C2 or C5), 62.1 (C7), 41.8 
(C1), 30.9 (C4), 27.0 (C3), 14.2 (C8); 
IR (KBr) 2860, 1717, 1234, 1054 cm-1; 
HRMS (ESI) m/z 174.1131 [M]+ (calcd for C8H16NO3 174.1130). 
 
IV.4.27 Synthesis of ethyl 5-(aminomethyl)tetrahydrofuran-2-carboxylate (23) 
 
To a solution of 33 (90 mg, 0.43 mmol), in dry DCM (2.9 mL), was added TEA (60.2 µL, 0.43 
mmol). The mixture was stirred for 3 h, at room temperature, under argon atmosphere. After that time, 
the reaction was cooled at 0ºC, filtered through celite and washed with cold DCM. The solvent was 
removed under reduced pressure, affording 23 in quantitative yield as a colorless oil. Compound 23 was 
used in the next step without further purification. 
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IV.4.28 Synthesis of tert-butyl 5-(benzyloxy)-3-bromo-1H-indole-1-carboxylate 
(34)61 
 
To a solution of 5-(benzyloxy)-1H-indole (1) (100 mg, 0.45 mmol), in dry DCM (0.6 mL), was 
added Boc2O (106.6 mg, 0.49 mmol) and DMAP (1.1 mg, 0.009 mmol). The mixture was stirred for 1 
h 30 min, under argon atmosphere, at room temperature. After this time the solvent was removed under 
reduced pressure. The crude was redissolved in n-hexane and washed with distilled water, dried over 
Na2SO4, filtered and concentrated, affording tert-butyl 5-(benzyloxy)-1H-indole-1-carboxylate with 
96% yield (139.4 mg) as a white solid. 
To a solution of tert-butyl 5-(benzyloxy)-1H-indole-1-carboxylate (130 mg, 0.40 mmol), in dry 
DCM (6.1 mL), was added NBS (75.8 mg, 0.43 mmol), under argon atmosphere. The reaction mixture 
was refluxed overnight. Then it was washed with distilled water, dried over Na 2SO4, filtered and 
concentrated. The crude was purified by flash chromatography (hexanes; hexanes/Et2O 2 to 4%) 
affording 70% yield (122.6 mg) of compound 27 as a white foam. 
1H NMR (400 MHz, CDCl3) δ 8.03-8.02 (m, 1H), 7.62 (s, 1H), 7.48 (d, J = 7.2 Hz, 2H), 7.40 
(t, J = 7.2 Hz, 2H), 7.34 (t, J = 7.2 Hz, 1H), 7.10-7.01 (m, 2H), 5.14 (s, 2H), 1.66 (s, 9H); 
13C NMR (101 MHz, CDCl3) δ 155.7, 149.0, 137.1, 130.3, 129.5, 128.7 (2 x CH), 128.13, 127.8 
(2 x CH), 125.5, 116.3, 115.4, 103.2, 97.8, 84.3, 70.7, 28.3 (3 x CH3); 
IR (KBr) 3158, 1728, 1477, 1271, 1155, 748 cm-1. 
Spectral data were in accordance with the literature.62 
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IV.4.29 Synthesis of ethyl 5-({[5-(benzyloxy)-1H-indol-3-yl]amino}methyl) 
tetrahydrofuran-2-carboxylate (21) 
IV.4.29.1 Via Pd catalysis 
 
IV.4.29.1.1 Pd(OAc)2/Xantphos system43 
General procedure: A dried ACE pressure tube, containing a solution of Pd(OAC)2 (2.8 mg, 
0.012 mmol), Xantphos (8.6 mg, 0.015 mmol) and compound 23 or 32 (0.15 mmol), in dry dioxane (0.2 
mL), under an argon atmosphere, was heated to 100ºC for 5 min. After this time, the mixture was 
allowed to cool and 34 (50 mg, 0.12 mmol) and Cs2CO3 (113.4 mg, 0.35 mmol) were added, under argon 
atmosphere. The reaction was stirred at 100ºC for 24 h. 
Only debromation of 34 was observed by the TLC control during the reaction of 34 with 23. 
Due to its instability, it was not possible to identify the product formed in the reaction of 
compound 34 with 32. However by analysis of the 1H-NMR spectra it was possible to conclude that the 
amine moiety was not present. 
 
IV.4.29.1.2 BrettPhos based catalyst system26 
Compounds 34 (50 mg, 0.12 mmol) and 23 (25.8 mg, 0.15 mmol), BrettPhos (0.7 mg, 1.2 µmol) 
and chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′, 6′-triisopropyl-1,1′-biphenyl][2-(2-
aminoethyl)phenyl]palladium(II) (BrettPhos precatalyst) (1.0 mg, 1.2 µmol) were added in a dried ACE 
pressure tube. The vial was evacuated and backfilled with argon, then a 1 M solution of LiHMDS (0.3 
mL, 0.3 mmol) in THF was added. The mixture was stirred at 65ºC, for 4 h. Only removal of the Boc 
group of the starting material 34 was observed by TLC. 
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IV.4.29.2 Via copper catalysis 
 
IV.4.29.2.1 CuI/L-proline system30 
In a dried Ace pressure tube, charged with 29 (50 mg, 0.11 mmol), 23 (57.8 mg, 0.33 mmol), 
CuI (2.1 mg, 0.011 mmol), L-proline (2.6 mg, 0.022 mmol) and K2CO3 (30.8 mg, 0.22 mmol), was added 
dry DMSO (0.1 mL). The mixture was stirred at 90ºC for 48 h. Only de-iodination and removal of the 
Boc group of the starting material 29 was observed by TLC. 
 
IV.4.29.2.2 CuI/DMEDA system 
In a dried schlenk, containing 29 (50 mg, 0.11 mmol), 23 (28.9 mg, 0.17 mmol), CuI (2.1 mg, 
0.011 mmol) and K2CO3 (30.8 mg, 0.22 mmol), in dry toluene (0.5 mL), was added DMEDA (2.4 µL, 
0.022 mmol), under argon atmosphere. The reaction was stirred at 105ºC, overnight. After that time the 
mixture was quenched with a saturated aqueous solution of NH4Cl, diluted with distilled water, extracted 
with EtOAc, dried over Na2SO4 anhydrous, filtered and concentrated. The crude was purified by flash 
chromatography (n-hexanes/EtOAc 1:1) affording of 5-({[5-(benzyloxy)-1-(tert-butoxycarbonyl)-1H-
indol-3-yl]amino}methyl)tetrahydrofuran-2-carboxylic acid (35) in 56% yield (28.9 mg), as white solid.  
 
5-({[5-(benzyloxy)-1-(tert-butoxycarbonyl)-1H-indol-3-yl]amino}methyl)tetrahydrofuran-2-
carboxylic acid (35) 
 
m.p. 158-160ºC (EtOAc/n-hexane) 
1H NMR (400 MHz, CDCl3) δ 8.05-8.03 (s, 1H, H7), 7.56 (s, 1H, H2), 7.46 (d, J = 7.2 Hz, 2H, 
H10), 7.39 (t, J = 7.2 Hz, 2H, H11), 7.32 (t, J = 7.2 Hz, 1H, H12), 7.03 (dd, J = 9.1, 2.4 Hz, 1H, H6), 
6.85 (d, J = 2.4 Hz, 1H, H4), 5.10 (s, 2H, H8), 4.75-4.68 (m, 2H, H17 and H20), 4.02 (dd, J = 11.4, 4.1 
Hz, 1H, 1 x H16), 3.26 (d, J = 11.4 Hz, 1H, 1 x H16), 2.39-2.18 (m, 3H, 1 x H18 and 2 x H19), 2.07-
1.98 (m, 1H, 1 x H18), 1.64 (s, 9H, 9 x H15); 
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13C NMR (101 MHz, CDCl3) δ 170.7 (C21), 155.3 (C5), 149.4 (C13), 137.7 (C9), 129.5 (C7’), 
128.7 (2 x C11), 128.0 (C12), 127.7 (2 x C10), 127.0 (C3’), 122.5 (C2), 122.1 (C3), 116.6 (C7), 114.6 
(C6), 102.9 (C4), 84.2 (C14), 77.7 (C20), 73.0 (C17), 70.8 (C8), 57.2 (C16), 32.0 (C19), 28.3 (3 x C15), 
28.2 (C18); 
IR (KBr) 3436, 1741, 1727, 1678, 1374, 1156 cm-1; 
HRMS (ESI) m/z 449.2970 [M-OH]+ (calcd for C26H26N2O5 449.2076). 
 
IV.4.30 QSAR studies 
Several QSAR models were built using Random Forests (RFs) and Associative Neural 
Networks (AsNNs) as machine learning techniques, and different types of descriptors from 
ADRIANA.Code (Molecular Networks GmbH) and Dragon (Talete s.r.l.) software. Several different 
training and test sets were built from publicly available data sets of compounds, including recent data 
deposited in the PubChem database. A set of virtual molecules was computationally generated as a 
combinatorial library, which comprised analogues of 1355 with distinct substitution patterns (not all 
possible structures were generated). The molecular structures were produced by in-house developed 
software that combines SMILES strings of molecular fragments. The data set of 1355 compounds was 
screened by the developed classification and regression models. The developed classification models 
were used to classify as active/inactive the virtual compounds and the regression models were used to 
predict the anti-tubercular activity of the virtual compounds. With predictions from all models a first 
ranking of these compounds was achieved taking into account their average anti-tubercular activity, 
determined by the average predictions from the regression models. When the average activity was the 
same, their average probability to be active, determined by the probability measure of the RFs was taken 
into account. After this initial ranking, two additional pruning operations were performed: i) virtual 
compounds classified as inactives by a classification model were excluded; and ii) virtual compounds 
with average probability of being active lower than 0.8 were also discarded. A further refinement of the 
virtual screening using the web interface OSIRIS, allowed an evaluation of these compounds in terms 
of predicted drug relevant properties such as toxicity (mutagenicity, tumorigenicity, irritation and 
reproductive effectiveness), drug-likeness, drug score, ClogP, solubility and synthetic accessibility. 
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The indole scaffold represents one of the most important structural subunits in drug discovery. 
The demonstration that several alkaloids contain the indole nucleus, and the recognition of the 
importance of the essential amino acid tryptophan in human nutrition, has led to an extensive research 
on indole chemistry. Indeed, a vast number of biologically active natural and synthetic indole derivatives 
have been reported, with a wide range of therapeutic activities, such as antioxidant, anti-inflammatory, 
antimicrobial, analgesic, anticonvulsant, and antimalarial. 
Taking into consideration the unique properties of this scaffold, three indole-based libraries 
were synthesized and its biological activity investigated, searching for novel drugs, including 
antioxidants, selective COX-2 inhibitors – anti-inflammatory, and tuberculostatic agents. 
Thus, a library of tryptamine and tryptophan derivatives was prepared and evaluated for the 
scavenging activity against reactive oxygen species (ROS) and reactive nitrogen species (RNS). The 
tested indole derivatives share a heteroaromatic ring system, differing among them by the presence 
of diverse side chains with different functionalization. The results obtained in the present study reveal 
a strong scavenging effect of tryptophan and tryptamine for the tested ROS and RNS, which activity 
varies in different extensions, depending on the substituents. Figure V.1 depicts the chemical structure 
and the respective ORAC or IC50 values of the best synthesized compounds evaluated. 
For the scavenging of ROO ,̇ 7 of the 18 compounds tested were more potent than trolox 
(which was used as control). The most and the less potent compounds tested for this ROS were 
tryptophan (ORAC = 2.74 ±0.07) and the tryptophan derivative 3 (ORAC = 0.21 ±0.03), respectively. 
In addition, the best synthesized compound evaluated against ROO  ̇was the tryptamine derivative 5 
with ORAC = 1.46 ±0.08 (figure V.1). Concerning to HOCl, all the tested compounds were found to 
be active against this ROS, and all hydrogenated compounds (except 15) were more active than the 
corresponding unsaturated compounds. The best results were obtained for the tryptophan (8) and 
tryptophan derivative 18 (figure V.1) with IC50 of 3.50 ± 0.4 and 3.75 ± 0.52 µM, respectively. The 
library was also evaluated against RNS. Concerning the ONOOˉ, scavenging activity was observed for 
all the studied compounds when the study was carried in the presence of NaHCO3, and the best result 
was obtained for the tryptophan derivative 18, with an IC50 of 14 ± 6.8 µM. 
 
 
ROO˙ ORAC = 1.46 ±0.08 
 
HOCl IC50 = 3.75 ± 0.52 µM 
ONOOˉ with NaHCO3 IC50 = 14.0 ± 6.8 µM 
Figure V.1 - Chemical structures and respective ORAC or IC50 values of the most potent synthesized and 
tested compounds. 
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The cyclic voltammetry studies showed that all the compounds have an oxidation potential 
peak lower than that observed for indole (Epox = 1.035 V), except for compound 10 (Epox = 1.054 V), 
but higher that those described for melatonin (Epox = 0.715 V). In addition, no reversibility was observed 
in the obtained voltammograms. The lack of reversibility is an advantage, meaning that once oxidized 
these species do not tend to receive electrons.  
 
Indole scaffold was further explored to find novel anti-inflammatory agents. For this purpose, 
an indole based library was synthesized and its ability for inhibiting COX-2 selectively was evaluated. 
From the 19 new indole based compounds synthesized, the biological tests revealed that the presence of 
a sulfonamide was more favorable for interaction with both COXs, being more active than the 
corresponding methylsulfones. Compound 17d was found to be the most promising showing 67 ± 5% 
COX-2 inhibition at 50 µM, demonstrating that fluorine seems to be crucial for inhibition. Also, the 
inhibition percentage of 17d is close to the one of celecoxib (75 ± 8%) at 10 µM. According to the 
docking results, compounds 17d-f, with a sulfonamide at C-5, are more active than the corresponding 
methylsulfones 17a-c, which is in accordance with the experimental data. From the 17 series, the 
computational study indicated that the most promising compounds are the fluorinated ones 17a and 17d, 
with a methylsulfone and a sulfonamide, respectively. In both cases these compounds strongly bind to 
COX-2, but not to COX-1. Saturation transfer difference (STD)-NMR studies performed with 17d 
highlighted that the sulfonamide group is indeed important to promote the interaction with COX-2 rather 
than with COX-1, as evidenced by the close proximity of the indolic proton H4 to COX-2, supporting 
the observed selectivity in the inhibition evaluation (figure V.2). 
 
 
Figure V.2 – Docking of compound 17d at the active site of COX-2, STD-NMR spectra of compound 17d 
with COX-1 and COX-2 and its inhibitory percentage at 50 M. 
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During the preparation of the indole-based library, an unexpected reactivity was observed in the 
reaction of alkylation at N-1 position of indole with a trifluoromethylated allyl methanesulfonate. 
Several experiments were carried in order to elucidate the mechanism involved in the formation of a 
mixture of isomers, (1Z,3E)-4-fluoro-4-(indol-1-yl)buta-1,3-dien-1-yl methanesulfonate [22(Z/E)] and 
(1Z,3Z)-4-fluoro-4-(indol-1-yl)buta-1,3-dien-1-yl methanesulfonate [22(Z/Z)]. 
A mechanism was proposed, based on DFT studies, which fully rationalizes the experimental 
data. The proposed mechanism identifies the importance of the metal ion (sodium) and the reaction 
conditions on the final reaction outcome. 
 
During this study the presence of sulfonamide group revealed to be important for the COX-2 
inhibition. However, the methods available for sulfonylation of heterocyclic compounds were limited.  
Due to the lack of versatile methods for the introduction of a sulfonamide group in aromatic systems, 
several attempts were made to develop a new and versatile reagent for this purpose. The first approach 
consisted on the synthesis of sodium benzotriazole/benzimidazole sulfinates, by reaction of 
benzotriazole/benzimidazole with sulfuryl or tionyl chloride. The second approach relied on the use of 
a carbene∙SO2 adduct. Both approaches reveal unsuccessful for the proposed goal, and further work 
must be performed to explore the metal-catalyzed approaches to generate a versatile sulfonylating 
reagent. 
 
Indole scaffold was also investigated in the search for novel and potent antitubercular agents. 
Thus, five indole-based compounds were synthesized and submitted to biological evaluation as 
antitubercular agents. Several structures were proposed for computational evaluation according to the 
structure of known antitubercular agents. The data obtained in the preliminary computational studies 
allowed establishment of the best candidates to be synthesized, and of the substitution patterns on the 
indole scaffold. The synthesis efforts involved several approaches for the functionalization of 
commercial indole derivatives as well as several synthetic approaches for the synthesis of the indole 
ring system properly functionalized, such as the Fischer indole synthesis. 
Thus, it is expected that the biological evaluation of the synthesized indole derivatives along 
with the quantitative structure-activity relationship (QSAR) studies will allow the validation of this 
strategy, opening a new path to the design of new antitubercular agents with improved activity. 
 
Overall, new compounds were synthetized through useful synthetic routes in order to achieve 
functionalized indole derivatives. The choice of the substitution patterns was based on an extensive 
study of the literature, in case of the antioxidants or anti-inflammatories, or preliminary computational 
studies for the antitubercular agents. The obtained data was fully rationalized by SAR studies 
(antioxidant) and validated by docking and STD-NMR studies (anti-inflammatory). 
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The generated data obtained from this work constitutes a platform for the rational design of new 
and more potent antioxidant, anti-inflammatory and antitubercular libraries based on the indole scaffold. 
